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Abstract
The scientific literature contains a variety of experimental studies centred on the theme of drug
delivery from orthopaedic implants (OIs). These experiments cover a wide range of ideas, in-
cluding the design of novel implant coatings to contain and control drug release; fabrication and
testing of prototype drug-filled devices and; preliminary investigations into the effect of the drug
when released into the biological environment. There are a multitude of issues that arise from
the use of OIs and of these, the problem of orthopaedic associated infection receives particular
attention. A key challenge is the prevention of bacterial infection in order to avoid the failure of
the associated implant-a serious complication for patients and a significant burden on health care
provider resources. A mathematical study is presented in this thesis which covers a wide variety
of topics: ranging from a more fundamental investigation into the use of porosity to control
the delivery of drug through to more practical modelling of two seemingly similar prototype or-
thopaedic fixation pins that have vastly different drug release properties. A common theme is the
consideration of how experimental conditions shape the outcome of the experiment and indeed
the mathematical model adopted. In order to be able to effectively control the release of drug
from an orthopaedic implant, one has to have sufficient knowledge of the purpose of the drug:
this determines the required dose and release rate. Thus, towards the end of the thesis, a gradual
investigation of the growth of bacteria subject to antibiotic release from the aforementioned pins
is carried out, to model the interplay between the two processes.
There are several conclusions that arise from the research contained within this thesis. These
include: there exists little-to-no mathematical modelling in the field of drug release from OIs;
porosity is likely a very fruitful approach to control the release of a drug from an OI; the con-
ditions in which an experiment is carried out is crucial; the dissolving process of a drug is an
important process and one that may be the governing means of limiting the rate of drug re-
lease; the use of 1D modelling is sometimes sufficient to answer key questions; there is a need
for collaborative efforts between mathematicians and experimentalists for the goal of effective
drug-releasing OIs to be realised and; the desired outcome, where infection is concerned, is
highly dependent on the drug release profile and, critically, the implant surface concentration of,
and potency of, the antibiotic delivered.
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Chapter 1
Introduction
For millions of people the world over, orthopaedic implants (OIs) have allowed for restored mo-
bility, reduced pain and an overall improvement in quality of life [1]. Some examples of current
OIs are plates, screws and intramedullary rods for fracture stabilisation and fixation and com-
plete joint replacements such as intervertebral discs, prosthetic hips and knees. OIs that serve as
fixation devices provide mechanical stabilisation that allows for load sharing and optimal bone
positioning, thus permitting the healing process of bone to occur in more favourable conditions.
In the event that a specific bone or joint has deteriorated beyond useful function, a prosthetic can
be used as a substitute to restore lost function.
More contemporary OIs began as simple mechanical devices, however, complications arose
from their use that could not be overlooked. The physical effect an OI has on bone and surround-
ing soft tissues; the potential of postsurgical infection; osseointegration (the fixation of the OI to
existing bone, such that function and structural rigidity are achieved); the possible foreign body
response and; the material used in OI construction are some factors that must be considered.
The endeavour to overcome these complications has resulted in many experimental ap-
proaches, investigating the various characteristics of OIs. Alongside the necessary mechanical
properties required of any OI [2–4], the materials of their construction must be biocompati-
ble [2,5] and so many studies have been conducted which examine the biocompatibility of novel
OI materials [2, 3]. These pieces of research look into aspects such as corrosion resistance and
possible cytotoxic effects [2–4].
Aside from any material constraints, one possible avenue of tackling the challenges that can
arise from the interaction of an OI and the bioenvironment (e.g. osseointegration, infection,
pain and inflammation) is through the local delivery of therapeutics. Postsurgical infection re-
ceives much of the focus when considering OI usage. This is not surprising when looking at the
economic impact such as in 2005, in the USA, the cost of knee revision surgery alone due to
infection was $1.27 billion [6]. In the UK, if infection rates of both primary hip and knee arthro-
plasties undertaken by the NHS were akin to infection rates within specialist hospitals (0.2%),
the predicted savings are over £300 million [6]. However, despite the care taken to sterilise
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surgical equipment and the implant to be fitted, infections do occur [5, 7–10].
Local delivery of drugs within an orthopaedic setting is not a new idea. Antibiotics have
been locally delivered routinely in surgery, such as joint replacements, for a number of years.
However, the method of delivery is for the drug to be mixed within the bone cement that is
used for securing the implant in place [5, 9], rather than contained within, or attached to, the
implant. This results in little to no control over the release and the antibiotic is usually delivered
at concentrations much greater than the Minimum Inhibitory Concentration (MIC) of bacteria
[11]. Moreover, the dependency on the porosity and surface area of the bone cement results
in difficulty in the control and reproducibility of a desired release profile. Additionally, these
problems are compounded by the unpredictable drying process of the bone cement, which results
in the formation of cracks and other defects [11]. There has, therefore, been a move away from
OIs which require the use of bone cement in recent times. One of the main reasons for this
change has been the introduction of newer OI materials which possess a rough surface which
can provide a “snug fit”, meaning that bone cement is no longer required. From this, there
is also the added benefit that there is no longer a wait time for the bone cement to dry. In
principle, antibiotics could be coated onto the rough surface of these newer implants, however,
no such approach is in regular clinical practice. The local delivery of antibiotics could be the
way forward, yet when it comes to OI applications, research has been limited and is likely
an area that would yield benefits from not only continued research, but also interdisciplinary
approaches.
Experimental research investigating ways to locally deliver drugs from OIs have typically
confined a drug within a hollow portion of the studied device [11–13]. There are also ap-
proaches looking into modifying the surface/structure of a device [14–16] and applying a coating
on the surface of the device [1, 5] as ways to contain a drug. The drug may be an antibacte-
rial/antimicrobial agent to fight off/prevent infection; growth factors to encourage bone healing;
an anti-inflammatory to help with the foreign body response or; analgesics for pain relief. The
experimental research undertaken thus far shows potential for the development of drug-eluting
OIs. However, one significant issue concerning the design of drug releasing OIs is that whilst
controlled release would be a great benefit, it is often not apparent what the required release
profile is. Controlled release is of paramount importance since toxic effects may occur should
the drug concentration be too high and conversely, if the drug concentration is too low, the ther-
apeutic effect may be diminished. The challenge therefore is to be able to maintain a suitable
drug concentration such that the therapeutic effect of a drug can be maintained, which in some
cases may be for a prolonged period. Adding to this challenge, it should be noted that in the case
of antibiotics, the delivery should not allow for the drug concentration to be maintained below
the MIC of the infecting bacteria, as long-term exposure is linked with antibiotic resistance [2].
To harness control of the release of drug for a given OI, a sound understanding of drug release
mechanisms is necessary.
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Valuable insight has been obtained via the numerous experimental approaches in the field.
However, when a number of conceivable mechanisms are involved, the relative importance of
each is not necessarily clear, thus predicting the effects of changes in system parameters can be
challenging. From an experiment it may be the case that diffusion appears to be the dominant
release mechanism for a given drug. However, if the drug is replaced with another of a markedly
lower solubility, then the release rate of the drug is more likely to be dominated by the rate of
dissolution. The variation of other system parameters such as material porosity and thickness of
a drug releasing coating; the material the coating is comprised of or; the physico-chemical prop-
erties of the drug, may result in the dominant release mechanism altering and could introduce
further effects such as swelling, erosion, degradation and even interactions between the drug and
the OI material.
There is a distinct lack of mathematical modelling of drug release from OIs in the literature.
A few exceptions include simple empirical models, which cannot alone solve the controlled
release issue. A mechanistic mathematical description can assist in determining the key drug
release mechanisms and reveal the rate limiting processes. The estimation of the values of
parameters controlling the system; the quantification of the effect of the interaction with the
biological environment and; the assistance in the design of optimisation strategies for controlled
drug release are other benefits of mathematical modelling. An important note is that OIs were
never designed to carry and release drugs, so integrating drugs into OIs and controlling their
release is an immense challenge [17].
3
Chapter 2
Mathematical modelling of drug releasing
OIs: an underexplored research area
2.1 Experimental approaches to enhance current knowledge
on drug release
The mechanical and biological processes of bone healing are what will determine the clini-
cal outcome. Therefore, it is essential that OIs must integrate with bone successfully to allow
the healing to continue unhindered and assist, if possible. There have been many research ap-
proaches investigating various avenues to ensure more reliable OIs. From the experimental
literature, there are two prevalent ideas for achieving this, either improving current OIs or pro-
ducing new device concepts with a view of combining drug release with such a device. Such
experiments include prototype drug-filled OI designs [11–13]; the application of a drug releas-
ing coating to the surface of an OI [1, 18]; modifying the surface and/or inner structure of an
OI to act as a drug reservoir [16, 19] and; experimenting with new materials for OI construction
which could hold drugs [2,20]. This chapter highlights some of the more motivating experimen-
tal investigations that cover a broad range of ideas. The questions that arise from such studies
and what the potential next steps in the research could be are discussed alongside prospective
mathematical modelling techniques.
2.1.1 Drug filled OI designs
With a view to preventing localised infection, Gimeno et al. [12] investigated the release charac-
teristics of the two antibiotics, Linezolid and Cefazolin, from prototype fixation-like pins (Figure
2.1, Image 1). These pins featured a hollow portion in which an antibiotic can be placed in its
dry powdered form. All pins were constructed of medical grade stainless-steel, were 25 mm
long, with an outer diameter of 6 mm and a wall thickness of 1.6 mm. The key difference
between the pins were the number of orifices that were machined into the wall of each which
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Figure 2.1: A selection of experimental approaches: Image 1 (top left): prototype drug releasing
tube by Gimeno et al. [12]. Image 2 (top right): a similar prototype drug releasing tube with
porous walls by Perez et al. [13]. Image 3 (bottom left): a view of the nanofibres experimented
with by Song et al. [21]. Image 4 (bottom right): an example of a nanotubular surface in the
experiments by Aninwene et al. [19].
resulted in pins having either 2, 4, 6 or 8 equidistant orifices, each with a diameter of 0.5 mm.
In brief, the in vitro experiment was to submerge each of the pins in simulated body fluid (SBF)
and measure the amount of antibiotic present in the fluid medium at various time points. The
in vitro experiments were performed in triplicate, under stirred conditions and without renewal
of the SBF. The results demonstrated that the release rate of the antibiotics could be altered by
the variation of the number of orifices the pin had. This experiment was a proof-of-concept that
drug-holding, hollow fixation pins could be a way of delivering drugs locally. In spite of a dif-
ference in solubility by an order of magnitude, the release profiles of the two drugs were similar
in the 2-orifice pin case, whilst in the other cases, the difference in the release profiles was more
appreciable (Figure 2.2). Also, in the case of the 6 and 8-orifice pins, the release profiles for
Linezolid show a plateauing behaviour at early times which were not explained by the authors.
Coinciding with the drug release experiment, the authors also demonstrated that the pins were
able to release enough antibiotic to combat a bacterial population within the SBF. Each antibi-
otic was used in the 4 and 6 orifice pins, along with controls with no antibiotic. It was found that
both drugs were able to dissolve and diffuse through the orifices into the surrounding medium
and begin to eliminate the bacteria, which suggests that these hollow fixation pins could be a
way to prevent OI associated infection. As expected, the bacterial population increased within
the control setups.
Continuing the pursuit to prevent OI associated infection Perez et al. [13], studied the drug
releasing traits of Linezolid from similar pins to that of Gimeno et al. [12]. However, instead
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Figure 2.2: Release profiles for drug-filled tubes with varied numbers of orifices. Reproduced
from [12].
of orifices to allow the antibiotic to be released, these pins featured a porous wall and rather
than loading the antibiotic directly into the hollow portion of the pin, the drug was loaded into
spherical mesoporous silica microparticles (Figure 2.1, Image 2) (Figure 2.3(a)). Under stirred
conditions, three identical pins were submerged in SBF and the concentration of Linezolid re-
leased was measured at several time points. The authors noted that in the later stages of the
experiment the final concentration was lower than expected. It was suggested that the SBF had
become saturated and so was renewed to permit further release (Figure 2.3(b)). Perez et al. also
conducted a bactericidal study and showed that the pin was able to release a sufficient amount
of Linezolid to reduce bacterial numbers by three orders of magnitude. The potential flexibility
of this device is noted since one could alter the characteristics of both the silica particles and the
porous wall of the pin independently to achieve the desired release profile.
This porous pin design was further investigated by Gimeno et al. [11], however, the silica
particles were omitted and the hollow section of the pin was loaded with Linezolid powder. This
new investigation also featured an in vivo ovine study to determine if the porous pin could deliver
antibiotic adequately to prevent an infection from taking hold. Biofilm forming bacteria were
applied directly to the site of implant insertion and the results showed that after 7 and 9 days,
there was no sign of infection, whereas in the control setup, an infection took hold. The authors
also carried out a drug release study, by submerging the pin in SBF, their results showed that
approximately 75% of the Linezolid was released after 4 days and the remaining drug continued
being released over the subsequent 3 days. One particularly interesting outcome is the shape of
the release profile, it is almost linear (Figure 2.4) until the later portions of the experiment. This
is fairly similar to the release profile from the same porous pin with silica particles in the hollow
6
(a) (b)
Figure 2.3: (a) Transmission Electron Microscopy image of a mesoporous silica particle used
in the experiment, with visible pores. For a sense of scale, the image is approximately 400 nm
across. Adapted from [13]. (b) Release profile from two-stage antibiotic releasing implant,
indicating that drug release continued after renewing release media. QF/Q0(%) represents the
cumulative % of drug released. Reproduced from [13].
centre, except for the slight initial delay (Figure 2.3(b)). Otherwise, the release in both plots
are almost linear at early times and gently curve towards 100%, which is most likely due to the
drugs in either experiment having fully dissolved.
Figure 2.4: Cumulative drug release from a porous hollow implant, showing an almost linear
profile. Reproduced from [11].
2.1.2 Drug releasing coatings for OIs
Coatings that release drugs for OIs have garnered much attention in the literature [1, 2, 7, 18,
22]. Such coatings are able to take numerous forms, such as Hydroxyapatite, which has good
biocompatibility, but also has been demonstrated to be able to retain and release drugs [1,2,18].
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However, concerns have been raised about the lack of controllability of the release [21]. Other
candidate coatings include durable/biodegradable polymers [10, 23], gels [24] and nanofibers
[21, 25].
Kaur et al. investigated the drug releasing potential of the biodegradable polymer poly-D,L-
lactide (PDLLA) in vitro [23]. PDLLA is in current use as a coating for other medical devices
because of its useful qualities: it is both biocompatible and mechanically stable [23]. There
were two components to the investigation of particular interest: a bacterial adhesion test and a
drug release experiment. For the bacterial adhesion study, the polymer was mixed with varying
amounts of Linezolid to give mixtures that were 2.5%, 5% and 10% Linezolid. These mixtures
were then used to coat Kirschner wires (K-wires). As controls two K-wires were used that were
free of drug, with one having a polymer only coating and the other being a bare wire. These
K-wires were then immersed in phosphate buffered saline (PBS) solution containing methicillin-
resistant staphylococcus aureus (MRSA). Measurements of the biomass adhering to each wire
was carried out using Colony Forming Unit (CFU) and ATP detection assays. The K-wires
that were coated with the PDLLA/Linezolid mixtures performed admirably and as expected
the drug-free wires seen bacterial growth for all times (Figure 2.5). The results show that the
bacteria had difficulty multiplying on the surface of the PDLLA/Linezolid coated wires, a result
which could go a long way in preventing infection. It is reported by the authors that the efficacy
of devices like the K-wires is dependent on the release profile. It is imperative that the antibiotic
concentration is above the MIC and so a high level of initial release followed by a sustained
release is what is needed to achieve this. The authors also point out that despite the bacteria
not being completely wiped out, the serious reduction in their numbers could allow the immune
system to handle the remaining bacteria, thus reducing the likelihood of postsurgical infection.
Figure 2.5: Total biomass of MRSA adhered to the various K-wires configurations.
PDLLA/Linezolid mixtures used: 2.5%, 5% and 10% indicated by K1, K2 and K3 respectively.
Reproduced from [23].
The other interesting part of the study was an investigation into the release of Linezolid from
the PDLLA/Linezolid coated K-wires. Each wire was placed into separate tubes containing
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PBS solution and at several time points, a sample was taken, and the concentration of Linezolid
was determined by two method. One approach was to take the samples and expose them to
methicillin-sensitive staphylococcus aureus (MSSA) bacteria and then measure the zone of in-
hibition to determine the concentration of Linezolid from a standard curve. The other method
used was a colorimetric assay in which the samples were treated in accordance with a known
method and the level of absorbance of 750nm light alongside a standard curve were used to
determine the Linezolid concentration. The results show that a Linezolid concentration above
the MIC of MSSA, was sustained for all wires (Figure 2.6). Wires K2 and K3 were reported
to sustain Linezolid release and although the concentrations at the end of the experiment were
minimal, they were still considerably higher than the MIC. Wire K1 as expected eluted the low-
est amount of Linezolid, with a peak around 24 hours and subsequent decline for the remainder
of the experiment duration.
Figure 2.6: Concentration profiles of drug released from K-wires. Three PDLLA/Linezolid
mixtures used: 2.5%, 5% and 10% indicated by K1, K2 and K3 respectively. Reproduced
from [23].
Argarate et al. [10] investigated the drug-eluting qualities of the biodegradable polymer
poly(L-lactic acid) (PLLA), coated onto poly(D,L-lactide-co-lactide) (PLDL) disks. Two drugs
were used in the experiment: Dexamethasone (DM) and Eugenol (EG), which gave the coated
PLDL disks antibacterial and anti-inflammatory abilities. The disks were coated via a dipping
process into solutions of varying concentrations of PLLA. It was observed that the thickness of
the coating could be altered through altering the concentration of PLLA in the dipping solution,
with increasing concentration increasing the coating thickness. The in vitro drug release exper-
iments featured three sets of coating configurations for the disks: a direct coating of EG; a coat
of PLLA/EG and; a layer of PLLA/EG followed by a second coat of PLLA/DM. The coated
disks were immersed in PBS solution and samples of the solution were taken and replace with
fresh PBS at time intervals up to 8 weeks, to determine the amount of drug released.
The authors note of their results (Figure 2.7(a)) that the direct application of EG to the disk
surfaces resulted in relatively rapid release compared to the single and two-layer coatings. This
is an expected result since the drug is in direct contact with the PBS release medium. It was also
9
(a)
(b)
Figure 2.7: (a) Cumulative release of the drugs from PLDL disks with various coating methods:
a direct coating of EG to the disk surface (), a single layer coating of PLLA/EG (N) and a
two layer coating with the inner layer containing EG and the outer layer containing DM (•).
Reproduced from [10]. (b) Cumulative release of the drugs from PLDL disks with two coats of
PLLA: The inner layer containing EG () and the outer layer containing DM (N). Reproduced
from [10].
shown that the two-layer coated disks released a lesser total amount of drug over the course of
the experiment when compared to the disks with a single coating. The authors suggested that
this could be due to the presence of the second coat and thus increase the diffusion distance for
a drug particle to travel.
The results from the release study in the case of the two-layer coated disks (Figure 2.7(b))
show that DM was released much more quickly than EG, this is likely the consequence of DM
being present in the outer layer. This resulted in quick release within the first week, continued
sustained release up to 4 weeks and afterwards began to plateau up to 8 weeks. The inner
layer managed to release most of the EG within the first 4 days of the experiment after which
release plateaued up to 8 weeks. The authors went on to conclude that the controlled sequential
release of two drugs from a two-layered coating of PLLA on implants is conceivable. It is
also noteworthy that the authors obtained a uniformly distributed coating on the disks, which
also featured a rough surface, which could assist in the adhesion of osteoblasts to the implant
surface, thus helping to achieve osseointegration.
Radin et al. [24] investigated the release of Vancomycin from thin sol-gel films applied to
titanium alloy plates, which is a material used in implant manufacture. The authors were inspired
to conduct this research as sol-gel films are biocompatible and at room temperature, silica sol-
gels are porous and nanostructured, features which are suited for controlled release of drugs.
The research looked at two components of interest: the degradation of the sol-gel films and the
release of Vancomycin into a PBS release media, which was renewed daily. The experimental
setup involved the repeated dipping of titanium alloy strips into sol-gel solutions containing
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differing Vancomycin concentrations, to build layers on the surface of the strips.
Figure 2.8: Cumulative release of vancomycin from sol-gel films with different layers (L). Re-
produced from [24].
The results show that the release rate of Vancomycin from the coatings that consisted of two
and three layers was considerably greater than that of a single layer of the sol-gel. Along with a
quicker release rate, it was found that the duration of release and the total amount of Vancomycin
release was also greater (Figure 2.8).
(a) (b)
Figure 2.9: (a) Cumulative release of Vancomycin. Reproduced from [24]. (b)Weight loss of
the films due to degradation. Reproduced from [24]. Each film was composed of three layers
with varying percentage loadings of Vancomycin.
The authors inferred from the results that there is a connection between the degradation of
the sol-gel coating and the release rates (Figure 2.9). The results suggest that the quicker the
sol-gel degrades, the faster the Vancomycin is released. This suggests that a governing release
mechanism in the release of Vancomycin from the sol-gel films is the degradation of the coat-
ings. For long-term release, the authors determined that multi-layer coatings could be a reliable
approach and the fine tuning of the release profile could be done by varying the parameters dur-
ing the production of the sol-gel. The authors also note the possibility of combining layers with
different drugs in each, such as antibiotics to fight infection and growth factors to aid in bone
healing [24].
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Song et al. [21] fabricated two-layer nanofibres (NFs) and investigated their osseointegra-
tion qualities and potential as a controlled drug release device. The NFs feature a distinctive
core-sheath structure (Figure 2.1, Image 3), with the outer sheath formed from a mixture of
polycaprolactone (PCL) and collagen (Col) and the inner core constructed from polyvinyl alco-
hol (PVA) and hydroxyapatite nanorods (HA). The PCL/Col sheath was noted as being suitable
for its role as an outer barrier due to its slow degradation rate and thus ability to reduce the drug
release rate. The inclusion of HA in the core of the NFs increased the mechanical strength of the
NFs, but also provided a rough surface to mimic the surface of bone and it is within the core of
the NFs that a drug can be held for delivery. The authors conducted drug release and bactericidal
studies.
The drug release experiments conducted to assess the potential of the NFs as a drug-deliver-
ing coating involved the use of two drugs: the antibiotic Doxycycline (Doxy) and the anti-inflam-
matory Dexamethasone (Dex). NFs loaded with either Doxy or Dex were immersed in distilled
water, which was neither stirred nor renewed, and concentrations of the drugs were determined
with a spectrometer. The results showed that PVA fibres mixed with Doxy exhibited a burst
release of the drug within the first 10 hours and full release within 48 hours. The addition of a
PCL sheath however, extended the duration of Doxy release to over 700 hours and was believed
to be the case due to the slow degradation of the PCL sheath. The release of Dex displayed
similar behaviour to Doxy when mixed with PVA fibres, with a burst release in the initial 10
hours and complete elution within 48 hours. The addition of a PCL sheath extended the release
duration to over to 150 hours, with yet another increase in duration when Dex was also included
in the PCL sheath. In the bactericidal study involving MRSA, it was found that when Doxy was
blended with both the sheath and the core of the NFs, release was sustained and continued for
152 hours, providing a long-lasting antibacterial effect. It was concluded by the authors that the
results demonstrated that the NFs were capable of delivering Doxy in a controlled manner such
that it effectively inhibited MRSA from colonisation and thus reduce the likelihood of infection
in vitro. Through the measurement of the adhesion of cells to the NFs, the experimental results
also showed that the NFs exhibited good biocompatibility and osteoconductivity.
2.1.3 Surface and structure alterations of OI materials for drug release
The materials that are used for OI construction have also been given considerable attention in
the literature. There are many aspects to this research area as proposed materials must not have
a deleterious effect on the body and must have the necessary physical properties before they can
be used. Such properties may be mechanical in nature, such as material strength in the form of
compression, tensile and fatigue. Other material characteristics may be consequential, such as a
toxic influence on surrounding tissues. The innate properties are not the only consideration, for
example, how and where the material will be used will also impact its suitability, for example,
corrosion and attrition resistance may be required over others [2]. Focussing on the controlled
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delivery of drug from OIs, one area that has produced many published works is the investigation
of nanotubes. The alteration of a material surface such that it forms nanotubes presents several
advantages, for example, they could act as reservoirs for a drug on the surface of an OI [2,
14, 16, 18] and some nanotubes are noted to have great mechanical strength, which could be
used as a way to reinforce OIs [14, 18]. It has also been suggested that the nanotubes of some
metal oxides could improve osseointegration [14, 16, 18] and cell viability [16, 18, 22] since
the rough surface produced by nanotubes is more similar to bone than materials with a smooth
surface [14, 16, 18, 19].
Aninwene et al. investigated the effect of a drug-coated anodised nanotubular surface (Figure
2.1, Image 4) on the adhesion of osteoblasts [19]. The surface roughness of titanium is increased
through anodising, this means the surface is more akin to bone. The inspiration behind this
research is because it is surfaces like bone that osteoblasts tend to attach to because of the
chemistry involved and the surface roughness [19]. The authors remarked that these nanotubes
could have the potential to act as reservoirs for anti-inflammatories, antibiotics and drugs which
promote the growth of bone [19].
In the experiments, the authors prepared anodised and non-anodised titanium samples, which
through physical adsorption or by soaking with SBF, were loaded with either a mixture of peni-
cillin/streptomycin or dexamethasone. These drug-loaded samples then had osteoblasts seeded
onto them, which were then cultured. The findings of the experiments showed that the os-
teoblasts adhered in far greater numbers to the anodised versus non-anodised titanium (Figure
2.10). Additionally, the titanium samples loaded with drugs by soaking with SBF, released more
drug than the samples load by physical adsorption. These are encouraging results since the en-
hanced adhesion of osteoblasts to the nanotube surface of anodised titanium is a potential way
to promote better osseointegration. The additional drug delivery prospects from the nanotubes
would go a long way in addressing the other issues from the use of OIs, in particular, postsurgical
infection.
Lyndon et al. reviewed numerous examples of metallic implant drug/device combinations
and outlined some promising materials for use in orthopaedic applications [2]. One material in
particular was a biodegradable porous magnesium foam investigated by Aghion et al. as way to
carry and release drugs. The authors used a powdered form of a magnesium alloy to create the
magnesium foam. The level of porosity of the resultant foam was determined by the quantity
of spacer material (ammonium hydrogen carbonate with a diameter range of 50-200 µm) used
in the mixture. The final stage in the preparation of the magnesium foam was to evaporate the
spacer material using a high temperature. In the experiment, two mixtures were used which
contained 10% and 25% spacer material, which gave the magnesium foams an average pore
size of 40µm and 140µm respectively. The authors noted that the 25% spacer material mixture
produced a foam which contained many more interconnected pores than the 10% mixture, whose
interconnected pores were only close to the surface. This was recognised as a limiting factor in
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Figure 2.10: Osteoblast density after culturing for 1 and 2 days, following drug release
from anodised nanotubes. Abbreviations: U, unanodised Ti; A, anodised Ti; A+PS, an-
odised+penicillin/streptomycin physical adsorption; A+DEX, anodised+dexamethasone phys-
ical adsorption; ASH, anodised, heat-treated and SBF-soaked Ti; ASH+PS, as previous but
with penicillin/streptomycin; ASH+DEXA, as previous but with dexamethasone. Reproduced
from [19].
how much drug could be retained and then released by the 10% spacer material foam. The
antibiotic gentamicin was loaded into the magnesium foams by immersion in a concentrated
gentamicin solution and then evaporating the water, leaving behind solid gentamicin within the
foams.
The gentamicin-loaded foams were submerged in PBS solution and the concentration of
gentamicin was measured at various time points. The results showed that the foam made from
10% spacer material released gentamicin relatively quickly. This result is most likely due to the
lack of interconnected pores throughout this foam. In contrast, the 25% spacer foam, whose
interconnected pores were much greater in number and hence increased porosity, was able to
hold and release considerably more gentamicin (Figure 2.11(a)).
The result of the experiment demonstrated that the porosity of the magnesium foam can
be changed by using varying amounts of spacer material. The consequence of this being with
greater porosity comes a greater capacity for holding a drug. The authors noted that the degra-
dation rate of the magnesium foam increased with increasing spacer material content (Figure
2.11(b)). This was expected since the greater the amount of spacer material used, increased the
level of porosity and thus increased the surface area of the magnesium foam exposed to the PBS
solution [20]. However, the authors note that the time taken for a high spacer material foam to
degrade completely may limit the foam to applications where prolonged periods of time in the
healing process are absent [20].
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(a)
(b)
Figure 2.11: (a) Concentration profiles of gentamicin release from magnesium foams with 10%
and 25% spacer material. Reproduced from [20]. (b) Mass loss of magnesium foam in PBS
solution against spacer content. Reproduced from [20].
2.2 Mathematical methods
As has been demonstrated in the preceding section, there is much in the way of experimental
approaches that investigate the potential of drug release from OIs. However, it appears that
mathematical modelling of drug release from OIs specifically is non-existent. This is rather
odd considering the innumerable examples of mathematical modelling research which has been
conducted in other drug release applications. Such applications include the modelling of drug
release from particular implants, such as coronary stents, or from specific materials and struc-
tures, such as porous layers and nanotubes, some of which may be used in OI construction. It
is therefore possible that there is published modelling research that through modification could
find future use in the design of drug-releasing OIs. The literature suggests that the release of
drugs from OIs is increasing in acceptance as the future of orthopaedic medicine. Therefore, it
would be prudent to consider the research conducted on other types of implants. In the early
development of coronary stents, for example, a purely empirical method was used to inform
their design, specifically via a combination of in vitro tests and ex vivo/in vivo animal studies.
However, it came to be understood that the use of computational and mathematical modelling
could reduce the number of experiments needed and also potentially save on the cost and time re-
quirements of further experimentation [26, 27]. Moreover, mathematical modelling can provide
additional insights and understanding, which is not easily attainable from experiments alone.
It is wise to remember that a mathematical model and an experiment are approximation tools.
A model of drug release from an implant may fit experimental data very well and thus could be
considered sufficient. However, the release process may not be modelled fully, as it is usually
the case that simplifications are required. A predictive mathematical model can be a useful
tool for the enhancement of understanding of the whole release process. The confidence in
such a model can be increased through the variation of experimental conditions and comparing
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the data with the model prediction. With validation of the model, input parameters can be
varied and the release profiles compared, this can be done without the need to repeat similar
experiments [26, 28].
2.2.1 Drug release mechanisms
There is a necessary level of understanding of the mechanisms that can control drug release
before one can examine a system mathematically. This can be challenging since these are often
not known for a particular system a priori. However, through the comparison of experimental
data and the results of an initial model, one can determine if further mechanisms are required
or if current mechanisms are redundant. The release of drug from an implant can be the re-
sult of several mechanisms, for example, diffusion, dissolution, convection, erosion, swelling
and degradation and others. However, it is recognised that the reason for a particular drug re-
lease scenario is frequently due to a combination of different mechanisms [26, 27, 29]. There
is a level of ambiguity however, with the term “release mechanism” as noted by Fredenberg
et al. [30]. Depending on the context it could indicate the manner in which drug particles are
transported or alternatively, it could be a description of the processes that can affect the release
rate. Fredenberg et al. note that the release mechanisms involved with poly(lactic-co-glycolic
acid)-based (PLGA) implants are diffusion, erosion and osmotic pumping. The processes that
govern the release rate are believed to be initially diffusion-controlled, with erosion/degradation
in the subsequent stages [30]. The authors point out that additional knowledge is essential to
form a clearer understanding of the whole system, which will arise from insight into the funda-
mental processes which drive release mechanisms, for example, erosion, hydrolysis and water
absorption [30]. The authors continue by stating that in the case of PLGA-based implants, there
are four ways for the release of drug to occur: the erosion of the polymer; drug transport through
the polymer; drug transport through water within pores and; osmotic pumping [30]. It is from
an understanding of the mechanisms of drug release and the processes that govern them, that a
greater comprehension of drug delivery will arise, which in turn will inform the mathematical
modelling.
2.2.2 Some existing mathematical models describing release mechanisms
There exists a myriad of mathematical models that attempt to describe drug release mechanisms
in a wide array of applications. For example, McGinty and Pontrelli [31] created a general
model which coupled drug release and tissue absorption, which may have applicability in the
modelling of particular OIs.
The two regions in the idealised geometry of Figure 2.12 are denoted by a subscript 0 for the
drug-loaded polymer layer of thickness l0 and 1 for the tissue layer of thickness l1. This notation
is similarly applied to the variables and parameters used in the model. The two variables b and
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Figure 2.12: The geometry considered by McGinty and Pontrelli. Reproduced from [31].
c represent the bound and free drug respectively. The polymer layer parameters D0, β0 and S
denote the drug diffusion coefficient in the polymer, drug solubility and the drug dissolution
rate, respectively. The tissue layer parameters v1 and D1 signify the fluid velocity and diffusion
coefficients within the tissue, respectively. Additionally, kf1 , k
r
1 and bmax are the drug binding
and unbinding rates and the density of binding sites, respectively. The value of the parameter
α is within the range 0 ≤ α ≤ 1 and is dependent on the dissolution model considered. The
Noyes-Whitney approach to dissolution is the assumption that the dissolution rate is proportional
to the difference in the drug solubility and the drug concentration [32], which would correspond
to a linear dissolution equation with α = 0. A nonlinear dissolution model was also considered
in which α = 2/3. This nonlinear model was provided by Hixson and Crowell [33], who
considered how the changes to the surface of dissolving particles influenced the dissolution rate.
Later work by Frenning [34] considered this nonlinear dissolution model within the context of
drug delivery. McGinty and Pontrelli note that the value of α is likely subject to the chemical
properties and structure of the dissolving drug. How the drug is contained within the device and
the geometry of the device itself may also have a role in the influence of α. Therefore, there
are other possible values that α could take that are very much applicable. It is in light of this
that McGinty and Pontrelli additionally consider the case where α = 1 which gives the simplest
nonlinear coupling between the bound and free drug phases. The model is given by:
∂b0
∂t
= −β0bα0 (S − c0) , −l0 < x < 0, t > 0, (2.1)
∂c0
∂t
= D0
∂2c0
∂x2
+ β0b
α
0 (S − c0) , −l1 < x < 0, t > 0, (2.2)
∂b1
∂t
= kf1 c1 (bmax − b1)− kr1b1, 0 < x < l1, t > 0, (2.3)
∂c1
∂t
= D1
∂2c1
∂x2
− v1∂c1
∂x
− kf1 c1 (bmax − b1) + kr1b1, 0 < x < l1, t > 0, (2.4)
−D0∂c0
∂x
= −D1∂c1
∂x
+ vc1, −D1∂c1
∂x
= P (c0 − c1) , x = 0, t > 0, (2.5)
−D0∂c0
∂x
= γ0c0, x = −l0, t > 0, (2.6)
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−D1∂c1
∂x
+ v1c1 = γ1c1, x = l1, t > 0, (2.7)
c0 = 0, −l1 ≤ x ≤ 0, b0 = 0, 0 < x ≤ l1, t = 0, (2.8)
c1 = 0, −l1 < x ≤ 0, b1 = B, 0 < x ≤ l1, t = 0. (2.9)
The model is adaptable in that it permits the coupling of the diffusion and dissolution pro-
cesses in a polymer layer, with the latter depending on the solubility of the drug and the dis-
solution rate. There are some assumptions made in the generation of the model which include
the instantaneous wetting of the polymer and the idealised one-dimensional (1D) geometry. The
distinction of this model from others in the literature however, is the inclusion of drug trans-
port in tissue after release. Models which account for the biological impact on the release and
function of a drug are likely to be necessary when in vivo scenarios are to be modelled. Thus,
the generality of this model is what opens it to see use in a variety of cases where a mix of
diffusion, advection and drug binding are present. Arguably the main feature of the model is
the ability to consider a variety of binding mechanisms which may be a combination of lin-
ear/nonlinear, reversible/irreversible and saturable/non-saturable processes [31]. Therefore, the
binding processes of drugs released from OIs to tissue could be potentially studied with this
model. McGinty and Pontrelli also note that special cases of the model which could arise under
certain circumstances that allow one process to become more influential than any other. One
example given is the scenario in which the drug has a very low initial concentration and/or a
very high solubility. This would likely result in rapid drug dissolution, meaning that a model
centred on diffusion may be sufficient [31]. The authors also include a case study in which the
model is used to predict release of drug from a drug-eluting stent (DES). The predictions show
reasonable agreement with experimental data in Figure 2.13 [31].
Figure 2.13: Model and in vivo experimental data comparison of total mass of drug in tissue.
Plot points are normalised with respect to the mass of first experimental time point (day 1).
Reproduced from [31].
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An article by Lauzon et al. reviewed delivery systems of growth factors and presented sev-
eral existing mathematical “models” that have the potential to model growth factor release. The
models presented considered only the release of growth factors and not the transport and inter-
action with tissue. The transport mechanisms of the semi-empirical/empirical and mechanistic
models shown are diffusion, erosion and swelling. The authors note another mechanism which
involves the potential interaction between the delivery device and the drug, which are known as
“Affinity-based models” [35]. The models considered do have limitations in that they largely
centre on assumptions such as constant diffusivity and infinite sink boundary conditions. It is
also noted that some models do not include the influence of other processes which could affect
the release, such as consumption of the drug in the tissue. There is some caution to be taken
though as the tabulated presentation of the “models” by Lauzon et al. may suggest that a “pick
and mix" method to mathematical modelling is suitable and in such a case, one would select a
model based on the system under examination. This however, is not always appropriate: simply
picking from a list of models does not provide the necessary details of its applicability regard-
ing modelling assumptions, which will inform how the underlying equations are derived. One
major consequence is that all the models presented are in 1D, but one must understand if such a
simplification is justified as there are devices which cannot be reduced to such a simple geome-
try. Another part of the modelling process to consider is how the experiments were carried out,
for instance, was the release setup stirred? If not, then perhaps infinite sink conditions are not
suitable.
The authors do acknowledge that the presented models may not be suitable for modelling
the release of growth factors. One major consideration is that the size of a growth factor protein
relative to a drug particle may be much greater [36], which suggests that the size of molecules
may need to be accounted for in a model. Although flexible, mathematical modelling must be
applied with some foresight and knowledge of the phenomena that govern release. Additionally,
device geometry and experimental conditions must also be included in the modelling process.
There are general models in the literature however, this generality may only be applicable within
a set of precise circumstances. Suppose a model of a particular system has reliable predictive
abilities, then what is known about the validity of this model if for example there is a change
to device geometry of experimental procedure? One should certainly not assume that it is still
valid, in fact one may need to go back to the drawing board. Although the modelling process can
be meticulous at times, it does have its place in the understanding of drug delivery as a whole.
The examination of the fundamental processes in a mathematical way may provide insight as
to the processes that drive drug release. Some of these processes within a given system may be
more influential than others and so their identification is paramount when in quest of controlled
drug delivery from OIs. With background on the subject of release mechanisms, the following
sections highlight some other mathematical modelling research and what may be learned from
these works.
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2.2.3 Mathematical modelling of drug release from some potential OI ma-
terials
Tzur-Balter et al. studied the release of the anti-cancer drug Mitoxantrone (MTX) from meso-
porous silicon and mathematically modelled the release [37]. The experiment consisted of two
samples of the mesoporous silicon, one in an unaltered form (PSi) and the other altered chem-
ically with 1-dodecene (d-PSi). This chemical treatment is hydrosilylation, which generates
hydrogen bonding on the surface of the silicon, which results in a more stable silicon sam-
ple [38]. The silicon samples were then loaded with MTX and immersed in PBS solution, with
MTX release measured via media sampling and replacing the sample volume with fresh PBS
solution.
Figure 2.14: MTX release and silicon degradation plots. The left image is for the unaltered
silicone sample (PSi) and the right image is for the chemically altered silicon sample (d-PSi).
Reproduced from [37].
The experimental results (Figure 2.14) show that the d-Psi sample was able to extend the
release of MTX over a considerably longer period of time and resist erosion to a greater degree
when compared to the Psi sample. Based on these results, the authors hypothesised that the
release of MTX from the Psi sample was due to two mechanisms: the erosion of the sample and
diffusion of MTX [37]. Given that the d-Psi sample had not eroded nearly as much and that the
release was considerably slower, the authors suggested that the release of MTX was governed
mainly by diffusion [37].
The mathematical modelling portion of the work by Tzur-Balter et al. used a fairly sim-
ple model which combined the diffusion of MTX and the erosion of the silicon samples. The
modelling consisted of a 1D domain of length L (0 ≤ z ≤ L), a zero-flux condition at z = 0,
an infinite sink condition at z = L and initial concentration C0 (Figure 2.15). Based on Fick’s
second law, the authors used Crank’s known classical solution [39], which was altered to include
the effects of the erosion of the silicon samples:
q(t) = 1− m(t)
m0
= 1− 8
pi2
∞∑
n=0
(2n+ 1)−2 exp
[(
−2n+ 1
2L
)2 ∫ t
0
σ(t)dt
]
, (2.10)
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Figure 2.15: Image showing an idealised porous section of a silicon sample and where the
boundary conditions are applied, along with the initial condition. Reproduced from [37].
where the cumulative fraction of drug released is given by q, m(t) is the mass of MTX in the
domain at time t and m0 is the initial mass of MTX. The authors assumed that the influence of
erosion of the silicon sample would only affect diffusivity, therefore the drug release equation
was altered to reflect this. This time-dependent diffusivity of MTX, as a result of erosion, is
represented by σ(t), which includes one of two polynomial functions, f2(x) or g2(x), where
x = Ds/Dp, which is the ratio of the hydrodynamic diameter of the solute and the average
pore diameter [37]. Therefore, x is a measure of the level of accessibility of the pores to the
solute. Function f2(x) accounts for the hampered Brownian motion of the solute inside the
pores, however, the authors note this function does not account for pore wall-solvent-solute
interactions, solute polydispersity or pore shape. Additionally, f2(x) does not account for the
increase in Silicon concentration due to the degradation of the pores and its potential interaction
with the solute and solvent. To address this, the authors adopted another function g2(x), which
accounted for all of these processes [37].
Figure 2.16: Image showing the comparison of predicted MTX release from the model of Tzur-
Balter et al. (g2(x)), a model which does not consider the influence of erosion (f2(x)) and the
unaltered Crank solution. Plotted alongside the model predictions is the experimental data from
both mesoporous silicon samples. Reproduced from [37].
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The model using g2(x) was able to fit the experimental results well and to further its validity,
release profiles from the unaltered Crank solution and a similar model which utilised f2(x)
were compared (Figure 2.16). The two models for comparison did not fit the data well, with
both overestimating the release in the early stages and underestimating in the later stages. To
showcase the adaptability of the model, the authors fit the model to experimental data from
the work of Anglin et al. [40], which focussed on the release of dexamethasone from dodecyl
modified porous silicon. The model involving g2(x) is a relatively good fit to the data when
compared to the original Crank solution and the model with function f2(x) (Figure 2.17). Tzur-
Balter et al. do note that if there had also been data on the mass change of the silicon during
degradation, then their model would be a considerably better fit [37].
Figure 2.17: Plot showing the predicted release of Dexamethasone by the model of Tzur-Balter
et al. (g2(x)), the model which ignores the influence of erosion (f2(x)) and the unaltered Crank
solution. The experimental data obtained by Anglin et al. [40] is plotted alongside the predic-
tions. Reproduced from [37].
Kumeria et al. investigated Indomethacin release from nanoporous anodic alumina (NAA)
(Figure 2.18(a)) whilst under dynamic flow conditions (Figure 2.18(b)) [15]. Aluminium foils
were prepared such that a self-ordered, nanoporous structure was produced on their surface,
with a pore diameter and depth of 30-35nm and 4.5-5µm respectively [15].The authors loaded
the NAA samples with Indomethacin in three ways: firstly, the drug was loaded into the pores
and adhered to the surface, secondly, the drug was loaded only into the pores and lastly, the drug
was adhered the surface only [15]. The prepared samples were then immersed in PBS solution
and subjected to a variety of flow speeds, which were 0, 10, 30 and 50 µL/min. The authors used
reflectometric interference spectroscopy to measure the in-situ release of Indomethacin from the
NAA samples via a change in effective optical thickness [15]. The authors note that the con-
ventional approach to evaluating drug release, being batch observation under static conditions,
does not include the dynamic in vivo effects on the release [15]. The inspiration to include flow
conditions arises from the fact that whilst under static conditions, the release media is constantly
receiving drug. This could eventually lead to the saturation of the release medium and from that
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a reduction in the concentration gradient, which will have an impact on the release rate. This
effect could potentially give rise to inaccurate results, therefore, it was seen as a more accurate
approach and more akin to the in vivo scenario, to examine drug release in-situ, under flow
conditions.
(a) (b)
Figure 2.18: (a) Scanning electron microscope image of the top of a of prepared NAA sample
showing the top of the nanoporous surface. Adapted from [15]. (b) Illustration of drug release
phases from nanoporous alumina under dynamic flow. Reproduced from [15].
The results were compared to drug release data under static conditions and theoretical data
via a modified Higuchi equation to ascertain the foremost mechanism of release [15]. The
release results from the static conditions show a burst release from the NAA samples, with ap-
proximately 75% of the Indomethacin being released in the first 100 minutes (Figure 2.21(a)).
During the subsequent 4 days the release is then steady until complete (Figure 2.21(b)). The
Higuchi equation is based on Fick’s second law and is used to model drug release from insol-
uble matrices [15]. It includes the assumptions of infinite sink conditions and an initial drug
concentration which is much greater than the solubility of the drug. This equation is able to
describe the diffusion governed release of water-soluble and poorly water-soluble drugs from
non-degradable porous devices [15]. The modified Higuchi equation used by Kumeria et al.
was:
m(t)
M
= at1/2 + b⇒ dm(t)
dt
= kt−1/2, (2.11)
where a and b are fitting parameters, M is the initial mass of drug and k is Ma/2. Fitting
parameter b was an addition to the standard Higuchi equation to capture the effects of fluid flow
on the release of Indomethacin. However, this only has the effect of shifting the curve up and
down the y-axis in a plot. Therefore, the addition of parameter b is not likely to adequately
capture the influence the flow has on the release.
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Flow Rate (µL/min) k (µg/min1/2) Coefficient of Determination (R2)
0 3.02± 0.02 0.95
10 2.23± 0.02 0.95
30 2.80± 0.06 0.99
50 12.47± 0.04 0.96
Table 2.1: Table showing the rate constants k obtained via the fitting of the modified Higuchi
equation [15]
The authors confirmed that the release of Indomethacin was inversely proportional to the
square root of time, this fact is obtained from the Higuchi equation directly. Through the fitting
of the model to the release results, the authors were able to determine the release rates of In-
domethacin from the NAA samples. Kumeria et al. noted that the flow rates 10 and 30 µL/min
gave rise to release rates that were comparable to the release rate obtained from static conditions.
In contrast to the lower flow rates, the flow rate of 50 µL/min, the release rate was approximately
4 times the release rate under static conditions. The results established that the release rate of In-
domethacin was increased when faster fluid flow was introduced. Through a combination of the
experimental results and the simple mathematical model, the authors concluded that fluid flow
can have a significant influence on the release rate of a drug [15]. The model fitting produced
high coefficients of determination, which validated that the release was dependent on the square
root of time, an important attribute of diffusion [15].
2.2.4 Mathematical modelling of drug release from porous structures
McGinty et al. produced a mathematical model to predict drug release from nanoporous ma-
terials, with special cases of drug release from smooth surface and nanotubular systems [41].
Although the focus of their work was on polymer-free DES, the authors note that the model
could in principle be applied to general drug-releasing implants with a nanoporous structure.
The model assumes that the drug must dissolve on a moving boundary before diffusive transport
through the water-filled pores and the release medium can occur (Figure 2.19). Also considered
is the possibility that drug particles may adhere to the walls of the pores, to account for this a
linear reversible reaction component is used in the model. A variety of scenarios are considered
and the model is derived based on the assumption that the release medium is unstirred.
The concentrations of the drug in water, within the pores and adhered to the pore walls are de-
noted by cw, cp and cb respectively. Dw, Da and De are the free, apparent and effective diffusion
coefficients respectively, cs is the drug solubility, K is the dissociation constant. Parameters φ
and φb represent the overall porosity and the volume fraction of the pores in which drug particles
could adhere to the pore walls, Ld is the initial thickness of the layer of drug within the porous
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Figure 2.19: Figure showing an example geometry considered by the authors with a bulk
nanoporous layer and coated with a pure drug layer. The release medium is assumed to be
semi-infinite. Reproduced from [41].
region and c0 denotes the initial drug concentration. The location of the moving boundary s(t)
is governed by an appropriate Stefan condition. With the equilibrium assumption (adsorption
and desorption rates are much quicker than the diffusivity), the model is:
∂cw
∂t
= Dw
∂2cw
∂x2
, 0 < x <∞, t > 0, (2.12)
∂cp
∂t
= Da
∂2cp
∂x2
, cb =
φcp
φbK
, s(t) < x < 0, t > 0, (2.13)
cp = cw, −De∂cp
∂x
= −Dw ∂cw
∂x
on x = 0, t > 0, (2.14)
cp = cs, −Da∂cp
∂x
=
ds
dt
on x = s(t), t > 0, (2.15)
cw → 0 as x→∞, t > 0, cw = 0 at t = 0, x > 0, (2.16)
cp = c0 at t = 0, −Ld < x < 0, s(t = 0) = 0. (2.17)
The diffusion coefficient associated with this equation was known as the apparent diffusion
coefficient due to the many effects the parameter accounted for. These effects included adsorp-
tion, desorption, porosity, tortuosity and constrictivity [41]. The well-posed moving boundary
problem was solved analytically using the self-similarity method by way of the Boltzmann vari-
able x/
√
t. The ability to obtain an analytical solution provides the advantage of being able to
compute the release profile directly. The solutions to the model (2.12-2.17) are:
cw(x, t) =
cs erfc
(
x
2
√
Dwt
)
1−
√
DaDw
De
erf
(
− θ
2
√
Da
) , 0 < x <∞, t > 0, (2.18)
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cp(x, t) =
cs
(
1−
√
DaDw
De
erf
(
x
2
√
Dat
))
1−
√
DaDw
De
erf
(
− θ
2
√
Da
) , 0 < x <∞, t > 0, (2.19)
where θ is determined by solving:
θ
2
√
Da
exp
(
θ2
4Da
)(
1−
√
DaDw
De
erf
(
− θ
2
√
Da
))
=
1√
pi
√
DaDw
De
cs
c0 − cs . (2.20)
The other cases considered are accounted for by altering the model slightly, such as choosing
particular values for some parameters. These cases include modelling release from a nanotubular
system, release from a smooth surface system in which pure drug is directly coated to a DES
and the case where the drug solubility is very low relative to the initial concentration (cs  c0).
Lastly, as part of the unstirred set of cases, a two-stage release is considered, in which drug a
pure drug layer is released from the DES surface and then further release of drug stored in the
nanoporous structure. The authors also consider cases in which the release medium is stirred
including release from a nanoporous DES and release from a pure drug layer like in the unstirred
case [41]. Key system parameters which have a governing influence on the release are identified
through a sensitivity analysis. Device design suggestions are provided by the authors such that a
required release profile may be generated that is appropriate for a specific application. Through
mathematical analysis of the underlying equations, the authors demonstrated that the rate of
drug dissolution in the stirred case was an order of magnitude quicker than in the unstirred case.
2.2.5 Mathematical modelling of drug release from stents and lessons to
be learned
One area which has received much mathematical modelling attention is in the understanding
of drug release from coronary stents and the mechanisms that drive it. Through a multidisci-
plinary approach, the modelling of stents has been used in conjunction with experimentation to
model drug release from a variety of stents and help determine the governing release mecha-
nisms [28]. A review article by McGinty [28] categorised modelling research into three groups,
those of: drug release from durable and biodegradable polymer coatings; uptake of drug into ar-
terial tissues through the use of diffusion-convection-reaction equations and; the coupling of the
release of drug and tissue absorption. The models range from simple 1D single layer convection-
diffusion systems to multi-layered 3D systems which include the effects of nonlinear saturable
binding, anisotropy and coupling with blood flow. The model outputs include analytical and
numerical solutions. The review by McGinty emphasises that for mathematical modelling to
give the greatest benefit, the model must reflect the experimental conditions which produced the
raw data. The author also notes the importance for mathematical modelling to run simultane-
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ously with experimentation and the accuracy of which are only as good as the accuracy of the
experimental inputs. This is especially the case when the model output is particularly sensitive
to variation one or more parameters.
For instance, Sirianni et al. modelled the release of drug from a commercially available
stent and noted that models based on diffusion, dissolution and osmotic gradients were able to
achieve a good fit with their experimental data [42]. The agreeable fit to the experimental data
was possible through the variation of the model parameters, although some parameter values
were unrealistic [42]. This example serves to underline the necessary care required when deriv-
ing a mathematical model for a given system and its output interpretation, this is particularly the
case if many system parameters have been inversely estimated. Although a model may fit exper-
imental data well with a particular set of parameters, the addition of other parameters to account
for other processes will reduce the confidence in the model [42]. One alternative is through
the use of a simpler semi-empirical model such as the Peppas equation [43], which utilises a
small number of nonphysical parameters. However, a mechanistic model has the advantage over
semi-empirical models in that its parameters are physically relevant and may, in principle, be
experimentally determined. With accurate parameters and experimental validation, the confi-
dence increase in the predictive capabilities of a mechanistic model outweigh the benefits of
other modelling approaches. When considering drug release mechanisms and likely coatings,
stents are similar to OIs, however, the environments where they are used are very different. For
instance, coronary stents will experience pulsatile blood flow which is a stark contrast to what
an OI must undergo, such as greater mechanical loading. However, the differences in the biolog-
ical setting between these devices does not impede the use of mathematical modelling. On the
contrary, mathematical modelling has been employed in various applications, each presenting
different biological environment challenges. For example, ocular drug delivery [44], such as
therapeutic eye drops, results in the drug experiencing fluid flow in the form of the lacrimal fluid
of the eye; tablets may be used to deliver a drug [45] and so the drug is immersed in gastric fluid
and surrounded by the gastro-intestinal tract and; in transdermal drug delivery, such as patches,
the drug must pass through a relatively tough barrier, the stratum corneum, before it is able to
reach the capillary beds.
Despite the bioenvironmental challenges, mathematical modelling has been a useful tool in
the prediction of drug release and in the optimising of device design. However, it is often the
case that due to the time and cost constraints associated with in vivo experimentation, experi-
mentalists and device manufacturers regularly examine drug release in an in vitro environment.
Irrespective of the bioenvironment destined for the device, such in vitro experiments are usually
conducted under static or agitated release mediums. Although such conditions are not necessar-
ily able to imitate the in vivo case accurately, they are able to produce a useful release profile,
which may be compared with the results of other device designs. Additionally, the in vitro case
allows one to test the repeatability of the release profile relatively easily compared to the in vivo
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case. Also, when in vitro experimentation is compared with a suitable mathematical model, in-
sight may be obtained as to what the mechanisms of release are and the relative importance of
each. Therefore, the lack of in vivo experimentation need not hamper the research effort. The
mathematical approaches which can simulate drug release under static or agitated conditions
can form an additional layer of assistance when attempting to characterise drug release and the
mechanisms involved. It must be stressed however, that the potential influence of the bioenvi-
ronment on the release can be important, more so if the intention is the comparison with in vivo
data. Bozsak et al., for instance, coupled blood flow and the binding of drug in tissue to their
model of drug release from stents [46]. From their work, the authors acknowledge that to be able
to fully optimise stent design, then such a comprehensive model is necessary. As it stands, the
literature highlights the benefits and challenges of OIs, however, they are far from insurmount-
able. The release of drug from coronary stents was studied thoroughly through a combination
of experimentation and mathematical modelling which yielded positive results. It is for these
reasons that orthopaedic devices should receive the mathematical modelling treatment to aid in
the prediction of drug release and assist in implant design.
2.3 Summary and thesis outline
This chapter clearly highlights the significant level of activity within the experimental research
community to investigate ways of incorporating drugs within OIs. It further highlights the lack
of mathematical modelling of drug release from OIs whilst showcasing several existing mathe-
matical models from other applications that may prove a useful starting point for modelling in
this new area. Whilst the experimental approaches do vary considerably, a number of common
themes emerge:
1. The use of porosity to control drug release [11, 13, 19, 20];
2. The influence of the particular experimental conditions on drug release [10,12,19–21,23,
24];
3. Using antibiotic release as a means of combating infection [10–13, 19–21, 23, 24].
The remainder of this thesis is dedicated to exploring these issues through mathematical
modelling. In chapter 3, the extent to which drug release can be controlled by varying the poros-
ity of a material is explored through a relatively simple two-layer diffusion model. Chapter 4
considers the porous pin by Gimeno et al. [11] and provides a model to describe dissolution and
subsequent drug release under a variety of experimental conditions, making use of analytical
and numerical solutions and spanning 1D-3D models. In chapter 5, drug release from the pin
featuring different numbers of orifices by Gimeno et al. [12] is modelled. Particular attention
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is paid to demonstrating that a 3D model is required and on the influence of the stirring ex-
perimental conditions on drug release from the pin. In chapter 6, a simple model of bacterial
colonisation is presented, including an exploration of how drug release from the afore-modelled
OIs (chapters 4-5) influence infection dynamics. Finally, in chapter 7, the results of the research
are summarised, along with some suggestions for future work.
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Chapter 3
Modelling of drug release from variable
porosity systems
In chapter 2, many examples of experimental approaches to containing and controlling release
of drugs from OIs were highlighted. A common theme was the use of porosity to control the
release of a drug and much of the experimental research was focussed on the containment,
transport through and release of drug from a single porous coating (layer). In this chapter,
through the development of a relatively simple mathematical model, the extent to which porosity,
and specifically variable porosity, can assist in the control of the release of drug from an OI is
investigated.
There are two important components to a porous medium that can influence how a drug parti-
cle moves through it: the level of porosity and the tortuosity. The porosity of a porous medium is
the ratio of the volume of void spaces within the medium to the total volume of the medium [47].
The tortuosity of a porous medium is a measure of how circuitous the pores of the medium are,
which may result in longer diffusion distances for a drug particle [48]. It is evident that the
movement of drug particles in a porous medium will be influenced by the relative thickness of
each layer, the initial drug distribution throughout the layers and the relative levels of porosity.
By generating release profiles based on a mathematical model, one can assess the impact of
varying design parameters such as coating porosity; how the drug is loaded and its distribution;
the physicochemical properties of the drug and; the type of release medium. Here, a two-layered
structure is considered over a single layer and the basic question of what effect the contrast in
microstructural properties (porosity, tortuosity) across the layers has on the drug release process
is examined. The key difference between the layers is their respective effective diffusivities,
although in principle, their thickness and initial drug loading could also be different. Through
analysis of an appropriate mathematical model of the drug release process, it may be possible to
determine the benefits of substituting single-layer porous coatings with two-layer or multi-layer
coatings and, perhaps most usefully, determine the microstructural properties of corresponding
layers so that a pre-defined drug release profile is obtained. Multi-layer systems are also worth
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investigating since in principle, the porosity can be spatially varying and the simplest way to
account for this is to add layers.
It is important to examine how porosity and tortuosity are accounted for when investigating
mass transport through a porous medium. Consider a representative elementary volume of a
porous medium, with porosity, φ, and tortuosity, τ . Within the medium there is a smaller,
effective diffusion coefficient, De, due to a smaller cross-sectional area for diffusion, relative to
a free-fluid phase. Suppose there are two pores, A and B, which span the medium (Figure 3.1).
Particles that move along pore A must travel a longer diffusive distance than particles travelling
through pore B.
Figure 3.1: Illustration showing a tortuous pore (A) and a linear pore (B) in a porous medium in
which drug particles (red dots) must travel.
This results in the apparent concentration gradient being less than the free concentration
gradient. This effect can be accounted for most simply through an adjustment to Fick’s first
law [48, p. 191] [49, 50]:
J = −De∇cV = −φ
τ
D∇cV , (3.1)
where D is the free-diffusion coefficient and cV is the volume-averaged concentration. This
measure of the flux and concentration gradient are with respect to the overall physical dimen-
sions of the porous media, not just the void spaces where diffusion may occur. Therefore, rather
than a volume-averaged concentration over the entire porous media, an intrinsic concentration,
c, is used, which accounts for the concentration of drug solely within the voids of the porous
medium. This intrinsic concentration is defined to be the ratio of the mass of drug within the
voids and the volume of the voids accessible to the drug particles. This alternative definition of
concentration may be achieved through the multiplication of the time derivative of concentration
with φ in the diffusion equation:
φ
∂c
∂t
= De∇2c. (3.2)
It should be noted that equations (3.1-3.2) are a simplification that assumes the porous media
is homogeneous and the impact of the media’s porosity and tortuosity on drug transport through
the media is a change to the drug’s free-diffusion coefficient. Although equation (3.2) is a
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simplified model of drug transport through porous media, it has formed the basis of scientific
research in a number of applications, including catalytic reactors and porous electrode theory
[51] [52, p. 104]. It is likely that the level of porosity and the tortuosity are linked in some
way and this may be accounted for through the use of the Millington and Quirk or Bruggeman
relations, for example, which are defined as τ = φ−1/3 and τ = φ−1/2, respectively [53, 54].
There also exists stochastic approaches to modelling diffusion through porous media, such as
random walk models [50]. However, research into diffusive transport through porous media is
a large field of interest in its own right, with many of the modelling approaches depending on
the scale of the pores. If, for example, the pores of a porous media are on the nanoscale, then
it is likely that a transport model would involve Knudsen diffusion. For the work in this thesis,
it is assumed that the overall effect of porosity on drug transport may be accounted for through
equation (3.2).
(a)
(b)
Figure 3.2: (a) Example of two adjacent polymer coatings with different microstructural prop-
erties that could be used as a method of controlling release of drug through layering of the
polymers. Adapted from [55]. (b) Idealised 1D geometry comprised of two porous layers, of
differing thickness, for drug release into a release medium. Positions x = −L1 and x = −L2
denote the leftmost and rightmost boundaries of the layers and x = 0 marks the position of the
interface between the layers. Figure not to scale. Adapted from [56]
3.1 Mathematical formulation
A 1D model is developed to answer the basic question: to what extent can variable porosity con-
trol the release of a drug? Among the many benefits of a 1D model is the possibility of obtaining
an analytical solution. Based upon realistic porous structures (Figure 3.2(a)), a simplified two-
layer counterpart can be created (Figure 3.2(b)). The two layers have thicknesses L1 and L2,
with porosities φ1 and φ2, respectively, and for later convenience, define L = L1 + L2. Let the
intrinsic drug concentrations in layers 1 and 2 be denoted by c1(x, t) and c2(x, t), respectively.
Variables x and t denote space and time, respectively. Since it is assumed that diffusion is the
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governing transport mechanism, the effective diffusion coefficients associated with concentra-
tions c1 and c2 are De1 and D
e
2, respectively. These effective diffusion coefficients are defined
as De1 = φ
e
1D
w/τ1 and De2 = φ
e
2D
w/τ2, where Dw is the free diffusion coefficient of the drug
in water and τ1 and τ2 are the tortuosities of each layer, which are a measure of the meander-
ing structure of the pores [48]. Parameters φe1 and φ
e
2 are the effective porosities of each layer
through which drug transport may occur. These parameters may in fact be less than the overall
porosities φ1 and φ2, which are the ratios of void volume to the physical volume [48], due to the
presence of inaccessible voids within the porous structure of the two layers. With the assump-
tions that the polymer coating is quickly wetted and the drugs are readily soluble, the model for
diffusion in a two-layer porous (composite) media is:
φ1
∂c1
∂t
= De1
∂2c1
∂x2
, −L1 < x < 0, t > 0, (3.3)
φ2
∂c2
∂t
= De2
∂2c2
∂x2
, 0 < x < L2, t > 0, (3.4)
−De1
∂c1
∂x
= K1c1, x = −L1, t > 0, (3.5)
−De1
∂c1
∂x
= P (c1 − c2), −De1
∂c1
∂x
= −De2
∂c2
∂x
, x = 0, t > 0, (3.6)
−De2
∂c2
∂x
= K2c2, x = L2, t > 0, (3.7)
c1 = c
0
1, −L1 ≤ x ≤ 0, c2 = c02, 0 < x ≤ L2, t = 0. (3.8)
For generality, the boundary conditions employed at either end of the domain are presented
as a mixed-type (3.5 and 3.7), in which inputs K1 and K2 may be derived from experimentally
measured flux. The generalisation of these conditions permits the use of extreme boundary
conditions, specifically zero-flux and infinite sink conditions, which can be achieved through
specific choices for the values of K1 and K2. The zero-flux boundary condition in the context of
an experiment means that a particle cannot pass through a solid structure, such as a stainless-steel
outer wall of an implant. With reference to experimental conditions, the infinite sink condition
is placed at the boundary where a drug particle is released into the surrounding medium where
it is assumed that the drug concentration cannot build up and reduce the concentration gradient.
In practice this is achieved either through the use of a large volume of release medium, with
or without stirring, or by replenishing the media at regular intervals. Continuity of flux (3.6)
is applied to the interface between the two layers. The remaining boundary condition required
to close the system is expressed in terms of flux and is able to account for imperfect contact
between the two porous layers or partitioning of the drug via a mass transfer coefficient P .
Initial drug concentrations in the two layers are defined to be the constants c01 and c
0
2.
A specific case is considered in which some of these boundary conditions are less general but
nonetheless applicable, these are zero-flux, infinite sink and continuity of concentration bound-
ary conditions. The full solution to the general model is presented in Section 3.2.5. Equation
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(3.5) permits the possibility that drug may enter the domain at x = −L1, for a zero-flux condi-
tion, simply let K1 = 0, giving:
−De1
∂c1
∂x
= 0, x = −L1, t > 0. (3.9)
Equation (3.7) describes the flux of drug leaving the porous medium, to obtain the infinite sink
condition, take the limit as K2 →∞:
c2 = 0, x = L2, t > 0. (3.10)
In the specific case, at the interface it is assumed that the porous layers are in perfect contact
and the drug does not partition, to account for this, continuity of concentration at the interface
is applied. Taking the limit as P →∞, the simplified interface conditions are:
c1 = c2, −De1
∂c1
∂x
= −De2
∂c2
∂x
, x = 0, t > 0. (3.11)
With the simplified boundary conditions obtained (3.9-3.11), the new model is:
φ1
∂c1
∂t
= De1
∂2c1
∂x2
, −L1 < x < 0, t > 0, (3.12)
φ2
∂c2
∂t
= De2
∂2c2
∂x2
, 0 < x < L2, t > 0, (3.13)
−De1
∂c1
∂x
= 0, x = −L1, t > 0, (3.14)
c1 = c2, −De1
∂c1
∂x
= −De2
∂c2
∂x
, x = 0, t > 0, (3.15)
c2 = 0, x = L2, t > 0, (3.16)
c1 = c
0
1, −L1 ≤ x ≤ 0, c2 = c02, 0 < x ≤ L2, t = 0. (3.17)
The simplified model given by (3.12)-(3.17) may be nondimensionalised using the following
relations:
c ′1 =
c1
c01
, c ′2 =
c2
c01
, x ′ =
x
L
, t ′ =
De1t
φ1L2
.
Dropping the primes for clarity and defining δ = L1/L, χ = De2/D
e
1, φ = φ2/φ1, C
0 = c02/c
0
1
and simplifying with χ¯ = χ/φ and δ¯ = 1 − δ gives the nondimensional model of diffusive
transport through composite porous media:
∂c1
∂t
=
∂2c1
∂x2
, −δ < x < 0, t > 0, (3.18)
∂c2
∂t
= χ¯
∂2c2
∂x2
, 0 < x < δ¯, t > 0, (3.19)
∂c1
∂x
= 0, x = −δ, t > 0, (3.20)
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c1 = c2,
∂c1
∂x
= χ
∂c2
∂x
, x = 0, t > 0, (3.21)
c2 = 0, x = δ¯, t > 0, (3.22)
c1 = 1, −δ ≤ x ≤ 0, c2 = C0, 0 < x ≤ δ¯, t = 0. (3.23)
3.2 Solution procedure
The model (3.18-3.23) is solved via the Laplace Transform (LT) which has the following defini-
tion [57]:
Definition 1 Let f(t) be a function of t specified for t > 0. Then the Laplace transform of f(t),
denoted by L[f(t)], is defined by:
L[f(t)] = f(s) =
∫ ∞
0
e−stf(t)dt.
It is assumed that f(t) is defined for all t ∈ (0,∞), s is real and that the integral is convergent.
A necessary condition for convergence [58] is when s > α, where α is a constant and f(t)
satisfies:
|f(t)| = O (eαt) as t→∞.
The LT of numerous functions and derivatives are standard results and are available in many
books, such as [57, 59]. The transformed solutions will be denoted by an overbar (e.g. c¯(x, s)).
Taking the LT of (3.18) and solving the resulting ordinary differential equation (ODE), subject
to (3.20), gives:
c¯1(x, s) = B(s)
[
cosh(
√
s(x+ δ))
sinh(
√
sδ)
]
+
1
s
.
Similarly, the LT of (3.19) and solving the resulting ODE, subject to (3.22), gives:
c¯2(x, s) = D(s)

sinh
(√
s
χ¯
(x− δ¯)
)
cosh
(√
s
χ¯
δ¯
)
+ C0s

cosh
(√
s
χ¯
δ¯
)
− cosh
(√
s
χ¯
x
)
cosh
(√
s
χ¯
δ¯
)
 .
The interface conditions (3.21) can now be applied to obtain the relationship between B(s) and
D(s). Starting with continuity of concentration:
B(s) =
D(s)

− sinh
(√
s
χ¯
δ¯
)
cosh
(√
s
χ¯
δ¯
)
+ C0s

cosh
(√
s
χ¯
δ¯
)
− 1
cosh
(√
s
χ¯
δ¯
)
− 1s
 sinh(
√
sδ)
cosh(
√
sδ)
. (3.24)
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Taking the LT of the equation for continuity of flux results in the simple relation:
B(s) =
√
χφD(s). (3.25)
With the relationship between B(s) and D(s) found, equations (3.24) and (3.25) can be com-
bined to obtain explicit expressions for B(s) and D(s):
B(s) =
√
χφ sinh(
√
sδ)
(
cosh
(√
s
χ¯
δ¯
)
(C0 − 1)− C0
)
s
(√
χφ cosh
(√
s
χ¯
δ¯
)
cosh(
√
sδ) + sinh
(√
s
χ¯
δ¯
)
sinh(
√
sδ)
) , (3.26)
D(s) =
sinh(
√
sδ)
(
cosh
(√
s
χ¯
δ¯
)
(C0 − 1)− C0
)
s
(√
χφ cosh
(√
s
χ¯
δ¯
)
cosh(
√
sδ) + sinh
(√
s
χ¯
δ¯
)
sinh(
√
sδ)
) . (3.27)
With expressions (3.26) and (3.27), explicit forms of the transformed equations c¯1(x, s) and
c¯2(x, s) can be obtained:
c¯1(x, s) =
√
χφ cosh (
√
s(x+ δ))
(
cosh
(√
s
χ¯
δ¯
)
(C0 − 1)− C0
)
s
(√
χφ cosh
(√
s
χ¯
δ¯
)
cosh(
√
sδ) + sinh
(√
s
χ¯
δ¯
)
sinh(
√
sδ)
) + 1
s
, (3.28)
c¯2(x, s) =
sinh
(√
s
χ¯
(x− δ¯)
)
sinh(
√
sδ)
(
cosh
(√
s
χ¯
δ¯
)
(C0 − 1)− C0
)
s cosh
(√
s
χ¯
δ¯
)(√
χφ cosh
(√
s
χ¯
δ¯
)
cosh(
√
sδ) + sinh
(√
s
χ¯
δ¯
)
sinh(
√
sδ)
)
−
C0 cosh
(√
s
χ¯
x
)
s cosh
(√
s
χ¯
δ¯
) + C0
s
. (3.29)
It is a fairly trivial task to apply LTs to a mathematical model to obtain the transformed
solution. However, inversion of the transformed solutions c¯1(x, s) and c¯2(x, s) back to functions
of the original variables requires considerably more effort. The inversion process may be carried
out through the use of the following two theorems [57, 58]:
Theorem 1 (The Complex Inversion Formula) If f(s) = L[f(t)], then L−1[f(s)] is given by:
L−1[f(s)] = f(t) = 1
2pii
∫ γ+i∞
γ−i∞
estf(s)ds, t > 0, (3.30)
and f(t) = 0 for t < 0.
36
Theorem 2 (Uniqueness theorem) If
f(s) =
∫ ∞
0
e−stf(t)dt, s > α, (3.31)
is satisfied by a continuous function f(t), there is no other continuous function which satisfies
equation (3.31).
Theorems 1 and 2 provide a direct approach to obtain the unique inverse LT for a given function
f(s). The integral in (3.30) is performed along the line s = γ in the complex plane, where
s = x + iy (Figure 3.3). The real number γ is chosen such that s = γ lies to the right of
all singularities of f(s), be they poles, branch points or essential singularities. In practice, the
integral in (3.30) is evaluated using the contour integral:
1
2pii
∮
C
estf(s)dt,
Figure 3.3: A Bromwich contour, C.
where C is the contour shown in Figure 3.3, which is composed of the arc BDEFA (Γ) of a
circle of radius R, centred at O and the line segment AB. By subtracting the integral along the
circle arc Γ from the closed contour integral along C, then (3.30) may be evaluated:
f(t) = lim
R→∞
1
2pii
∫ γ+i∞
γ−i∞
estf(s)ds = lim
R→∞
1
2pii
[∮
C
estf(s)ds−
∫
Γ
estf(s)ds
]
, (3.32)
since T =
√
R2 − γ2, as R → ∞ then T → ∞. For (3.32) to be valid, then the integral along
Γ must approach zero as R → ∞. A sufficient condition for this to be true is the following
theorem [57]:
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Theorem 3 If constants M > 0 and k > 0 can be found such that on Γ,
|f(s)| < M
Rk
, then lim
R→∞
∫
Γ
estf(s)ds = 0.
The remaining contour integral may then be evaluated using the following theorem [58]:
Theorem 4 (The Residue Theorem) Let C be a positively orientated simple closed contour in
the complex plane and let f be a function defined on C, except for some points a1, a2...ak inside
C, then: ∮
C
estf(s)ds = 2pii
k∑
k=1
Res(estf(s), ak).
For a pole ak of order n, then [60]:
Res(estf(s), ak) =
1
(n− 1)! lims→ak
[
dn−1
dsn−1
((s− ak)nestf(s))
]
. (3.33)
Theorem 4 and (3.33) may now be used on the transformed solutions (3.28) and (3.29).
Starting with (3.28), s = 0 is a simple pole of order one and has a residue of−1. The inverse LT
of 1/s has the standard result of 1 and this will cancel with the residue of s = 0, leaving only
the case where an infinite number of simple poles exists at s = sn, which are the roots of the
transcendental equation:(√
χφ cosh
(√
s
χ¯
δ¯
)
cosh
(√
sδ
)
+ sinh
(√
s
χ¯
δ¯
)
sinh
(√
sδ
))
= 0. (3.34)
The residue at s = sn is given by:
lim
s→sn
[
c¯1(x, s)(s− sn)est
]
= lim
s→sn

√
χφ cosh (
√
s(x+ δ))
(
cosh
(√
s
χ¯
δ¯
)
(C0 − 1)− C0
)
est
s

× lim
s→sn
 s− sn√
χφ cosh
(√
s
χ¯
δ¯
)
cosh(
√
sδ) + sinh
(√
s
χ¯
δ¯
)
sinh(
√
sδ)
 .
The second limit of the above expression has an indeterminant form. However, using L’Hôpital’s
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rule, the limit can be obtained:
lim
s→sn
 s− sn√
χφ cosh
(√
s
χ¯
δ¯
)
cosh(
√
sδ) + sinh
(√
s
χ¯
δ¯
)
sinh(
√
sδ)
 ,
= lim
s→sn

δ
2
√
s
[√
χφ sinh
(√
sδ
)
cosh
(√
s
χ¯
δ¯
)
+ cosh
(√
sδ
)
sinh
(√
s
χ¯
δ¯
)]
+
δ¯
2
√
sχ¯
[√
χφ cosh
(√
sδ
)
sinh
(√
s
χ¯
δ¯
)
+ sinh
(√
sδ
)
cosh
(√
s
χ¯
δ¯
)]

−1
.
Evaluating the limits, gives the residue of the infinite number of simple poles:
2
√
χφ cosh
(√
sn(x+ δ)
)(
cosh
(√
sn
χ¯
δ¯
)
(C0 − 1)− C0
)
esnt
√
sn

δ
[√
χφ sinh
(√
sδ
)
cosh
(√
s
χ¯
δ¯
)
+ cosh
(√
sδ
)
sinh
(√
s
χ¯
δ¯
)]
+
δ¯√
χ¯
[√
χφ cosh
(√
sδ
)
sinh
(√
s
χ¯
δ¯
)
+ sinh
(√
sδ
)
cosh
(√
s
χ¯
δ¯
)]

.
With the residue found, the semi-analytical solution for c1(x, t) can be determined as an infinite
sum over the solutions of (3.34):
c1(x, t) =
∞∑
n=1
2
√
χφ cosh
(√
sn(x+ δ)
)(
cosh
(√
sn
χ¯
δ¯
)
(C0 − 1)− C0
)
esnt
√
sn

δ
[√
χφ sinh
(√
sδ
)
cosh
(√
s
χ¯
δ¯
)
+ cosh
(√
sδ
)
sinh
(√
s
χ¯
δ¯
)]
+
δ¯√
χ¯
[√
χφ cosh
(√
sδ
)
sinh
(√
s
χ¯
δ¯
)
+ sinh
(√
sδ
)
cosh
(√
s
χ¯
δ¯
)]

,
(3.35)
and the application of (3.20) shows that the boundary condition is satisfied.
Equation (3.29) has simple poles at s = 0 in all of the fractions, which have the following
residues respectively: 0, −C0 and C0, which of course sum to 0. The first fraction in (3.29) has
infinitely many simple poles at:
cosh
(√
s
χ¯
δ¯
)
= 0, (3.36)
letting sl denote this sequence of infinite poles, then:
sl =
−χ¯pi2 (2m− 1)2
4δ¯2
⇒
√
sl
χ¯
=
ipi (2m− 1)
2δ¯
l = 1, 2, 3, ...
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and the residue, through the use of L’Hôpital’s rule, is:
lim
s→sl
[
c¯2(x, s)(s− sl)est
]
= lim
s→sl

sinh
(√
s
χ¯
(x− δ¯)
)
sinh(
√
sδ)
(
cosh
(√
s
χ¯
δ¯
)
(C0 − 1)− C0
)
est
s
(√
χφ cosh
(√
s
χ¯
δ¯
)
cosh(
√
sδ) + sinh
(√
s
χ¯
δ¯
)
sinh(
√
sδ)
)

× lim
s→sl
 (s− sl)
cosh
(√
s
χ¯
δ¯
)

= −
4(−1)l+1C0 cos
(
pi (2l − 1)
2δ¯
x
)
exp
(
− χ¯pi
2 (2l − 1)2
4δ¯2
t
)
pi (2l − 1) l = 1, 2, 3, .... (3.37)
Another source of infinitely many simple poles exists in the first fraction of (3.29) at s = sm,
are found by solving:(√
χφ cosh
(√
s
χ¯
δ¯
)
cosh
(√
sδ
)
+ sinh
(√
s
χ¯
δ¯
)
sinh
(√
sδ
))
= 0. (3.38)
Since equation (3.38) is identical to equation (3.34), the poles are the same, thus following the
same procedure, the residue is:
2 sinh
(√
sm
χ¯
(x− δ¯)
)
sinh
(√
smδ
)(
cosh
(√
sm
χ¯
δ¯
)
(C0 − 1)− C0
)
esmt
√
sm cosh
(√
sm
χ¯
δ¯
)
×

δ
[√
χφ sinh (
√
smδ) cosh
(√
sm
χ¯
δ¯
)
+ cosh (
√
smδ) sinh
(√
sm
χ¯
δ¯
)]
+
δ¯√
χ¯
[√
χφ cosh (
√
smδ) sinh
(√
sm
χ¯
δ¯
)
+ sinh (
√
smδ) cosh
(√
sm
χ¯
δ¯
)]


. (3.39)
Finally, there are the infinite number of simple poles in the second fraction of (3.29), in which
the poles are the solutions of:
cosh
(√
s
χ¯
δ¯
)
= 0. (3.40)
Since (3.40) is identical to (3.36) found in the first fraction of (3.29), the poles are also identical,
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therefore the residue is:
lim
s→sp
−
(s− sp)C0 cosh
(√
s
χ¯
x
)
est
s cosh
(√
s
χ¯
δ¯
)

=
4(−1)p+1C0 cos
(
pi(2p− 1)
2δ¯
x
)
exp
(
− χ¯pi
2(2p− 1)2
4δ¯2
t
)
pi(2p− 1) , p = 1, 2, 3, ... (3.41)
With the residues in the case of (3.29) found, the solution for c2(x, t) can be determined. Since
residues (3.37) and (3.41) sum to 0 and (3.38) is identical to (3.34), the solution c2(x, t) can also
be summed over n as with c1(x, t):
c2(x, t) =
∞∑
n=1
2 sinh
(√
snδ
)
sinh
(√
sn
χ¯
(x− δ¯)
)(
cosh
(√
sn
χ¯
δ¯
)
(C0 − 1)− C0
)
esnt
√
sn cosh
(√
sn
χ¯
δ¯
)
×

δ
[√
χφ sinh (
√
snδ) cosh
(√
sn
χ¯
δ¯
)
+ cosh (
√
snδ) sinh
(√
sn
χ¯
δ¯
)]
+
δ¯√
χ¯
[√
χφ cosh (
√
snδ) sinh
(√
sn
χ¯
δ¯
)
+ sinh (
√
snδ) cosh
(√
sn
χ¯
δ¯
)]


,
(3.42)
and with the application of (3.22), the boundary condition is satisfied.
Solution equations (3.34), (3.35) and (3.42) can be rewritten via:
sn = −α2n ⇒
√
sn = iαn,
to give: √
χφ cos (αnδ) cos
(
αnδ¯√
χ¯
)
− sin (αnδ) sin
(
αnδ¯√
χ¯
)
= 0, (3.43)
c1(x, t) =
∞∑
n=1
2
√
χφ cos (αn (x+ δ))
(
cos
(
αnδ¯√
χ¯
)
(1− C0) + C0
)
e−α
2
nt
αn

δ
[√
χφ sin (αnδ) cos
(
αnδ¯√
χ¯
)
+ cos (αnδ) sin
(
αnδ¯√
χ¯
)]
+
δ¯√
χ¯
[√
χφ cos (αnδ) sin
(
αnδ¯√
χ¯
)
+ sin (αnδ) cos
(
αnδ¯√
χ¯
)]

, (3.44)
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c2(x, t) =
∞∑
n=1
2 sin (αnδ) sin
(
αn√
χ¯
(
x− δ¯))(cos(αnδ¯√
χ¯
)
(C0 − 1)− C0
)
e−α
2
nt
αn cos
(
αnδ¯√
χ¯
)
×

δ
[√
χφ sin (αnδ) cos
(
αnδ¯√
χ¯
)
+ cos (αnδ) sin
(
αnδ¯√
χ¯
)]
+
δ¯√
χ¯
[√
χφ cos (αnδ) sin
(
αnδ¯√
χ¯
)
+ sin (αnδ) cos
(
αnδ¯√
χ¯
)]


. (3.45)
Model solution equations (3.43-3.45) may be simplified to:
(√
χφ+ 1
)
cos
(
αn
(
δ +
δ¯√
χ¯
))
+
(√
χφ− 1
)
cos
(
αn
(
δ − δ¯√
χ¯
))
= 0, (3.46)
c1(x, t) =
∞∑
n=1
4
√
χφ cos (αn (x+ δ))
(
cos
(
αnδ¯√
χ¯
)
(1− C0) + C0
)
e−α
2
nt
αn

(√
χφ+ 1
)(
δ +
δ¯√
χ¯
)
sin
(
αn
(
δ +
δ¯√
χ¯
))
+
(√
χφ− 1
)(
δ − δ¯√
χ¯
)
sin
(
αn
(
δ − δ¯√
χ¯
))

, (3.47)
c2(x, t) =
∞∑
n=1
4 sin (αnδ) sin
(
αn√
χ¯
(
x− δ¯))(cos(αnδ¯√
χ¯
)
(C0 − 1)− C0
)
e−α
2
nt
αn cos
(
αnδ¯√
χ¯
)
×

(√
χφ+ 1
)(
δ +
δ¯√
χ¯
)
sin
(
αn
(
δ +
δ¯√
χ¯
))
+
(√
χφ− 1
)(
δ − δ¯√
χ¯
)
sin
(
αn
(
δ − δ¯√
χ¯
))


, (3.48)
3.2.1 Special cases
There exists two analytical solutions from special cases that arise from when the microstructural
properties in both layers are identical (χ = φ = 1):
c(x, t) =
4
pi
∞∑
n=1
(−1)n
2n− 1
cos
(
(2n− 1)pi
2
(x+ δ)
)
exp
(
−(2n− 1)
2pi2t
4
)
×
[
(−1)n+1 sin
(
(2n− 1)piδ
2
)(
C0 − 1)− C0]
 , −δ < x < δ¯,
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and additionally when the drug loading is uniform (χ = φ = C0 = 1), a solution similar to
Crank’s classical solution [39] is obtained:
c(x, t) =
4
pi
∞∑
n=1
(−1)n+1
2n− 1
[
cos
(
(2n− 1)pi
2
(x+ δ)
)
exp
(
−(2n− 1)
2pi2t
4
)]
, −δ < x < δ¯.
3.2.2 Equations for mass
Dimensionally, the mass of drug at some time t is:
M(t) = M1(t) +M2(t) = A
[∫ 0
−L1
φ1c1(x, t)dx+
∫ L−L1
0
φ2c2(x, t)dx
]
,
where M1(t) and M2(t) are the masses of drug in layer 1 and layer 2 respectively, A is the total
cross-sectional area of the planar surface of the porous structure. Mass can be normalised via
M0, the total initial mass of drug in the pores:
M0 = M01 +M
0
2 + = Aφ1c
0
1L1 + Aφ2c
0
2(L− L1).
Using the nondimensional relations, the initial mass of drug, M0, may be expressed as:
M0 = ALφ1c
0
1
(
δ + (1− δ)φC0) .
Therefore, the normalised mass is:
M(t)
M0
= M ′(t ′) =
ALφ1c
0
1
ALφ1c01 (δ + (1− δ)φC0)
[∫ 0
−δ
c ′1(x
′, t ′)dx ′ + φ
∫ 1−δ
0
c ′2(x
′, t ′)dx ′
]
,
then simplifying and dropping the primes for clarity:
M(t) =
1
(δ + (1− δ)φC0)
[∫ 0
−δ
c1(x, t)dx+ φ
∫ 1−δ
0
c2(x, t)dx
]
.
Where the integrals are equal to:
∫ 0
−δ
c1(x, t)dx =
∞∑
n=1
4
√
χφ sin (αnδ)
(
cos
(
αnδ¯√
χ¯
)
(1− C0) + C0
)
e−α
2
nt
α2n

(√
χφ+ 1
)(
δ +
δ¯√
χ¯
)
sin
(
αn
(
δ +
δ¯√
χ¯
))
+
(√
χφ− 1
)(
δ − δ¯√
χ¯
)
sin
(
αn
(
δ − δ¯√
χ¯
))

,
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∫ 1−δ
0
c2(x, t)dx =
∞∑
n=1
4
√
χ¯ sin (αnδ)
(
cos
(
αnδ¯√
χ¯
)
− 1
)(
cos
(
αnδ¯√
χ¯
)
(C0 − 1)− C0
)
e−α
2
nt
α2n cos
(
αnδ¯√
χ¯
)
×

(√
χφ+ 1
)(
δ +
δ¯√
χ¯
)
sin
(
αn
(
δ +
δ¯√
χ¯
))
+
(√
χφ− 1
)(
δ − δ¯√
χ¯
)
sin
(
αn
(
δ − δ¯√
χ¯
))


.
3.2.3 Release profile
The fraction of drug released at some time t can be found via:
Mfrac(t) =
M0 −M(t)
M0
= 1− M(t)
M0
.
Therefore, the fraction of drug released is:
Mfrac(t) = 1−M(t) = 1− 1(
δ + δ¯φC0
) [∫ 0
−δ
c1(x, t)dx+ φ
∫ 1−δ
0
c2(x, t)dx
]
, (3.49)
which is a function that can be used to generate a plot of cumulative release of a drug as a
percentage vs time, known as a release profile.
3.2.4 Release profile special cases
For the special case in which χ = φ = 1, the fraction of drug released is:
Mfrac(t)
= 1 +
8
pi2
(
δ + δ¯C0
) ∞∑
n=1
1
(2n− 1)2

[
(−1)n+1 sin
(
(2n− 1)piδ
2
)(
C0 − 1)− C0]
× exp
(
−(2n− 1)
2pi2t
4
)
 ,
and for the second special case where χ = φ = C0 = 1, the fraction of drug released is:
Mfrac(t) = 1− 8
pi2
∞∑
n=1
1
(2n− 1)2 exp
(
−(2n− 1)
2pi2t
4
)
.
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3.2.5 Full model solution
Although the simplified model (3.18-3.23) is the focus of this chapter, the full model, with more
general boundary conditions, may be more realistic in other scenarios. For example, the sim-
plified model assumes that there is perfect contact between the porous layers and the overall
structures coincide, despite a potential difference in their respective porosities. However, this
may not always be applicable and to account for this, the full model (3.3-3.8) utilises a mass
transfer coefficient to allow for misaligned pores. Additionally, the full model also features
general flux conditions. The nondimensional full model is the combination of transport equa-
tions (3.18-3.19), initial conditions (3.23) and the following nondimensional general boundary
(3.50, 3.52) and interface conditions (3.51), derived using the same scalings as in the case of the
simplified model:
− ∂c1
∂x
= Γ1c1, x = −δ, t > 0, (3.50)
∂c1
∂x
= Π(c1 − c2), ∂c1
∂x
= χ
∂c2
∂x
, x = 0, t > 0, (3.51)
− χ∂c2
∂x
= Γ2c2, x = δ¯, t > 0, (3.52)
where Π = PL/De1, Γ1 = K1L/D
e
1 and Γ2 = K2L/D
e
1. The solution to this full model is
solved and reported in [56]. The semi-analytical solution to the nondimensional full model is:
c1(x, t) =
∞∑
m=1
AmX˜1,m exp
(−λ21,mt) ,
c2(x, t) =
∞∑
m=1
AmX˜2,m exp
(−χ¯λ22,mt) ,
where:
Am =
∫ 0
−δ
X˜1,mdx+ φC
0
∫ δ¯
0
X˜2,mdx∫ 0
−δ
X˜21,mdx+ φ
∫ δ¯
0
X˜22,mdx
,
X˜1,m = a˜1,m cos (λ1,mx) + b˜1,m sin (λ1,mx) ,
X˜2,m = a˜2,m cos (λ2,mx) + sin (λ2,mx) ,
a˜2,m =
χλ2,m + Γ2 tan
(
λ2,mδ¯
)
χλ2,m tan
(
λ2,mδ¯
)− Γ2 ,
a˜1,m = a˜2,m − χ
Π
λ2,m,
b˜1,m =
√
χφ.
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The required eigenvalue pairs (λ1,m, λ2,m) are found by solving:
(λ1 sin (λ1δ) + Γ1 cos (λ1δ))
× [Π (χλ2 cos (λ2δ¯)+ Γ2 sin (λ2δ¯))+ χλ2 (Γ2 cos (λ2δ¯)− χλ2 sin (λ2δ¯))]
−Π
√
χφ (λ1 cos (λ1δ)− Γ1 sin (λ1δ))
× (Γ2 cos (λ2δ¯)− χλ2 sin (λ2δ¯)) = 0.
The nondimensional mass of drug in each layer is:
M1(t) =
1
δ + δ¯φC0
∞∑
m=1
Am
(
a˜1,m sin (λ1,mδ) + b˜1,m (cos (λ1,mδ)− 1)
λ1,m
)
exp
(−λ21,mt) ,
M2(t) =
φ
δ + δ¯φC0
∞∑
m=1
Am
(
a˜2,m sin
(
λ2,mδ¯
)− cos (λ2,mδ¯)+ 1
λ2,m
)
exp
(−χ¯λ22,mt) ,
and from these nondimensional mass equations, the drug release profile may be calculated and
is defined Mfrac = 1− (M1(t) +M2(t)).
3.3 Results and discussion
A sensitivity analysis is conducted to provide insight into what system parameters are the most
influential on the shape of the release profile and to what extent. Therefore, some initial pa-
rameter values are required to generate suitable ranges for the model parameters. Particles
which are freely diffusing in liquids have diffusion coefficients which are typically of the order
10−10 − 10−9m2s−1 [61]. Effective porosities will assume values within the range 0 < φei < 1
(i = 1, 2) although, in reality, values will likely be restricted to 0.1− 0.9 due to mechanical and
drug-loading constraints. Values for tortuosity are typically found in the range 1 < τi < 6,
however, values as high as 10 have been reported [48]. Considering this range of values,
it is reasonable to assume that effective diffusion coefficients, Dei , will fall within the range
10−11 − 10−9m2s−1. Since the purpose of the model is to determine the potential benefits of re-
placing a drug-releasing single porous layer, with a composite porous layer of identical thickness
and initial mass of drug, the range of values for χ should encompass the extreme values of the
typical ranges for Dei and φ
e
i . Therefore, the values considered for ratio of the effective diffusion
coefficients, χ, are 1/10, 1 and 10. The parameter δ will influence the relative thicknesses of the
two layers and the values chosen are 0.25, 0.5 or 0.75. Since the model is nondimensional, no
specific values for initial drug loading in each layer are chosen, so values simulated for C0 are 0
(no drug in layer 2), 1 (same initial concentration in each layer) and 10 (an order of magnitude
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greater initial drug concentration in layer 2 than in layer 1). It may be shown that:
C0 =
(
M0
M01
− 1
)
δ
φ (1− δ) . (3.53)
Since M0 is fixed, then if φ remains constant, any change to C0 must be accommodated through
a redistribution of the initial mass between the two layers, as seen in equation (3.53).
The effect of varying the ratio of the porosity of the two layers, φ, is a little more complicated
to probe. Any changes to φ will cause changes in χ, so much so that the parameter cannot be
tested in isolation. This dependency may be shown by considering the definition of χ:
χ =
De2
De1
=
φe2D
w
τ2
φe1D
w
τ1
=
φe2τ1
φe1τ2
. (3.54)
It is observed that since φe2 and φ
e
1 are constrained by φ1 and φ2, respectively (φ
e
2 ≤ φ2 and
φe1 ≤ φ1), then any change to φ will induce a change in the effective diffusivity in each layer,
as shown in equation (3.54). Although χ may, in principle, be maintained at 1 if τ1/τ2 varies to
compensate the change in φe2/φ
e
1.
Equations (3.47), (3.48) and (3.49) are used for the sensitivity analysis, however, these equa-
tions feature infinite series whose infinite summation is unknown. The sum will have to be trun-
cated to approximate the infinite sum. The truncation value chosen is N , the number of roots in
a given interval of (3.46). The value of N will affect the accuracy of the results and should too
few roots be used or missed entirely, the solution will not converge. The values of the system
parameters will change (3.46) and hence the location of the roots. For a certain parameter set,
more/less roots may be required for an accurate solution. To accomplish this, the initial root
searching interval used in the simulations, is [0, 100]. To determine whether or not N is a suffi-
cient number of roots to produce an accurate solution, the theoretical masses MSN+1 and MSN
for the sequences of roots SN+1 and SN , are considered and if:
100×
∫ t
0
MSN+1(t)dt−
∫ t
0
MSN (t)dt∫ t
0
MSN (t)dt
< 1%,
for some time t, then N is deemed sufficiently accurate. To ensure smooth plots for concen-
tration profiles and release profiles, the intervals considered for the nondimensional variables x
and t, are divided into 100 equally spaced increments.
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3.3.1 Baseline study
To be able to assess the effect that altering the parameters will have on the concentration profiles,
generated by (3.47) and (3.48), and the release profiles, generated by (3.49), a baseline study
is considered. This study assumes that the layers of the porous media have the same structural
properties and initial drug concentration (χ = φ = C0 = 1). The net result is a reduction of
the model to essentially a single-layer system. All simulated parameter values are presented in
Table 3.1.
Study χ C0 φ δ
Baseline 1 1 1 0.5
1
0.1
10
1 1
0.25
0.5
0.75
2 1
0
10
1
0.25
0.5
0.75
Table 3.1: Table of parameter values used in the simulations.
(a) (b)
Figure 3.4: Baseline case: (a) Nondimensional concentration profiles versus nondimensional
space at three nondimensional times. The vertical dashed line in (a) is to mark where the inter-
face between the layers lies. (b) Fraction of drug released versus nondimensional time. For all
cases N = 32.
Figure 3.4 shows the results of the baseline study. Due to the parameter values (χ = φ =
C0 = 1) and the perfect contact at the interface between the layers, the problem is essentially
one-layer. Therefore, the shape of the concentration profiles and the release profile, are not
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influenced by the location of the interface. There is a delay in the release of drug from layer
1, whilst the drug in layer 2 is released relatively quickly. From the release profile, complete
release is achieved at approximately a nondimensional time of t = 3.
3.3.2 Sensitivity analysis
To assess the influence varying system parameters has on the shape of the release profile, each
parameter is considered separately, varied around the baseline values and the resultant release
and concentration profiles compared. Two studies are considered: Study 1 and Study 2, in
which the effect of varying χ and C0, respectively, are investigated. In each case, the value of
δ is varied between the three values in Table 3.1. It is assumed that the overall thickness of the
layers, L, and the initial mass, M0, are constant.
3.3.3 Study 1: effect of varying effective diffusivity ratio χ
The influence of varying the relative structural parameters between the layers is assessed. In
column (a) of Figure 3.5, χ is chosen such that the effective diffusivity within layer 2 is a tenth
that of layer 1, while in column (b) the effective diffusivity is ten times greater. Figure 3.5
features three plots in each column, one for each value of δ considered. When χ = 1/10, drug
transport from layer 1 is hindered by the much lower effective diffusivity in layer 2, this results
in a delay in the release of drug from layer 1 and so the concentration remains relatively high
(Figure 3.5 (a)). When χ = 10 the transport of drug within layer 2 is boosted considerably,
and this results in a quicker release of drug from layer 1. This results in a rapidly depleting
concentration in both layers (Figure 3.5 (b)).
A noteworthy feature of the concentration plots (Figure 3.5 (a)), is the linearity of the profile
when δ = 0.25, δ = 0.75, in layers 1 and 2, respectively, for certain times. This phenomena
can be explained by the order of magnitude difference in the values of effective diffusivities
between the layers. This results in a near-negligible derivative of concentration with respect to
time, therefore the solution is approximately linear. This can be seen when considering equation
(3.12) and using the same scaling for concentration and a slight alteration to the scaling for time:
t ′ =
De2t
φ1L2
⇒ χ∂c1
∂t
=
∂2c1
∂x2
.
When χ = 1/10, this equation is approximated by the much simpler second-order ODE:
d2c1
dx2
= 0⇒ c1 = A(t)x+B(t),
where A(t) and B(t) are time-dependent scalars, whose values will depend on the boundary
conditions. The similar behaviour in layer 2, when δ = 0.75, can also be explained via a similar
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approach with equation (3.13). In Figure 3.5 (b), the concentration profiles at early times in
layer 1 produce a “bump” close to the interface with layer 2. This is likely due to the order of
magnitude greater effective diffusivity in layer 2 and so, as particles reach the interface, they
will experience a sudden increase in transport rate.
The release profiles for these two cases are shown alongside the baseline release profile for
comparison in Figure 3.6. The variation of δ highlights a relationship between χ and δ. In the
case where χ = 1/10 and as δ is increased (layer 2 becomes narrower), the release of drug is
quicker. This is expected behaviour since drug particles will have to traverse a shorter distance
with a smaller effective diffusivity as δ increases. Conversely, when χ = 10 and as δ is increased,
the release begins to slow down considerably. This can be explained by drug particles having to
travel through a progressively thicker layer 1 with an effective diffusivity which is an order of
magnitude lower than that in layer 2.
The plots generated in this study demonstrate that structural parameter χ has the potential to
be strongly influential in altering the release rate (shape of the release profile) and therefore, the
duration of release. This result is expected though as χ consists of not only the effective levels
of porosity of each layer, but also the level of tortuosity. These are arguably the main structural
design parameters of the layers. Not only does χ feature heavily in the solutions (3.47) and
(3.48), but also in equation (3.46), which is crucial in obtaining the results. The results also
suggest that it is the combination of parameters φ and τ that will define the release profile since
a value of χ = 10 may be achieved through increasing the effective porosity of layer 2 relative
to layer 1 or via increasing the tortuosity of layer 1 relative to layer 2.
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(a) (b)
Figure 3.5: Nondimensional concentration profiles versus nondimensional space at three nondi-
mensional times for δ = 0.25, δ = 0.5 and δ = 0.75 for two values of χ, with (a) χ = 1/10 (as
δ increases N = 83, 66, 49) and (b) χ = 10 (as δ increases N = 16, 21, 26).
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(a) (b)
(c)
Figure 3.6: Fraction of drug released versus nondimensional time for different values of χ with
(a) δ = 0.25 (N = 83, 32, 16) (b) δ = 0.5 (N = 66, 32, 21) and (c) δ = 0.75 (N = 49, 32, 26),
with increasing χ. Approximate time for complete release with χ = 1/10: (a) t = 20, (b) t = 18
and (c) t = 12
3.3.4 Study 2: effect of varying initial concentration ratio C0
The effect of varying the ratio of initial concentrations of the two layers is investigated. In
Figure 3.7 (a), C0 is set to zero, this means that there is no initial drug concentration in layer 2.
In Figure 3.7 (b), C0 is set such that the initial concentration in layer 2 is ten times greater than
the initial concentration in layer 1. With C0 = 0, drug is observed entering layer 2 rapidly and
the drug concentration dropping quickly over time. With increasing δ, it appears as though the
concentrations are greater at the same time points in Figure 3.7 (a). By fixing the values of φ, δ
and M0, any variation in C0 must induce a change in M01 and by extension, M
0
2 . Therefore, to
keep the total mass of drug constant, the distribution of this total drug mass will be distributed
differently when C0 is altered. Thus, the concentrations shown in Figure 3.7 (a), although the
nondimensional scale is the same, the curves will be scaled with a different value of c01, as δ is
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increased, which can be seen in equation (3.53). This is also true of the concentration plots in
Figure 3.7 (b), as c02 is dependent on the value of c
0
1 through the definition of C
0. With C0 = 10
it is observed that drug from layer 2 diffuses into layer 1 due to the large concentration gradient
between the layers. As drug diffuses into layer 1 and is released from layer 2, the concentration
gradient will change direction. Therefore, drug will then diffuse from layer 1 to layer 2 until
complete release is achieved. This scenario is unlikely to be desirable as it may influence the
drug release profile unnecessarily. The value of δ appears to have a considerable effect on the
release process. In Figure 3.7 (a), where C0 = 0, when δ = 0.75, there is a relatively short
diffusion distance in layer 2 compared to when δ = 0.25. This results in a shorter delay for
release of drug to occur since drug particles will have to travel a shorter distance. Also, in
Figure 3.7 (b), where C0 = 10, when δ = 0.75, the large concentration gradient which exists
between the two layers is diminished more quickly and complete release is attained rapidly
when compared to the concentration plots for δ = 0.25. When comparing the release profiles of
Figure 3.8 to those of Figure 3.6, the influence that the variation of C0 has on the release profile
is considerably smaller than the influence of χ. Interestingly, despite some variation in the early
stages of release, the time until complete release is approximately identical for all plots in Figure
3.8.
The variation of C0 may have suitable applications in certain scenarios, for example, it may
be advantageous for there to be a delay before drug release occurs, therefore, C0 = 0 may be a
feasible parameter value and could take the form of a drug-free top-coat. It may also be useful
for a large burst release to occur initially in certain circumstances, such as antibiotic delivery,
therefore, C0 = 10 may be a useful parameter value to achieve this. However, from Figure 3.8,
the time for complete release is approximately identical, so rather than a parameter to alter the
shape of the release profile, C0 could be used as a means of controlling the total amount of drug
delivered, which will depend on the application. One noteworthy observation is the small point
of inflection at the start of the release profile for C0 = 0, which is likely due to drug from layer
1 having to diffuse into, the initially empty, layer 2. This may also be a desirable scenario in
some applications, however, it is possible that drug could enter layer 2 during the manufacturing
process.
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(a) (b)
Figure 3.7: Nondimensional concentration profiles versus nondimensional space for δ = 0.25,
δ = 0.5 and δ = 0.75 for two values of C0, with (a) C0 = 0 and (b) C0 = 10 at three
nondimensional times. For all cases N = 32. Since M0 is kept constant, varying C0 results
in a different value of normalising concentration, c01, between the left and right plot columns,
i.e. even though the vertical axis has the same scale between the left and right plot columns, the
corresponding dimensional values of concentration will differ.
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(a) (b)
(c)
Figure 3.8: Fraction of drug released versus nondimensional time for different values of C0 with
(a) δ = 0.25, (b) δ = 0.5 and (c) δ = 0.75. For all cases N = 32.
3.3.5 Practical examples of model use
There are certain scenarios that could be realised through the use of the model in this chapter
via certain combinations of parameter values. One possibility is delaying the release of drug
and an example of suitable parameter values that can achieve this are χ = 0.1, φ = 9, C0 = 0
and δ = 0.25. From Figure 3.9, it is observed that drug release is delayed until an approximate
nondimensional time of t = 3.
Another possible scenario is where drug is released quickly, such as the need to infuse the
surface of an OI and the surrounding tissues with an antibiotic to kill any potential bacteria, thus
preventing OI associated infection. An example parameter combination that can give rise to this
scenario is χ = 10, φ = 1/9, C0 = 10 and δ = 0.25. From Figure 3.10, there is a very rapid
release initially and a sustained release until approximately t = 0.2 nondimensional time.
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Figure 3.9: Fraction of drug released versus nondimensional time showing a delay in the release
of drug. Where χ = 0.1, φ = 9, C0 = 0, δ = 0.25 and N = 234.
Figure 3.10: Fraction of drug released versus nondimensional time showing rapid release of
drug. Where χ = 10, φ = 1/9, C0 = 10, δ = 0.25 and N = 74.
3.3.6 Conclusions
In this chapter, a mathematical model of the diffusion of drug through two porous layers was pre-
sented and the influence of the model parameters on the concentration and release profiles was
investigated. The results of the sensitivity analysis demonstrated that through the use of variable
porosity coatings, a greater degree of controlled drug release may be achieved, be it in the form
of release duration or in the quantity of drug delivered within a required time. The variation of δ
and C0 had some influence on the concentration and release profiles, however, it would appear
from this study that the most influential parameter was χ. This is somewhat expected since χ
is comprised of both the porosity and the tortuosity of each layer. These parameters govern
the microstructural properties of each layer and hence the effective diffusive transport through
the layers. Therefore, it is reasonable to conclude that χ may be the dominant parameter in
the model and so provides considerable flexibility and tuneability from a design/manufacturing
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point of view.
This model is an example of how simple the process of generating release profiles is, and
in some cases, where a semi-analytical or fully-analytical solution is available, a mere few sec-
onds is required. In theory, the transport and release of a variety of drugs and porosity lev-
els, potentially providing wildly different parameter values, may be modelled relatively quickly
when compared to the time scales required for drug-release experiments. Such experiments also
require monetary costs to be met, however, with a validated mathematical model, theoretical
simulation after initial experimentation removes the need for further experimental investigation.
There are limitations with this model, chief among which is the assumption that the drug is
initially in a solute phase, which could limit the practical use in cases where the drug is poorly
soluble. Therefore, one possible enhancement to this model would be the inclusion of the drug
dissolution process. It should be noted that this work is quite general and not focussed on a par-
ticular implant/device. In the next chapter, however, a specific device is investigated (a porous
prototype fixation pin) and this model is adapted accordingly.
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Chapter 4
Modelling drug release from
porous-walled orthopaedic pins
In chapter 2, it was found that many drug-release studies that focus on the potential for drug-
releasing OIs featured porosity as a key means of controlling the release. In chapter 3, a math-
ematical model was devised and studied to assess the extent to which variable porosity systems
can provide a flexible method of control in the context of drug delivery. In this chapter, the aim
is to devise a mathematical model of drug release from a particular prototype device, specifically
the porous pin by Gimeno et al. (Figure 4.1 (a)) [11], and conduct a sensitivity analysis on the
various system parameters and how they influence the release profile.
(a)
(b)
Figure 4.1: (a) A: Illustration of the porous pin with blue arrows showing drug transport through
the porous wall of the pin. B: The real macroporous stainless steel pin. C: Scanning electron
microscopy view of the porous wall of the pin, with a volumetric porosity of 17 %. (b) Release
profile of Linezolid expressed as a percentage of the Linezolid initially loaded in the porous pin.
The primary reason for modelling this particular device is due to the availability of some in-
formation on the experimental setup, such as the volume of the release medium and the physical
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dimensions of the pin, which is crucial in setting up a mathematical model. There is also some
limited drug release data (Figure 4.1 (b)), which may be used to attempt to validate the model. It
is stated that the implants have a porous length of 25.4 mm, an outside diameter of 6.35 mm and
a wall thickness of 1.6 mm [11]. The release media volume was 100 mL of SBF and the release
data was obtained without renewal of the release media [11].
4.1 Preliminary model
For an initial model, it is assumed that diffusion is the sole component driving drug transport
and that the porous pin is comprised of two distinct regions, the inner drug core, with radius Ld
and the porous wall of the pin, with thickness Lp, with the subscript d and p denoting the inner
drug core and the porous wall, respectively. The inner drug core has length H , effectively the
height of the pin. In these regions, the respective drug concentrations are defined cd(r, θ, z, t)
and cp(r, θ, z, t), the intrinsic drug concentration within the porous wall. Along with the con-
centration definitions are the constant initial concentrations cd = c0d and cp = 0. The position of
the interface between the drug and porous layers and the position of the outer edge of the porous
region are defined as L1 = Ld and L2 = Ld+Lp, respectively (Figure 4.2 (b)). Additionally, the
level of porosity and tortuosity of the porous wall are defined as φ and τ , respectively. The value
of τ used throughout the chapter is 3, which is considered an average value of the typical range
of tortuosities. The rationalisation for this average value is that solutes diffuse in 3D and thus
have three directions of travel and so will travel around three times the distance compared to just
one direction [48]. The diffusivity of drug within the inner drug layer is assumed to be the free-
diffusion coefficient, Df , which for this chapter is assumed to be both constant and isotropic,
and takes the greatest value in the typical range of diffusion coefficients in liquids, which is
1× 10−9 m2/s. From the free-diffusion coefficient, the effective diffusion coefficient within the
porous wall, Dp, can be calculated via Dp = φeDf/τ , following chapter 3 [48], where φe is the
effective porosity of the porous wall and is assumed to be 90 % of the overall porosity, φ, for this
chapter. Additionally, the angular and vertical position variables are defined as θ, 0 < θ ≤ 2pi,
and z, 0 ≤ z ≤ H , respectively. Assuming that the drug is in the solute phase, the 3D diffusion
model is:
∂cd
∂t
= Df∇2cd, 0 < r < L1, 0 < θ ≤ 2pi, 0 < z < H, t > 0, (4.1)
φ
∂cp
∂t
= Dp∇2cp, L1 < r < L2, 0 < θ ≤ 2pi, 0 < z < H, t > 0, (4.2)
− nˆ ·Df∇cd = 0, r = 0, 0 < θ ≤ 2pi, 0 < z < H, t > 0, (4.3)
− nˆ ·Df∇cd = 0, 0 < r < L1, −nˆ ·Dp∇cp = 0, L1 < r < L2,
0 < θ ≤ 2pi, z = 0, H, t > 0, (4.4)
cd = cp, −nˆ ·Df∇cd = −nˆ ·Dp∇cp,
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r = L1, 0 < θ ≤ 2pi, 0 < z < H, t > 0, (4.5)
cp = 0, r = L2, 0 < θ ≤ 2pi, 0 < z < H, t > 0, (4.6)
cd = c
0
d, 0 ≤ r ≤ L1, 0 < θ ≤ 2pi, 0 ≤ z ≤ H, t = 0, (4.7)
cp = 0, L1 < r ≤ L2, 0 < θ ≤ 2pi, 0 ≤ z ≤ H, t = 0, (4.8)
where nˆ is the outward facing unit normal to applicable boundary surfaces.
(a)
(b)
Figure 4.2: (a) 3D porous pin geometry with the ends of the geometry capped to prevent drug
transport through either end of the pin. Variables cd and cp highlight the regions where the
concentrations are defined. The red dot marks the position of the origin. (b) A 2D cross-
sectional slice at the bottom of the 3D geometry, to clearly show the inner drug core radius, Ld,
and the porous wall thickness, Lp. The image also shows how θ is defined, the angle of rotation
around the central axis. The red dot marks the position of the origin.
Figure 4.2 shows the 3D geometry considered and a cross-sectional slice of the geometry,
indicating the locations of cd and cp and how geometric parameters are defined. Model equations
(4.1-4.8) consists of a pair of coupled diffusion equations (4.1-4.2) which model diffusive drug
transport through the inner drug core and the porous wall, respectively. Equation (4.3) is a
compatibility condition, which ensures that the solution is finite when r = 0. Equations (4.4) are
zero-flux boundary conditions, which are applied to the top and bottom of the pin geometry, such
that drug cannot cross the solid boundary. Equations (4.5) are continuity of concentration and
flux conditions which are applied at the interface between the drug region and the porous wall
at r = L1. Equation (4.6) is an infinite sink condition, which is used in lieu of a release medium
for model simplification. This is likely suitable since the release medium in the experimental
setup is stirred and is comprised of 100 mL of SBF, which is much greater than the volume of
the pin, which is approximately 0.8 mL. The applicability of the infinite sink condition will be
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explored later in the chapter. Equations (4.7-4.8) are the initial conditions applied to each region
of the pin. The model is normalised via the following scalings:
c ′d =
cd
c0d
, c ′p =
cp
c0d
, z ′ =
z
Ld
, r ′ =
r
Ld
, t ′ =
Df
L2d
t,
additionally, for simplification, D = Dp/Df . Dropping the primes for clarity, the nondimen-
sional model is:
∂cd
∂t
= ∇2cd, 0 < r < 1, 0 < θ ≤ 2pi, 0 < z < H/Ld, t > 0, (4.9)
φ
∂cp
∂t
= D∇2cp, 1 < r < L2/Ld, 0 < θ ≤ 2pi, 0 < z < H/Ld, t > 0, (4.10)
nˆ · ∇cd = 0, r = 0, 0 < θ ≤ 2pi, 0 < z < H/Ld, t > 0, (4.11)
nˆ · ∇cd = 0, 0 < r < 1, nˆ · ∇cp = 0, 1 < r < L2/Ld,
0 < θ ≤ 2pi, z = 0, H/Ld, t > 0, (4.12)
cd = cp, nˆ · ∇cd = nˆ ·D∇cp, (4.13)
r = 1, 0 < θ ≤ 2pi, 0 < z < H/Ld, t > 0,
cp = 0, r = L2/Ld, 0 < θ ≤ 2pi, 0 < z < H/Ld, t > 0, (4.14)
cd = 1, 0 ≤ r ≤ 1, 0 < θ ≤ 2pi, 0 ≤ z ≤ H/Ld, t = 0, (4.15)
cp = 0, 1 < r ≤ L2/Ld, 0 < θ ≤ 2pi, 0 ≤ z ≤ H/Ld, t = 0, (4.16)
4.1.1 Model reduction
From Figure 4.1 (a), the porous pin is approximately cylindrical in shape, therefore, it may be
possible to reduce the geometry through the use of symmetry. If this were to be achievable, then
a 3D model may not be required if a 1D model can produce the same results. The main benefits
to this are a reduction in computation costs and the possibility that analytical, or even semi-
analytical, solutions may be obtainable. To explore if symmetry can be exploited, equations
(4.9-4.16) of the 3D diffusion model were transformed into the required 1D and 2D equivalent
models by neglecting the θ and z components of the model equations.
The 3D, 2D and 1D models were solved numerically by means of the finite element method
(FEM), using the commercial software package COMSOL Multiphysics®, version 5.3a. It
should be noted that although the 1D model is solved numerically using a cylindrical coordi-
nate system (the radial coordinate only), the 2D and 3D models were numerically solved in the
software using the Cartesian coordinate system. This is the default coordinate system and does
not affect the results for the 2D and 3D models. The basic operation in the software involves
designing a model geometry, which is discretised with a finite number of elements to form an
approximation of the original geometry. Points where mesh elements meet are known as nodes.
The meshing may be performed manually, or it may be done with built-in meshing tools with a
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variety of mesh density settings. For the model (4.9-4.16) the “Extremely Fine” mesh settings
were used to generate a mesh based on tetrahedral elements for the 3D model and triangular
elements for the 2D model, these meshes are shown in Figure 4.3. The “Extremely Fine” mesh
settings were also used to discretise the interval geometry of the 1D model, consisting of 101
equally spaced points. To determine if the chosen mesh was suitable, a much finer custom mesh
was constructed and the results were compared. There was no appreciable difference in the
release profiles generated for the 3D, 2D or 1D models, therefore, the “Extremely Fine” mesh
settings were deemed suitable. Since the studies are time-dependent, the original equations are
approximated locally by ODEs at each node of the mesh, then a system of simultaneous ODEs
are compiled and can be solved by various methods. Depending on the chosen physics, a suit-
able default solver is selected from the several built-in methods, which may also be changed
within the solver settings. In the case of the diffusive transport models, the generalized mini-
mal residual method (GMRES), an iterative method for solving nonsymmetric systems of linear
equations, was used. The implicit Backward Differentiation Formula (BDF) of orders one and
two, was used as the time-advancing solver. Free time-stepping was used for efficiency, the
time-step taken at a particular point may be smaller or greater than the previous time-step. This
is done within the software by checking if the solution varies considerably at the current time,
subject to the specified tolerance levels, and if the solution does vary too much, then the software
reduces the size of the time-step.
(a)
(b)
Figure 4.3: (a) FEM mesh generated for the 3D porous pin geometry. Mesh consists of 136, 059
domain elements, 11, 316 boundary elements, and 664 edge elements. (b) FEM mesh generated
for the 2D porous pin geometry. Mesh consists of 24, 930 domain elements and 472 boundary
elements. The red circle indicates the interface between the two regions of the geometry.
Figure 4.2 shows the 3D and 2D geometries and the 1D geometry is the interval [0, L1] ∪
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[L1, L2], or nondimensionally, [0, 1] ∪ [1, L2/Ld]. Figure 4.3 shows the 3D and 2D meshes
used for the study. To determine if the porous pin is a suitable candidate for 1D mathematical
modelling, the release profiles of all models are compared. This requires one to know the mass
of drug in each region for each model at any given time, which are defined Md(t) and Mp(t),
the masses of drug within the inner drug region and the porous wall, respectively. From this,
the total mass, M(t) = Md(t) + Mp(t), can be determined. Dimensionally, the mass of drug at
some time t for the models is:
M(t) = Md(t) +Mp(t) =
∫ H
0
∫ 2pi
0
∫ L1
0
cd r dr dθ dz + φ
∫ H
0
∫ 2pi
0
∫ L2
L1
cp r dr dθ dz.
Mass can be normalised via M0d , the total initial mass of drug in the core of the pin:
M0d = piL
2
dHc
0
d,
hence, normalised mass is:
M(t)
M0d
=
c0dL
3
d
piL2dHc
0
d
[∫ H/Ld
0
∫ 2pi
0
∫ 1
0
c ′d r
′ dr ′ dθ ′ dz ′ + φ
∫ H/Ld
0
∫ 2pi
0
∫ L2/Ld
1
c ′p r
′ dr ′ dθ ′ dz ′
]
.
Simplifying and dropping the primes for clarity:
M(t)
M0d
=
Ld
piH
[∫ H/Ld
0
∫ 2pi
0
∫ 1
0
cd rdr dθ dz + φ
∫ H/Ld
0
∫ 2pi
0
∫ L2/Ld
1
cp r dr dθ dz
]
.
The release profile is:
Mfrac(t) =
M0d −M(t)
M0d
= 1− M(t)
M0d
= 1− Ld
piH
[∫ H/Ld
0
∫ 2pi
0
∫ 1
0
cd rdr dθ dz + φ
∫ H/Ld
0
∫ 2pi
0
∫ L2/Ld
1
cp r dr dθ dz
]
.
(4.17)
For the 1D model, equation (4.17) will simplify to the summation of the integrals along the
radial line. The required mass equations for the 2D and 3D models are similar to equation
(4.17), however, the integrals are solved in the Cartesian coordinate system in the software. The
required integrals are performed within the software using Gaussian quadrature.
4.1.2 Model results and discussion
The diffusion models are solved computationally and the release data from all three models are
plotted to generate release profiles and the plots are compared. Parameter values may be inferred
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from [11]. The parameter values used in the model reduction study are shown in Table 4.1.
Parameter Value
Ld 1.575 mm [11]
Lp 1.6 mm [11]
H 25.4 mm [11]
φ 0.17 [11]
φe 0.9× φ
τ 3
Df 1× 10−9 m2/s
Dp = φeDf/τ 5.1× 10−11 m2/s
Table 4.1: Table of parameter values used in the model reduction study.
Figure 4.4: Plot showing fraction of drug released, versus nondimensional time, for the porous
pin for the 1D, 2D and 3D models.
The results plotted in Figure 4.4 show that the use of a 1D model is sufficient in the modelling
of drug release from the porous pin. This is expected when considering the lines of symmetry of
a cylinder. This 1D diffusion model will be solved semi-analytically in Section 4.2. There is one
other aspect to the experimental setup that must be considered: the release medium is stirred.
This agitation of the release medium may have an impact on the release process by potentially
providing a considerable advective component to the transport of the drug and hence, influencing
the release of the drug. To investigate this, in Section 4.1.3 a system of fluid dynamic equations
are coupled with advection-diffusion equations and the release results compared to a purely
diffusive case. In all cases, the drug is assumed to be in the solute phase.
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4.1.3 Influence of fluid flow on release of drug from the porous pin
In the experiments by Gimeno et al., the porous pins were submerged in 100 mL of SBF within
an unknown container. It is also noted that the experimental set-up included stirring, the method
of which is not reported. Assuming that the porous pin is submerged in the release media within
a beaker and that the stirring is supplied by the beaker rotating at a set number of revolutions per
minute (RPM), specifically, 30 RPM (pi rad/s), the theoretical influence the rotating fluid would
have on the release of the drug may be determined. This value of rotational speed was chosen as
the authors reported this speed in other published work [12]. Although a 1D approximation is
suitable for the purely diffusive case, it is not suitable to gauge the importance a stirred release
medium has on the release of a drug. Therefore, a full 3D model is used to investigate this.
(a)
(b)
Figure 4.5: (a) 3D geometry of the porous pin experimental set-up, where the domains Ω1, Ω2
and Ω3 represent the release medium, the porous wall of the pin and the inner drug core of
the pin, respectively. Γ1 is the outer boundary of the release medium, θ is the angle that Ω1
makes with respect to its original position as it rotates and r is the radius from the central z-
axis to the outer wall. (b) Close-up of the 3D porous pin that highlights Ω2 and Ω3. The outer
boundary of the porous wall of the pin in contact with the release medium is denoted Γ2 and the
interface between the inner drug core and the porous wall is represented by Γ3. The collection
of boundaries that form the top and bottom caps of the pin are designated Γ4
It should be noted that the following 3D model is solved in COMSOL Multiphysics®, version
5.3a, using the software’s default Cartesian coordinate system. As the model is 3D choosing a
cylindrical coordinate system will only give the same results. Additionally, the θ and r shown
in in Figure 4.5 (a) are not model variables, they are separately defined within the software to
be able to define a moving wall boundary condition, described shortly. To model the potential
influence that fluid flow has on the release drug from the porous pin, some assumptions are
made. It is assumed that the container for the release medium is a beaker of radius 30 mm [62]
and since the volume of release medium is known, the height of the release medium, Hm, may
65
be easily calculated to provide an as accurate a representation as possible for the model. The
porous pin geometry (Figure 4.5 (b)) is then suspended in the centre of the beaker geometry as
seen in Figure 4.5 (a). Correspondence with the authors provided some experimental details of
other work, which involved similar devices being suspended in the centre of a release medium.
Therefore, it is assumed that in the case of the porous pin, a similar setup was used. Another
unknown from the experiment is how the stirring of the release medium is performed. Without
this knowledge, for the sake of simplicity, it is assumed that the beaker containing the release
medium is rotated about its central axis. In this scenario, the walls of the beaker will provide the
driving-force for the release medium to flow via a no-slip/no-penetration condition. Addition-
ally, the release medium is assumed to be water as the fluid properties of SBF, such as density
and kinematic viscosity, are unknown.
While the fluid is in motion, the resultant velocity field is denoted u, which has velocity
components (ux, uy, uz). As the outer boundary of the release medium is rotated, the thin film
of fluid close to the boundary assumes the velocity of this moving boundary. This results in
an angular motion of the fluid, decreasing in magnitude as the radial distance from the outer
boundary approaches the centre. However, the porous wall of the pin presents a wholly different
environment for the fluid to navigate. The equations proposed to model fluid behaviour in the
system are as follows:
∂u
∂t
= ν∇2u− (u · ∇)u− 1
ρ
∇p, in Ω1 and Ω3, t > 0, (4.18)
1
φ
∂u
∂t
=
ν
φ
∇2u− 1
φ2
(u · ∇)u− 1
ρ
∇p− ν
κ
u, in Ω2, t > 0, (4.19)
∇ · u = 0, in Ω1, Ω2 and Ω3, t > 0, (4.20)
with the following boundary conditions:
u = (−r sin(θ), r cos(θ), 0)u, on Γ1, t > 0, (4.21)
uns = ubr, pns = pbr, on Γ2 and Γ3, t > 0, (4.22)
u = 0, on Γ4, t > 0, (4.23)
p = 0, at an arbitrary point t ≥ 0 (4.24)
u = 0, in Ω1, Ω2 and Ω3, t = 0. (4.25)
Model equations (4.18-4.25) consist of the time-dependent, incompressible Navier-Stokes (4.18),
Brinkman (4.19) and continuity equations (4.20). The Brinkman equation is used over Darcy’s
Law for modelling fluid flow through the porous wall of the pin because it is a more appropriate
way to account for fluid-porous transitions [47, p. 16]. Parameters ρ and ν are the density and
kinematic viscosity of the fluid (the ratio of the fluid properties of dynamic viscosity and den-
sity), respectively, and κ and φ are the permeability and the porosity of the porous wall of the
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pin (Ω2), respectively. A moving wall boundary condition (4.21), with angular velocity magni-
tude u, is applied to Γ1. Boundary conditions (4.22) ensure continuity of the velocity field and
pressure across the boundaries Γ2 and Γ3. The subscript ns and br are to indicate the velocity
field and pressure associated with one of the governing flow equations, either Navier-Stokes
(ns) or Brinkman (br). A no-slip/no-penetration boundary condition (4.23) is applied to Γ4. The
pressure, p, is set to be zero at an arbitrary point in the form of a pressure point constraint (4.24).
This is necessary as it is not possible to specify the pressure level using a boundary condition,
thus by constraining the pressure at a single point, the numerical solution can output the ap-
propriate pressure gradient. Lastly, the fluid is at rest initially, as indicated by initial condition
(4.25).
To model the potential influence of fluid flow on drug-release from the porous pin, the fluid
dynamic equations (4.18-4.25) are coupled with a set of advection-diffusion equations. Since
the release medium is now accounted for, cm(x, y, z, t) is defined as the concentration of drug
within the release medium. Additionally, the drug concentration in the inner drug core and in
the porous wall of the pin are defined cd(x, y, z, t) and cp(x, y, z, t), respectively. The proposed
model is:
∂cm
∂t
= Df∇2cm − u · ∇cm, in Ω1, t > 0, (4.26)
φ
∂cp
∂t
= Dp∇2cp − u · ∇cp, in Ω2, t > 0, (4.27)
∂cd
∂t
= Df∇2cd − u · ∇cd, in Ω3, t > 0, (4.28)
∂u
∂t
= ν∇2u− (u · ∇)u− 1
ρ
∇p, in Ω1 and Ω3, t > 0, (4.29)
1
φ
∂u
∂t
=
ν
φ
∇2u− 1
φ2
(u · ∇)u− 1
ρ
∇p− ν
κ
u, in Ω2, t > 0, (4.30)
∇ · u = 0, in Ω1,Ω2 and Ω3, t > 0, (4.31)
Equations (4.26-4.31) consist of coupled advection-diffusion equations (4.26-4.28) and the in-
compressible form of the Navier-Stokes (4.29), Brinkman (4.30) and continuity equations (4.31).
These governing equations are paired with the boundary and initial conditions:
cd = cp, nˆ · (−Df∇cd + cdu) = nˆ · (−Dp∇cp + cpu) , on Γ3, t > 0, (4.32)
cp = cm, nˆ · (−Dp∇cp + cpu) = nˆ · (Df∇cm + cmu) , on Γ2, t > 0, (4.33)
nˆ · (−Df∇cm + cmu) = 0, u = (−r sin(θ), r cos(θ), 0)u, on Γ1, t > 0, (4.34)
u = 0, −nˆ ·Df∇cd = −nˆ ·Dp∇cp = −nˆ ·Df∇cm = 0, on Γ4, t > 0, (4.35)
uns = ubr, pns = pbr, on Γ2 and Γ3, t > 0, (4.36)
p = 0, at an arbitrary point, t ≥ 0, (4.37)
cd = c
0
d, in Ω3, c
0
p = 0, in Ω2, c
0
m = 0, in Ω1, t = 0, (4.38)
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u = 0, in Ω1, Ω2 and Ω3, t = 0. (4.39)
Continuity of concentration and flux conditions (4.32-4.33) are applied to boundaries Γ2 and
Γ3. On Γ1, a zero-flux boundary condition is applied to prevent drug from leaving the system,
alongside the moving wall condition, which provides the force to cause the fluid to move (4.34).
On Γ4, a no-slip/no-penetration condition is applied along with a zero-flux condition, which pre-
vents drug moving through the top and bottom caps of the porous pin geometry (4.35). Initially,
there is a non-uniform initial drug concentration (4.38) and the fluid is assumed to initially be at
rest throughout the entire geometry (4.39). The model equations (4.26-4.39) are nondimension-
alised with the following scalings:
c ′i =
ci
c0d
, x ′ =
x
Ld
, y ′ =
y
Ld
, z ′ =
z
Ld
, t ′ =
Df
L2d
t, p ′ =
L2d
ρD2f
p, u ′ =
Ld
Df
u,
where i = d, p,m. Dropping the primes for clarity, these scalings result in the nondimensional
model:
∂cm
∂t
= ∇2cm − u · ∇cm, in Ω1, t > 0, (4.40)
φ
∂cp
∂t
= D∇2cp − u · ∇cp, in Ω2, t > 0, (4.41)
∂cd
∂t
= ∇2cd − u · ∇cd, in Ω3, t > 0, (4.42)
∂u
∂t
= Sc∇2u− (u · ∇)u−∇p, in Ω1 and Ω3, t > 0, (4.43)
1
φ
∂u
∂t
=
Sc
φ
∇2u− 1
φ2
(u · ∇)u−∇p− L
2
dSc
κ
u, in Ω2, t > 0, (4.44)
∇ · u = 0, in Ω1,Ω2 and Ω3, t > 0, (4.45)
with the nondimensional boundary and initial conditions:
cd = cp, nˆ · (−∇cd + cdu) = nˆ · (−D∇cp + cpu) , on Γ3, t > 0, (4.46)
cp = cm, nˆ · (−D∇cp + cpu) = nˆ · (∇cm + cmu) , on Γ2, t > 0, (4.47)
nˆ · (−∇cm + cmu) = 0, u = L
2
d
Df
(−r sin(θ), r cos(θ), 0)u, on Γ1, t > 0, (4.48)
u = 0, nˆ · ∇cd = nˆ · ∇cp = nˆ · ∇cm = 0, on Γ4, t > 0, (4.49)
uns = ubr, pns = pbr, on Γ2 and Γ3, t > 0, (4.50)
p = 0, at an arbitrary point, t ≥ 0, (4.51)
cd = 1, in Ω3, c0p = 0, in Ω2, c
0
m = 0, in Ω1, t = 0, (4.52)
u = 0, in Ω1, Ω2 and Ω3, t = 0, (4.53)
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where D = Dp/Df and Sc is the Schmidt number which is defined as the ratio of kinematic
viscosity to the free-diffusion coefficient (ν/Df ).
A required parameter that is not known is the level of permeability of the pin’s porous wall,
κ. Therefore, an estimation of the permeability is sought. Yang et al. derived an analytical ex-
pression for permeability, assuming isotropic porosity, as a function of two parameters: porosity
and pore size [63]. Based upon the notion of a representative elementary volume, referred to
by the authors as a “unit cell”, and research conducted by other groups, Yang et al. provide the
following expression:
κ =
φ
(
1− (1− φ)1/3
)
108
(
(1− φ)1/3 − (1− φ)
)P 2, (4.54)
where P is the cross-sectional pore size. Equation (4.54) was used by the authors to unify ex-
perimental data for a range of porosities and pore sizes, with good estimation results. However,
it must be noted that the range of values that the experimental data covered were porosities and
pore sizes in the ranges of 0.55− 0.98 and 0.254− 5.08 mm, respectively. Assuming that equa-
tion (4.54) is valid, to estimate the permeability of the porous wall, an idea of the pore size is
required. Figure 4.1 (a) shows a scanning electron microscopy view of the pin’s porous wall
with a scale of 10µm, assuming that this is a representative value of the pore sizes and using
the level of porosity of the porous pin, an estimation of the permeability can be made. Another
parameter required is the kinematic viscosity, ν, of the assumed release medium fluid, water. It
is stated by Gimeno et al. that the experimental setup was at 37 ◦C. Therefore, the following
empirical expressions for the density and dynamic viscosity of water [64, p. 1862], which are
functions of temperature, T , in ◦C, were used:
ρ =
(
999.83952 + 16.945176× T − 7.9870401× 10−3T 2
−46.170461× 10−6T 3 + 105.56302× 10−9T 4 − 280.54253× 10−12T 5
)
1 + 16.879850× 10−3T ,
µ = 1.002× 10−310B,
B =
1.3272(20− T )− 0.001053(T − 20)2
T + 105
.
4.1.4 Equations for mass
The dimensional equations for the mass of drug in each region are:
MΩ1(t) =
∫
Ω1
cm dΩ1, MΩ2(t) = φ
∫
Ω2
cp dΩ2, MΩ3(t) =
∫
Ω3
cd dΩ3,
where dΩj = dxdydz, with j = 1, 2, 3. The equations for mass can be normalised with M0d ,
the initial drug mass. As this is a purely numerical investigation, not only are the drug masses
in each region approximated, but so too is the initial drug mass, which can be calculated via the
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integral:
M0d = c
0
d
∫
Ω3
dΩ3.
Using the nondimensional scalings, the normalised equations for mass are:
MΩ1(t)
M0d
=
c0dL
3
d
∫
Ω ′1
c ′m dΩ
′
1
c0dL
3
d
∫
Ω ′3
dΩ ′3
,
MΩ2(t)
M0d
=
c0dL
3
dφ
∫
Ω ′2
c ′p dΩ
′
2
c0dL
3
d
∫
Ω ′3
dΩ ′3
,
MΩ3(t)
M0d
=
c0dL
3
d
∫
Ω ′3
c ′d dΩ
′
3
c0dL
3
d
∫
Ω ′3
dΩ ′3
.
Simplifying and dropping the primes for clarity:
MΩ1(t)
M0d
=
∫
Ω1
cm dΩ1∫
Ω3
dΩ3
,
MΩ2(t)
M0d
=
φ
∫
Ω2
cp dΩ2∫
Ω3
dΩ3
,
MΩ3(t)
M0d
=
∫
Ω3
cd dΩ3∫
Ω3
dΩ3
.
4.1.5 Release profile
The release profile may be calculated through the mass of drug lost from the porous pin:
Mfrac(t) =
M0d − (MΩ2(t) +MΩ3(t))
M0d
= 1− MΩ2(t) +MΩ3(t)
M0d
= 1−
φ
∫
Ω2
cp dΩ2 +
∫
Ω3
cd dΩ3∫
Ω3
dΩ3
.
The simpler method to calculate the release profile is to determine the mass which accumulates
in the release medium:
Mfrac(t) =
MΩ1(t)
M0d
=
∫
Ω1
cm dΩ1∫
Ω3
dΩ3
. (4.55)
4.1.6 Model results and discussion
Model equations (4.40-4.53) were solved numerically and the drug release data was obtained
using COMSOL Multiphysics®, version 5.3a. Special attention was made to the construction
of a suitable mesh, in that additional boundary layers were applied to Γ1 and the mesh was
considerably denser within the domains Ω2 and Ω3 to assist in improving conservation of mass.
Additionally, the advection-diffusion equations of the model were solved whilst in conservative
form: this typically leads to a more accurate approximation of the numerical solution and there-
fore improves mass conservation of drug. To give a measure of accuracy, each mesh considered
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was used in the time-dependent study and the theoretical mass within the whole system was
calculated. If mass conservation is achieved, then this value should be constant:∫
Ω1
cm dΩ1 + φ
∫
Ω2
cp dΩ2 +
∫
Ω3
cd dΩ3 = a constant.
In particular, this constant is equal to the initial drug mass. Since the model is solved numeri-
cally, this constant will be approximated and so the difference between the largest and smallest
mass values were taken. If the percentage difference between these values was less than 1 %,
mass was assumed to be sufficiently conserved. The final mesh used was custom made, was con-
structed from tetrahedral elements, and consisted of 243, 870 domain elements, 8652 boundary
elements, and 652 edge elements. Mesh elements had a maximum and minimum nondimen-
sional size of 1.97 and 0.587, respectively, and a maximum growth rate of 1.15. The mesh was
made using the “Normal” mesh setting calibrated for “Fluid Dynamics”, for all regions, how-
ever, 3 additional boundary layers were added to each surface to aid computational accuracy in
fluid/boundary interactions. This mesh (Figure 4.6) gave an error in mass conservation of much
less than 1 % and was used in all studies.
Figure 4.6: FEM mesh generated for the 3D porous pin geometry for the influence of flow study.
Mesh consists of 243, 870 domain elements, 8652 boundary elements, and 652 edge elements.
In addition to the time-dependent model, a similar steady state model was also derived in
which the stationary velocity field was calculated and this acted as input for the advection-
diffusion equations. A model based purely on diffusion was also derived for comparison pur-
poses. The additional models can be formulated by neglecting relevant parts of the model equa-
tions (4.40-4.53) to give steady-state and the diffusion-only equivalent models. All models were
solved using the GMRES iterative method, alongside the BDF to handle time advancement,
where applicable. The integrals in release profile equation (4.55) were calculated in the software
using Gaussian quadrature. To assess whether or not the inclusion of fluid flow is necessary, the
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release profiles of the three models were compared: the time-dependent model (4.40-4.53), its
steady-state and diffusion-only equivalents. Parameter values used in the simulations are those
in Table 4.1, together with the new parameters for the flow inclusion study in Table 4.2.
Parameter Value
Lm 30 mm [62]
Hm 35.65 mm
u pi rad/s [11]
κ 8.63× 10−14 m2 [63]
ν 6.96× 10−7 m2/s [64]
Table 4.2: Table of parameter values used in the influence of flow studies.
Figure 4.7: Plot showing fraction of drug released, versus nondimensional time, for the porous
pin for the three models considered.
Figure 4.7 shows that when compared to a diffusion-only problem, the inclusion of fluid
flow has a negligible impact on the release of drug from the porous pin. Since there is no
appreciable influence by fluid flow, the 1D approximation is viable. This result is somewhat
expected considering the reasonably low level of porosity and the calculated permeability of
the porous wall of the pin: 0.17 and 8.63 × 10−14 m2, respectively. Given the values of these
parameters, it is not surprising that fluid flow is hindered to insignificant levels within the porous
pin. A suitable measure of the influence fluid flow has on the release of drug from the porous pin
is to compare it to the diffusive transport rate in the pin’s inner drug region (Ω3) and porous wall
(Ω2). This can be achieved via an average Péclet number (Pe), which is the ratio of advective
to diffusive transport rates and may be calculated from:
PeΩ2 =
uΩ2Lp
Dp
, P eΩ3 =
uΩ3Ld
Df
,
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where uΩ2 and uΩ3 are the average fluid velocity magnitudes within the pin’s porous wall and
inner drug core, respectively. The calculated Péclet numbers of the pin’s porous wall and inner
drug core are approximately 0.022 and 0.0012, respectively. These numbers suggest that the
transport due to advection is much slower than what diffusion can achieve. This evidence further
suggests that modelling fluid flow within the pin is not important when considering drug-release
from this porous pin.
4.2 1D radial diffusion model
The previous section demonstrated that drug release from the porous pin is a 1D problem. This
is not unexpected since the geometry is symmetric both angularly and along the z-axis, and
although the wall of the pin is porous, the low level of its porosity and permeability restrict the
flow of fluid within the pin. This permits the reduction of the geometry to a radial line from the
centre of the inner drug core, through the porous and the bulk release medium layers (Figure
4.8).
Figure 4.8: 1D geometry showing the drug, porous and release medium regions, with their
respective concentrations cd(r, t), cp(r, t) and cm(r, t) and thicknesses Ld, Lp and Lm. The
position of boundaries and interfaces are marked with r = 0, L1, L2 and L3.
Model parameters, inner drug core radius, porous layer thickness, interface and boundary
locations are as they were defined earlier in the chapter. However, as the model is based on a 1D
cylindrical coordinate system, the drug concentrations in the inner drug core, the porous wall and
the release medium are now defined: cd(r, t), cp(r, t) and cm(r, t). As before, the position of the
boundaries and the interfaces are a combination of the thicknesses of each layer. An additional
boundary location is the endpoint of the release medium and is defined L3 = Ld + Lp + Lm.
Assuming that the drug is fully wetted and is readily soluble the proposed model is:
∂cd
∂t
= Df
(
1
r
∂cd
∂r
+
∂2cd
∂r2
)
, 0 < r < L1, t > 0, (4.56)
φ
∂cp
∂t
= Dp
(
1
r
∂cp
∂r
+
∂2cp
∂r2
)
, L1 < r < L2, t > 0, (4.57)
∂cm
∂t
= Df
(
1
r
∂cm
∂r
+
∂2cm
∂r2
)
, L2 < r < L3, t > 0, (4.58)
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−Df ∂cd
∂r
= 0, r = 0, t > 0, (4.59)
cd = cp, −Df ∂cd
∂r
= −Dp∂cp
∂r
, r = L1, t > 0, (4.60)
cp = cm, −Dp∂cp
∂r
= −Df ∂cm
∂r
, r = L2, t > 0, (4.61)
−Df ∂cm
∂r
= 0, r = L3, t > 0, (4.62)
cd = c
0
d, 0 ≤ r ≤ L1, cp = 0, L1 < r ≤ L2, cm = 0, L2 < r ≤ L3, t = 0. (4.63)
The model (4.56-4.63) consists of coupled diffusion equations (4.56-4.58) to describe diffu-
sive mass transport in each layer. The endpoints of the geometry, where r = 0 and r = L3, have
zero-flux conditions applied (4.59, 4.62). At the interfaces, where r = L1 and r = L2, both con-
tinuity concentration and flux conditions are applied (4.60-4.61). It is assumed that initially, the
drug is only present in the first layer, as shown by initial conditions (4.63). The model equations
(4.56-4.63) are nondimensionalised with the following scalings:
c ′i =
ci
c0d
, r ′ =
r
Ld
, t ′ =
Df
L2d
t,
where i = d, p,m. For the sake of simplicity, let D = Dp/Df , r2 = L2/Ld and r3 = L3/Ld
and by definition r1 = 1. Dropping the primes for clarity, the scalings give the following
nondimensional model:
∂cd
∂t
=
(
1
r
∂cd
∂r
+
∂2cd
∂r2
)
, 0 < r < 1, t > 0, (4.64)
φ
∂cp
∂t
= D
(
1
r
∂cp
∂r
+
∂2cp
∂r2
)
, 1 < r < r2, t > 0, (4.65)
∂cm
∂t
=
(
1
r
∂cm
∂r
+
∂2cm
∂r2
)
, r2 < r < r3, t > 0, (4.66)
∂cd
∂r
= 0, r = 0, t > 0, (4.67)
cd = cp,
∂cd
∂r
= D
∂cp
∂r
, r = 1, t > 0, (4.68)
cp = cm, D
∂cp
∂r
=
∂cm
∂r
, r = r2, t > 0, (4.69)
∂cm
∂r
= 0, r = r3, t > 0, (4.70)
cd = 1, 0 ≤ r ≤ 1, cp = 0, 1 < r ≤ r2, cm = 0, r2 < r ≤ r3, t = 0. (4.71)
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4.2.1 Solution procedure
Model equations (4.64-4.71) are solved via the Separation of Variables method. It is assumed
that the solution in each layer has the following form:
ci(r, t) = Ri(r)Ti(t), i = d, p,m. (4.72)
Substituting solution form (4.72) into equations (4.64-4.66) gives rise to the following ODEs in
time, t:
T˙d(t) + λ
2
dTd(t) = 0, T˙p(t) +
Dλ2p
φ
Tp(t) = 0, T˙m(t) + λ
2
mTm(t) = 0,
where the single dot notation indicates the first derivative with respect to time. The ODEs have
the solutions:
Td(t) = exp
(−λ2dt) , Tp(t) = exp(−Dλ2pφ t
)
, Tm(t) = exp
(−λ2mt) . (4.73)
From the solutions in time (4.73), a relationship between the eigenvalues is obtained by setting
Td(t) = Tp(t) = Tm(t):
λ2d =
Dλ2p
φ
= λ2m, (4.74)
Additionally, from the substitution of (4.72) into (4.64-4.66), a Sturm–Liouville eigenvalue
problem is obtained. Where single and double superscript primes indicate the first and second
spatial derivatives, respectively, the ODEs in space can be expressed in the following general
form:
R′′i (r) +
1
r
R′i(r) + λ
2
iRi(r) = 0, (4.75)
with boundary conditions:
R′d(r) = 0, r = 0, t > 0, (4.76)
Rd(r) = Rp(r), R
′
d(r) = DR
′
p(r), r = 1, t > 0, (4.77)
Rp(r) = Rm(r), DR
′
p(r) = R
′
m(r), r = r2, t > 0, (4.78)
R′m(r) = 0, r = r3, t > 0. (4.79)
Equation (4.75) can be rearranged into the following form:
r2R′′i (r) + rR
′
i(r) + λ
2
i r
2Ri(r) = 0. (4.80)
This is in the form of Bessel’s differential equation. Due to the Neumann (zero-flux) boundary
conditions, λ2i ≥ 0. For λ2i = 0, it is found that Rd = Rp = Rm = a constant. Therefore,
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T˙i = 0⇒ Ti = γ, a constant. For λ2i > 0, (4.80) has the general solution [65–67]:
Ri(r) = αiJ0 (λir) + βiY0 (λir) , (4.81)
where αi and βi are constants and J0 (λir) and Y0 (λir) are the zero-order Bessel functions of
the first and second kind, respectively. More generally, Bessel functions of the first and second
kind, of integer order ν, are defined as [65, 66]:
Jν (λir) =
∞∑
n=0
(−1)n
n!Γ(n+ ν + 1)
(
λir
2
)2n+ν
,
Yν (λir) =
2
pi
Jν (λir) ln
(
λir
2
)
− 1
pi
ν−1∑
n=0
(ν − n− 1)!
n!
(
λir
2
)2n−ν
− 1
pi
∞∑
n=0
(−1)n
n!Γ(n+ ν + 1)
(
λir
2
)2n+ν
(ψ(n+ ν + 1) + ψ(n+ 1)),
where Γ and ψ are the gamma and digamma functions, respectively. With the general solutions
obtained (4.81), the boundary conditions can be applied and starting with (4.76,4.79), it is found
that βd = 0, so that the solution remains finite, and that αm can be expressed in terms of βm,
thus the solutions have the form:
Rd = αdJ0 (λdr) , (4.82)
Rp = αpJ0 (λpr) + βpY0 (λpr) , (4.83)
Rm = βm
(
J1 (λmr3)Y0 (λmr)− Y1 (λmr3) J0 (λmr)
J1 (λmr3)
)
. (4.84)
The continuity of concentration conditions in (4.77-4.78) allow αd and βm to be rewritten, giv-
ing:
αd =
αpJ0 (λp) + βpY0 (λp)
J0 (λd)
, (4.85)
βm =
J1 (λmr3) [αpJ0 (λpr2) + βpY0 (λpr2)]
Y0 (λmr2) J1 (λmr3)− J0 (λmr2)Y1 (λmr3) . (4.86)
Through a combination of (4.85-4.86) and the continuity of flux conditions in (4.77-4.78), the
following relations are obtained:
λdJ1 (λd) [αpJ0 (λp) + βpY0 (λp)] = DλpJ0 (λd) [αpJ1 (λp) + βpY1 (λp)] , (4.87)
Dλp [αpJ1 (λpr2) + βpY1 (λpr2)] [Y0 (λmr2) J1 (λmr3)− J0 (λmr2)Y1 (λmr3)]
=λm [αpJ0 (λpr2) + βpY0 (λpr2)] [Y1 (λmr2) J1 (λmr3)− J1 (λmr2)Y1 (λmr3)] . (4.88)
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Equations (4.87-4.88) can be rewritten with αp and βp as common factors:
αp [λdJ1 (λd) J0 (λp)−DλpJ0 (λd) J1 (λp)]
=βp [DλpJ0 (λd)Y1 (λp)− λdJ1 (λd)Y0 (λp)] , (4.89)
αp
[
DλpJ1 (λpr2) [Y0 (λmr2) J1 (λmr3)− J0 (λmr2)Y1 (λmr3)]
−λmJ0 (λpr2) [Y1 (λmr2) J1 (λmr3)− J1 (λmr2)Y1 (λmr3)]
]
=βp
[
λmY0 (λpr2) [Y1 (λmr2) J1 (λmr3)− J1 (λmr2)Y1 (λmr3)]
−DλpY1 (λpr2) [Y0 (λmr2) J1 (λmr3)− J0 (λmr2)Y1 (λmr3)]
]
. (4.90)
Equations (4.89-4.90) form a system of two homogeneous linear equations in the two unknowns
αp and βp. One could make a simple substitution with these equations, however, this will give
rise to the trivial solution of αp = βp = 0. To avoid this, the determinant of the matrix of
coefficients must be equal to zero, that is:
[λdJ1 (λd) J0 (λp)−DλpJ0 (λd) J1 (λp)]
×
[
λmY0 (λpr2) [Y1 (λmr2) J1 (λmr3)− J1 (λmr2)Y1 (λmr3)]
−DλpY1 (λpr2) [Y0 (λmr2) J1 (λmr3)− J0 (λmr2)Y1 (λmr3)]
]
−

[DλpJ0 (λd)Y1 (λp)− λdJ1 (λd)Y0 (λp)]
×
[
DλpJ1 (λpr2) [Y0 (λmr2) J1 (λmr3)− J0 (λmr2)Y1 (λmr3)]
−λmJ0 (λpr2) [Y1 (λmr2) J1 (λmr3)− J1 (λmr2)Y1 (λmr3)]
] = 0. (4.91)
Transcendental equation (4.91) has infintely many roots which take the form of eigenvalue
triplets (λd, λp, λm). However, equation (4.91) may be expressed solely in terms of λd using
(4.74), such that an eigen-condition is obtained. If satisfied, this condition gives αp in terms of
βp and provides expressions for αd and βm, both in terms of βp. For simplicity, the following
function is defined:
Λ(λd, λp) =
DλpJ0 (λd)Y1 (λp)− λdJ1 (λd)Y0 (λp)
λdJ1 (λd) J0 (λp)−DλpJ0 (λd) J1 (λp) ,
Therefore constants αp, αd and βm of equations (4.82-4.84) are:
αp = βpΛ(λd, λp), (4.92)
αd = βp
(
Λ(λd, λp)J0 (λp) + Y0 (λp)
J0 (λd)
)
, (4.93)
βm = βp
(
J1 (λmr3) [Λ(λd, λp)J0 (λpr2) + Y0 (λpr2)]
Y0 (λmr2) J1 (λmr3)− J0 (λmr2)Y1 (λmr3)
)
. (4.94)
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For every eigenvalue triplet (λd,g, λp,g, λm,g), g = 1, 2, 3..., the values of αp,g, αd,g and βm,g are
obtained from (4.92-4.94). The constants βp,g associated with each eigenvalue triplet may be
calculated via the initial condition. Therefore, the corresponding eigenfunctions are:
Rd,g = βp,gR˜d,g,
Rp,g = βp,gR˜p,g,
Rm,g = βp,gR˜m,g,
where R˜i,g are:
R˜d,g =
(
Λ(λd,g, λp,g)J0 (λp,g) + Y0 (λp,g)
J0 (λd,g)
)
J0 (λd,gr) ,
R˜p,g = Λ(λd,g, λp,g)J0 (λp,gr) + Y0 (λp,gr) ,
R˜m,g =
(
Λ(λd,g, λp,g)J0 (λp,gr2) + Y0 (λp,gr2)
Y0 (λm,gr2) J1 (λm,gr3)− J0 (λm,gr2)Y1 (λm,gr3)
)
× (J1 (λm,gr3)Y0 (λm,gr)− Y1 (λm,gr3) J0 (λm,gr)) .
The final solutions are then a linear superposition of the fundamental solutions Ri and Ti and
have the form:
cd(r, t) = γ +
∞∑
g=1
βp,gR˜d,g exp
(−λ2d,gt) , (4.95)
cp(r, t) = γ +
∞∑
g=1
βp,gR˜p,g exp
(
−Dλ
2
p,g
φ
t
)
, (4.96)
cm(r, t) = γ +
∞∑
g=1
βp,gR˜m,g exp
(−λ2m,gt) . (4.97)
4.2.2 Application of the initial condition
Evaluating the solutions (4.95-4.97) at t = 0, the values of γ and βp,g can be determined. Starting
with γ, the constant eigenfunction associated with the eigenvalue λi = 0, multiplying throughout
by r, integrating over the domains and summing gives:
γ
∫ 1
0
rdr + γφ
∫ r2
1
rdr + γ
∫ r3
r2
rdr =
∫ 1
0
rdr,
evaluating the integrals and solving for γ:
γ =
1
1− φ+ r22 (φ− 1) + r23
. (4.98)
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For λi > 0, βp,g may be determined by evaluating the solutions at t = 0 and by multiplying
(4.95) by rR˜d,h, (4.96) by rR˜p,h and (4.97) by rR˜m,h, h = 1, 2, 3..., integrating over the domains
and summing: ∫ 1
0
∞∑
g=1
βp,grR˜d,gR˜d,hdr
+ φ
∫ r2
1
∞∑
g=1
βp,grR˜p,gR˜p,hdr
+
∫ r3
r2
∞∑
g=1
βp,grR˜m,gR˜m,hdr =
∫ 1
0
rR˜d,hdr. (4.99)
In order to determine the value of βp,g within (4.99), the orthogonality condition of the eigen-
function system (R˜d,g, R˜p,g, R˜m,g) must be established, that is:∫ 1
0
rR˜d,gR˜d,hdr + φ
∫ r2
1
rR˜p,gR˜p,hdr +
∫ r3
r2
rR˜m,gR˜m,hdr = 0, g 6= h. (4.100)
Consider two different eigenvalues λd,g and λd,h and the corresponding eigenfunctions R˜d,g and
R˜d,h. Equation (4.75) can be rewritten as:
d
dr
(
rR˜′d,g
)
+ λ2d,grR˜d,g = 0, (4.101)
and similarly for R˜d,h:
d
dr
(
rR˜′d,h
)
+ λ2d,hrR˜d,h = 0. (4.102)
By multiplying (4.101) by R˜d,h and (4.102) by R˜d,g, then subtracting the two:
R˜d,g
d
dr
(
rR˜′d,h
)
− R˜d,h d
dr
(
rR˜′d,g
)
+
(
λ2d,h − λ2d,g
)
rR˜d,gR˜d,h = 0, (4.103)
integrating (4.103) and simplifying:
(
λ2d,h − λ2d,g
) ∫ 1
0
rR˜d,hR˜d,gdr =
[
rR˜d,hR˜
′
d,g
]1
0
−
[
rR˜d,gR˜
′
d,h
]1
0
,
= R˜d,h(1)R˜
′
d,g(1)− R˜d,g(1)R˜′d,h(1). (4.104)
Similarly for the eigenvalue pair λp,g and λp,h and the corresponding eigenfunctions R˜p,g and
R˜p,h, with the result multiplied by D:
D
(
λ2p,h − λ2p,g
) ∫ r2
1
rR˜p,hR˜p,gdr = D
[
rR˜p,hR˜
′
p,g
]r2
1
−D
[
rR˜p,gR˜
′
p,h
]r2
1
,
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=
[
r2R˜p,h(r2)DR˜
′
p,g(r2)− R˜p,h(1)DR˜′p,g(1)
]
−
[
r2R˜p,g(r2)DR˜
′
p,h(r2)− R˜p,g(1)DR˜′p,h(1)
]
,
(4.105)
and again for the eigenvalue pair λm,g and λm,h and the associated eigenfunctions R˜m,g and
R˜m,h:
(
λ2m,h − λ2m,g
) ∫ r3
r2
rR˜m,hR˜m,gdr =
[
rR˜m,hR˜
′
m,g
]r3
r2
−
[
rR˜m,gR˜
′
m,h
]r3
r2
,
=
[
r3R˜m,h(r3)R˜
′
m,g(r3)− r2R˜m,h(r2)R˜′m,g(r2)
]
−
[
r3R˜m,g(r3)R˜
′
m,h(r3)− r2R˜m,g(r2)R˜′m,h(r2)
]
.
(4.106)
Combining equations (4.104-4.106) and using boundary conditions (4.76-4.79), the right-hand
side of the resultant equation reduces to zero:
(
λ2d,h − λ2d,g
) ∫ 1
0
rR˜d,hR˜d,gdr
+D
(
λ2p,h − λ2p,g
) ∫ r2
1
rR˜p,hR˜p,gdr
+
(
λ2m,h − λ2m,g
) ∫ r3
r2
rR˜m,hR˜m,gdr = 0, (4.107)
using the relationship between the eigenvalues (4.74), equation (4.107) reduces to:
(
λ2d,h − λ2d,g
)(∫ 1
0
rR˜d,hR˜d,gdr + φ
∫ r2
1
rR˜p,hR˜p,gdr +
∫ r3
r2
rR˜m,hR˜m,gdr
)
= 0, (4.108)
thus demonstrating (4.100). Rewriting equation (4.99) and using orthogonality condition (4.100),
the value of βp,g can be determined:
βp,g =
∫ 1
0
rR˜d,gdr∫ 1
0
rR˜2d,gdr + φ
∫ r2
1
rR˜2p,gdr +
∫ r3
r2
rR˜2m,gdr
. (4.109)
The integrals within (4.109) can be calculated analytically by considering Bessel’s differen-
tial equation of an arbitrary function R(r):
d
dr
(rR′) + λ2rR = 0, (4.110)
and integrating over an arbitrary interval [a, b]:∫ b
a
rRdr = − 1
λ2
[rR′]ba . (4.111)
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Considering (4.110) again, multiplying throughout by 2rR′ and simplifying gives:
d
dr
(rR′)2 + λ2r2
d
dr
(
R2
)
= 0.
Integrating over an arbitrary interval [a, b] gives rise to:∫ b
a
rR2dr =
1
2λ2
[
(rR′)2 + λ2r2R2
]b
a
. (4.112)
Using relations (4.111) and (4.112), an analytical expression for βp,g can be derived, the integrals
within equation (4.109) are found to be:∫ 1
0
rR˜d,gdr =
(
Λ(λd,g, λp,g)J0 (λp,g) + Y0 (λp,g)
J0 (λd,g)
)
J1 (λd,g)
λd,g
,
∫ 1
0
rR˜2d,gdr =
1
2
(
Λ(λd,gλp,g)J0 (λp,g) + Y0 (λp,g)
J0 (λd,g)
)2 (
J1 (λd,g)
2 + J0 (λd,g)
2) ,
φ
∫ r2
1
rR˜2p,gdr =
φr22
2
(
(Λ(λd,gλp,g)J1 (λp,gr2) + Y1 (λp,gr2))
2
+ (Λ(λd,gλp,g)J0 (λp,gr2) + Y0 (λp,gr2))
2
)
− φ
2
(
(Λ(λd,gλp,g)J1 (λp,g) + Y1 (λp,g))
2
+ (Λ(λd,gλp,g)J0 (λp,g) + Y0 (λp,g))
2
)
,
∫ r3
r2
rR˜2m,gdr =
(
Λ(λd,gλp,g)J0 (λp,gr2) + Y0 (λp,gr2)
Y0 (λm,gr2) J1 (λm,gr3)− J0 (λm,gr2)Y1 (λm,gr3)
)2
×

r23
2
(J1 (λm,gr3)Y0 (λm,gr3)− Y1 (λm,gr3) J0 (λm,gr3))2
−r
2
2
2
(
(J1 (λm,gr3)Y1 (λm,gr2)− Y1 (λm,gr3) J1 (λm,gr2))2
+ (J1 (λm,gr3)Y0 (λm,gr2)− Y1 (λm,gr3) J0 (λm,gr2))2
)
 .
In summary, the complete set of solutions are:
cd(r, t) = γ +
∞∑
g=1
βp,gR˜d,g exp
(−λ2d,gt) , (4.113)
cp(r, t) = γ +
∞∑
g=1
βp,gR˜p,g exp
(
−Dλ
2
p,g
φ
t
)
, (4.114)
cm(r, t) = γ +
∞∑
g=1
βp,gR˜m,g exp
(−λ2m,gt) . (4.115)
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where:
γ =
1
1− φ+ r22 (φ− 1) + r23
,
βp,g =
∫ 1
0
rR˜d,gdr∫ 1
0
rR˜2d,gdr + φ
∫ r2
1
rR˜2p,gdr +
∫ r3
r2
rR˜2m,gdr
,
R˜d,g =
(
Λ(λd,g, λp,g)J0 (λp,g) + Y0 (λp,g)
J0 (λd,g)
)
J0 (λd,gr) ,
R˜p,g = Λ(λd,g, λp,g)J0 (λp,gr) + Y0 (λp,gr) ,
R˜m,g =
(
Λ(λd,g, λp,g)J0 (λp,gr2) + Y0 (λp,gr2)
Y0 (λm,gr2) J1 (λm,gr3)− J0 (λm,gr2)Y1 (λm,gr3)
)
× (J1 (λm,gr3)Y0 (λm,gr)− Y1 (λm,gr3) J0 (λm,gr)) .
The eigenvalues are obtained via solving the transcendental equation:
[λd,gJ1 (λd,g) J0 (λp,g)−Dλp,gJ0 (λd,g) J1 (λp,g)]
×
[
λm,gY0 (λp,gr2) [Y1 (λm,gr2) J1 (λm,gr3)− J1 (λm,gr2)Y1 (λm,gr3)]
−Dλp,gY1 (λp,gr2) [Y0 (λm,gr2) J1 (λm,gr3)− J0 (λm,gr2)Y1 (λm,gr3)]
]
−

[Dλp,gJ0 (λd,g)Y1 (λp,g)− λd,gJ1 (λd,g)Y0 (λp,g)]
×
[
Dλp,gJ1 (λp,gr2) [Y0 (λm,gr2) J1 (λm,gr3)− J0 (λm,gr2)Y1 (λm,gr3)]
−λm,gJ0 (λp,gr2) [Y1 (λm,gr2) J1 (λm,gr3)− J1 (λm,gr2)Y1 (λm,gr3)]
] = 0.
4.2.3 Equations for mass of drug
Dimensionally, the mass of drug at some time t in each region is:
Md(t) =
∫ z
0
∫ 2pi
0
∫ L1
0
cd r dr dθ dz,
Mp(t) = φ
∫ z
0
∫ 2pi
0
∫ L2
L1
cp r dr dθ dz,
Mm(t) =
∫ z
0
∫ 2pi
0
∫ L3
L2
cm r dr dθ dz.
Mass can be normalised with M0d , the total initial mass of drug in region d. Since the inner drug
core is cylindrical, M0d is therefore:
M0d = c
0
dpiL
2
dz.
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Therefore, the normalised mass in each region is:
Md(t)
M0d
=
1
c0dpiL
2
dz
2pizc0dL
2
d
∫ 1
0
c ′d r
′ dr ′,
Mp(t)
M0d
=
1
c0dpiL
2
dz
2pizc0dL
2
dφ
∫ r2
1
c ′p r
′ dr ′,
Mm(t)
M0d
=
1
c0dpiL
2
dz
2pizc0dL
2
d
∫ r3
r2
c ′m r
′ dr ′.
Simplifying and dropping the primes for clarity:
Md(t)
M0d
= 2
∫ 1
0
cd r dr,
Mp(t)
M0d
= 2φ
∫ r2
1
cp r dr,
Mm(t)
M0d
= 2
∫ r3
r2
cm r dr.
The time dependent equations for nondimensional mass in each region can be computed from
solutions (4.113-4.115) via integration:
Md(t)
M0d
= 2
∫ 1
0
(
γ +
∞∑
g=1
βp,gR˜d,g exp
(−λ2d,gt)
)
r dr,
= 2
(
γd +
∞∑
g=1
βp,gR
∗
d,g exp
(−λ2d,gt)
)
,
where:
γd =
1
2 (1− φ+ r22 (φ− 1) + r23)
,
R∗d,g =
(
Λ(λd,g, λp,g)J0 (λp,g) + Y0 (λp,g)
J0 (λd,g)
)
J1 (λd,g)
λd,g
.
Mp(t)
M0d
= 2φ
∫ r2
1
(
γ +
∞∑
g=1
βp,gR˜p,g exp
(
−Dλ
2
p,g
φ
t
))
r dr,
= 2φ
(
γp +
∞∑
g=1
βp,gR
∗
p,g exp
(
−Dλ
2
p,g
φ
t
))
,
where:
γp =
φ (r22 − 1)
2 (1− φ+ r22 (φ− 1) + r23)
,
R∗p,g = Λ(λd,g, λp,g)
(r2J1 (λp,gr2)− J1 (λp,g))
λp,g
+
r2Y1 (λp,gr2)− Y1 (λp,g)
λp,g
.
Mm(t)
M0d
= 2
∫ r3
r2
(
γ +
∞∑
g=1
βp,gR˜m,g exp
(−λ2m,gt)
)
r dr,
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= 2
(
γm +
∞∑
g=1
βp,gR
∗
m,g exp
(−λ2m,gt)
)
,
where:
γm =
(r23 − r22)
2 (1− φ+ r22 (φ− 1) + r23)
,
R∗m,g =
(
Λ(λd,g, λp,g)J0 (λp,gr2) + Y0 (λp,gr2)
Y0 (λm,gr2) J1 (λm,gr3)− J0 (λm,gr2)Y1 (λm,gr3)
)
× r2
λm,g
(Y1 (λm,gr3) J1 (λm,gr2)− J1 (λm,gr3)Y1 (λm,gr2)) .
4.2.4 Release profile
The released profile can be found either by the loss of mass from the first two regions, d and p,
or by the accumulation of mass in the release medium, which is then normalised with the initial
mass in the system, M0d . Then the cumulative fraction released, Mfrac, is:
Mfrac(t) =
M0d − (Md(t) +Mp(t))
M0d
= 1−
(
Md(t)
M0d
+
Mp(t)
M0d
)
,
= 1− 2
[
γd +
∞∑
g=1
βp,gR
∗
d,g exp
(−λ2d,gt)+ φ
(
γp +
∞∑
g=1
βp,gR
∗
p,g exp
(
−Dλ
2
p,g
φ
t
))]
,
= 1− 2
[ ∞∑
g=1
βp,g
(
R∗d,g exp
(−λ2d,gt)+ φR∗p,g exp(−Dλ2p,gφ t
))]
− φ (r
2
2 − 1) + 1
1− φ+ r22 (φ− 1) + r23
,
the simpler approach to generating the release profile is to plot the growing mass in the release
medium, this leads to a simpler expression for the release profile:
Mfrac(t) =
Mm(t)
M0d
= 2
[
γm +
∞∑
g=1
βp,gR
∗
m,g exp
(−λ2m,gt)
]
,
= 2
∞∑
g=1
βp,gR
∗
m,g exp
(−λ2m,gt)+ (r23 − r22)1− φ+ r22 (φ− 1) + r23 . (4.116)
4.2.5 Model results and discussion
Equations (4.113-4.115) are used to calculate the concentration solutions and equation (4.116)
is used to calculate the release profile, however, these equations feature infinite series whose
infinite summations are unknown. The sums will have to be truncated to approximate these in-
finite sums. The truncation value chosen is N , the number of roots of (4.91) in a given interval.
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The value of N will affect the accuracy of the results and if too few roots are used or missed
entirely, the solution will not converge. The values of the system parameters will change (4.91)
and hence the location of the roots. For a certain parameter set, more/less roots may be required
for an accurate solution. To accomplish this, the initial root searching interval used in the simu-
lations is [0, 100]. To determine whether or not N is a sufficient number of roots to produce an
accurate solution, the theoretical masses MSN+1 and MSN for the sequences of roots SN+1 and
SN , are considered and if:
100×
∫ t
0
MSN+1(t)dt−
∫ t
0
MSN (t)dt∫ t
0
MSN (t)dt
< 1%,
for some time t, then N is deemed sufficiently accurate. To ensure smooth plots for concentra-
tion profiles and release profiles, the intervals considered for the nondimensional variables r and
t, are divided into 100 equally spaced increments. The solution of the 1D radial diffusion model
can be evaluated using MATLAB®R2019a via a series of for-loops to calculate concentration
and drug release data. Rather than solving the transcendental equation (4.91) in its current form,
using relation (4.74), the equation may be transformed into an expression of one eigenvalue,
which is simpler to solve. Additionally, solution equations (4.113-4.115) can also be rewrit-
ten using relation (4.74) for simplicity in their evaluation. The parameter values used in the
evaluation are shown in Table 4.3.
Parameter Value
Ld 1.575 mm [11]
Lp 1.6 mm [11]
Lm 30 mm
φ 0.17 [11]
φe 0.9× φ
τ 3
Df 1× 10−9 m2/s
Dp = φeDf/τ 5.1× 10−11 m2/s
Table 4.3: Table of parameter values used in the evaluation of the 1D radial diffusion model.
Figure 4.9 (a) Shows an example concentration plot at three times, which demonstrates the
zero-flux boundary conditions, in that drug cannot leave the system. The release medium accu-
mulates drug until the steady-state, γ, is reached. Physically, γ is the steady-state concentration
in which the initial drug concentration, c0d, is spread throughout all regions. Figure 4.9 (b) shows
the release profile generated by the 1D radial diffusion model. Since the shape of the release
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(a) (b)
Figure 4.9: (a) Magnified plot showing nondimensional concentration verses nondimensional
space at three nondimensional times. (b) Plot showing fraction of drug release verses nondi-
mensional time.
profile is a gentle curve, which is characteristic of pure-diffusion models, the 1D radial model
is not sufficient to be able to replicate the near-linear release data in Figure 4.1 (b). Since the
cylindrical geometry of the porous pin may be reduced to a 1D problem, this suggests that the
coordinate system is not at fault. Further reading of the experimental details shows that the drug
(Linezolid), is loaded into the porous pin in a dry, solid form. This means that the drug must
transition into the solute phase (dissolve), before diffusion of drug particles out of the pin may
occur. Since one of the assumptions in the 1D radial diffusion model was that the drug was
already in the solute phase, it would appear that the next step in modelling drug-release from the
porous pin must include the dissolution process.
4.3 1D radial diffusion-dissolution model
In previous sections, it was found that a mathematical model of drug release from the porous
pin could be reduced to a 1D model, through a combination of symmetry and the insignificant
influence the stirring of the release medium has on the transport of the drug. However, a purely
diffusive process is not suitable to model the release of drug from the porous pin and a new
process is included: drug dissolution. The dissolution model of choice is based on the Noyes-
Whitney model of dissolution, which assumes that the rate of dissolution is proportional to the
difference in the drug solubility and the concentration of dissolved drug [32]. Using the same
geometry from Section 4.2 (Figure 4.8) and assuming that the drug is initially fully wetted, the
proposed diffusion-dissolution model is:
∂b
∂t
= −βbα (S − cd) , 0 < r < L1, t > 0, (4.117)
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∂cd
∂t
= Df
(
1
r
∂cd
∂r
+
∂2cd
∂r2
)
+ βbα (S − cd) , 0 < r < L1, t > 0, (4.118)
φ
∂cp
∂t
= Dp
(
1
r
∂cp
∂r
+
∂2cp
∂r2
)
, L1 < r < L2, t > 0, (4.119)
∂cm
∂t
= Df
(
1
r
∂cm
∂r
+
∂2cm
∂r2
)
, L2 < r < L3, t > 0, (4.120)
−Df ∂cd
∂r
= 0, r = 0, t > 0, (4.121)
cd = cp, −Df ∂cd
∂r
= −Dp∂cp
∂r
, r = L1, t > 0, (4.122)
cp = cm, −Dp∂cp
∂r
= −Df ∂cm
∂r
, r = L2, t > 0, (4.123)
−Df ∂cm
∂r
= 0, r = L3, t > 0, (4.124)
b = b0, 0 ≤ r ≤ L1, cd = 0, 0 ≤ r ≤ L1, t = 0, (4.125)
cp = 0, L1 < r ≤ L2, cm = 0, L2 < r ≤ L3, t = 0, (4.126)
Model equations (4.117-4.126) are identical to the 1D diffusion model (4.56-4.63) considered
in the previous section. However, there is an additional equation of variable, b(r, t), the concen-
tration of undissolved drug (4.117), which describes the dissolution process. The equation for
drug transport in the inner drug region (4.118) has an added component, a reaction term which
supplies drug in the solute phase to the inner drug region as b is depleted. There are also new
parameters, which include, S, the solubility of the drug, β, the dissolution rate and b0, the initial
undissolved drug concentration. Also added to the model is α, which is a constant, the value of
which is likely influenced by the geometrical configuration/device design and chemical proper-
ties of the drug. The work by Hixson and Crowell [33] modified the Noyes-Whitney dissolution
model [32], in which a nonlinear version of dissolution model was derived, with α = 2/3, to ac-
count for potential influences to the dissolution rate as the surface of dissolving drugs changed.
Later work by Frenning [34] concluded that α = 2/3 is likely the most suitable choice for drug
delivery, provided that the solid drug particles are initially, approximately uniform in size and
retain their shape during the dissolution process. Model equations (4.117-4.126) are nondimen-
sionalised with the following scalings:
c ′i =
c
S
, b ′ =
b
b0
, r ′ =
r
Ld
, t ′ =
Df
L2d
t,
where i = d, p,m. Dropping the primes for clarity, these scalings give the following nondimen-
sional model:
∂b
∂t
= −DaIIS∗bα (1− cd) , 0 < r < 1, t > 0, (4.127)
∂cd
∂t
=
(
1
r
∂cd
∂r
+
∂2cd
∂r2
)
+DaIIb
α (1− cd) , 0 < r < 1, t > 0, (4.128)
87
φ
∂cp
∂t
= D
(
1
r
∂cp
∂r
+
∂2cp
∂r2
)
, 1 < r < r2, t > 0, (4.129)
∂cm
∂t
=
(
1
r
∂cm
∂r
+
∂2cm
∂r2
)
, r2 < r < r3, t > 0, (4.130)
∂cd
∂r
= 0, r = 0, t > 0, (4.131)
cd = cp,
∂cd
∂r
= D
∂cp
∂r
, r = 1, t > 0, (4.132)
cp = cm, D
∂cp
∂r
=
∂cm
∂r
, r = r2, t > 0, (4.133)
∂cm
∂r
= 0, r = r3, t > 0, (4.134)
b = 1, 0 ≤ r ≤ 1, cd = 0, 0 ≤ r ≤ 1, t = 0, (4.135)
cp = 0, 1 < r ≤ r2, cm = 0, r2 < r ≤ r3, t = 0, (4.136)
where DaII is the second Damköhler number and is equal to L2dβb
α
0/Df and S
∗ is defined as
S/b0.
4.3.1 Equations for mass of drug
The dimensional mass in each region of the geometry may be found via:
Md(t) =
∫ z
0
∫ 2pi
0
∫ L1
0
b r dr dθ dz +
∫ z
0
∫ 2pi
0
∫ L1
0
cd r dr dθ dz,
Mp(t) = φ
∫ z
0
∫ 2pi
0
∫ L2
L1
cp r dr dθ dz,
Mm(t) =
∫ z
0
∫ 2pi
0
∫ L3
L2
cm r dr dθ dz.
The mass in each region can be normalised via M0d , the total initial mass of undissolved drug in
the core of the pin:
M0d = piL
2
dzb0,
hence, the normalised mass in each region is:
Md(t)
M0d
=
1
piL2dzb0
[
2pizb0L
2
d
∫ 1
0
b r ′ dr ′ + 2pizSL2d
∫ 1
0
cd r
′ dr ′
]
,
Mp(t)
M0d
=
1
piL2dzb0
2pizφSL2d
∫ r2
1
cp r
′ dr ′,
Mm(t)
M0d
=
1
piL2dzb0
2pizSL2d
∫ r3
r2
cm r
′ dr ′.
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Simplifying and dropping the primes for clarity:
Md(t)
M0d
= 2
[∫ 1
0
b r dr + S∗
∫ 1
0
cd r dr
]
,
Mp(t)
M0d
= 2φS∗
∫ r2
1
cp r dr,
Mm(t)
M0d
= 2S∗
∫ r3
r2
cm r dr.
4.3.2 Release profile
The release profile may be obtained through the mass of drug released from the porous pin:
Mfrac(t) =
M0d − (Md(t) +Mp(t))
M0d
= 1−
(
Md(t)
M0d
+
Mp(t)
M0d
)
,
= 1− 2
[∫ 1
0
b r dr + S∗
(∫ 1
0
cd r dr + φ
∫ r2
1
cp r dr
)]
,
or by the accumulation of mass in the release medium:
Mfrac(t) =
Mm(t)
M0d
= 2S∗
∫ r3
r2
cm r dr. (4.137)
4.3.3 Sensitivity analysis
Model equations (4.127-4.136) were solved numerically using COMSOL®, version 5.3a, specif-
ically using the direct PARDISO method, with the BDF to handle time advancement. The 1D
geometry was discretised into 2500 spatial points, which was found to produce negligible er-
ror due to mass loss. The integral in the equation used to calculate the release profile (4.137)
was performed within the software using Gaussian quadrature. A sensitivity analysis is a use-
ful approach to obtain a thorough understanding of model performance. Therefore, key model
parameters are fixed at baseline values (Table 4.4) and varied sequentially to determine their
influence on the release profile and thus gauge their relative importance. The authors state that
the porous pins used in their experiments were loaded with 95 − 120 mg of the drug for the re-
lease experiments. This imprecise drug loading introduces unnecessary uncertainty to the model
output. However, for the sake of simplicity, it is assumed that the drug loading is 100 mg for the
model sensitivity analysis and validation.
To adequately test the sensitivity of the release profile to changes in model parameters, a
suitable range of parameter values is required. It is assumed that the baseline value for reac-
tion exponent is α = 2/3, due to the work of Frenning [34], therefore the range chosen for the
sensitivity study was decided to be 1/3 greater than, and less than, the baseline value. Addi-
tionally, α = 0 is also included within the range of test parameter values to cover the simplest
linear reaction, and so 0 ≤ α ≤ 1. The dissolution rate, β, is unknown and so the baseline
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value of β = 10−5 was chosen such that the associated second Damköhler number would be of
order 1. Therefore, to cover a suitable range of possible values of β, it was decided that values
which cover two orders of magnitude above and below the baseline value would be sufficient
i.e. 10−7 ≤ β ≤ 10−3. The baseline value for the free-diffusion coefficient was chosen to be the
upper limit of the accepted range of values for diffusivities in liquids. The lower limit within this
range is 10−11 and so the values considered for the sensitivity analysis would cover the interme-
diate values within this range such that 10−11 ≤ Df ≤ 10−9. The length scale of the release
medium, Lm, is unknown and so a baseline value was chosen based upon known suitable sizes
of beakers. Therefore, for the sensitivity study, it was decided that two values of Lm greater, and
smaller, than the baseline would suffice to give an idea of what influence the variation of Lm
would have on the release profile. The level of porosity of the pin is known, φ = 0.17, therefore,
since the value is on the lower end of possible porosity values, most values considered for the
sensitivity analysis cover values higher in the porosity scale, with an additional value lower than
the known value to cover extremely low porosities. Preliminary modelling suggested that the
solubility of the drug would be very influential on the release profile and since the reported value
of the drug used, 3 kg/m3, is relatively low, the values considered for the sensitivity study are
all greater than this stated value.
Parameter Value
Ld 1.575× 10−3 m [11]
Lp 1.6× 10−3 m [11]
Lm 3× 10−2 m [62]
τ 3 [48]
φ 0.17 [11]
φe 0.9× φ
α 2/3 [34]
Df 1× 10−9 m2/s
Dp = φeDf/τ 5.1× 10−11 m2/s
β 10−5 s−1(m−3kg)2/3
b0 505.19 kg/m
3 [11]
S 3 kg/m3 [12]
Table 4.4: Baseline parameter values. These values are taken from the literature or inferred
from [11]. The length scale of the release medium, Lm, is the same as was assumed in the
influence of flow study. The initial mass concentration, b0, is calculated from the assumed drug
mass loading and dividing by the interior volume of the porous pin.
90
(a) (b)
Figure 4.10: Plots showing the release profiles obtained through varying the system parame-
ters:(a) reaction exponent (α) (b) dissolution rate (β).
In Figure 4.10, plot (a) shows the effect of changing the value of the reaction exponent,
α. Given the significant differences between most of the release profiles, this suggests that
α is fairly influential which is also evidenced by the range of release times shown in Table 4.5.
Although, this level of influence is reduced as α is increased. The spread of the plots generated is
to be expected as this parameter can account for both linear and nonlinear dissolution processes.
In Figure 4.10, plot (b) shows the effect of varying the dissolution rate β. The plot displays
the general behaviour one would expect, that is the higher the dissolution rate, the quicker the
release. However, when increasing β from 10−4 to 10−3, the difference in the release profiles
is almost nonexistent. This outcome is also shown by the near-identical values for both 50 %
and 95 % release times in Table 4.5. Given that there is no significant decrease in the release
time, should one increase β further, it is reasonable to conclude that it will become even less
apparent. Despite not being immediately clear why this is the case, looking at the change to
the second Damköhler number (DaII), it can be see why this is the case. The first three values
of β, 10−7, 10−6 and 10−5 (the baseline value of β) are associated with the second Damköhler
numbers 0.016, 0.16 and 1.6, respectively. These values show the ratio of the dissolution reac-
tion rate to the diffusive transport rate (or, equivalently, the ratio of the diffusion timescale to the
dissolution reaction timescale). Initially, the dissolution timescale is larger than that of the dif-
fusive timescale. As β is increased through two orders of magnitude, the associated Damköhler
number increases and the dissolution timescale is reduced, so the release becomes quicker, as
one would expect. This trend is also shown in Table 4.5, in that a sizable reduction in release
times is gained by increasing β from 10−7 to 10−6. However, the decrease in release times be-
comes limited with further increases to β since DaII  1, meaning the dissolution timescale
is already much smaller than the diffusive timescale and so further increases to β will have a
minimal effect, meaning the rate-limiting process in this scenario is diffusion. Physically, the
91
scenario would be that the reaction must wait for dissolved drug molecules to diffuse, so that
further dissolution may occur.
(a) (b)
Figure 4.11: Plots showing the release profiles obtained through varying the system parame-
ters:(a) free-diffusion coefficient (Df ) (b) release medium length scale (Lm).
In Figure 4.11, plot (a) shows the effect of altering the free-diffusion coefficient, Df , and
displays the trend that one would expect, that is, the greater the free-diffusion coefficient, the
quicker the release. This trend is also displayed in Table 4.5, which shows that for a one order
of magnitude increase in Df from 10−11 to 10−10, an order of magnitude reduction in both
the 50 % and 95 % release times is observed. Similarly, there is a further order of magnitude
reduction in the 50 % and 95 % release times, by increasing Df from 10−10 to 10−9. The plot
also shows a relatively large jump between the release profiles generated by Df values of 10−10
and 5 × 10−10. This can be explained by examining the Damköhler numbers associated with
these free-diffusion coefficients, which are 16 and 3.1, respectively. These Damköhler numbers
show that when increasing Df from 10−10 to 5×10−10, the reaction rate is no longer an order of
magnitude greater than the diffusive rate. Therefore, both of these processes have fairly similar
timescales, meaning that one process is not necessarily hampered by the other.
In Figure 4.11, plot (b) shows the effect of altering the length scale of the release medium,
Lm. This shows a trend one would expect when considering the concentration gradient. With a
larger release medium, the concentration gradient can be maintained relatively higher for longer
since the diffusing drug particles take longer to reach the boundary. Therefore, one would ex-
pect a more significant difference in the later stages of release, but fairly similar release profiles
during earlier times. This is the trend shown in Table 4.5: the 50 % release times show a dif-
ference of between one and three days with respect to the baseline case. In contrast, the 95 %
release times display a more appreciable difference from the baseline case, which may be due to
the effect of a larger release medium length scale allowing for a relatively higher concentration
gradient to maintained for considerably longer. However, the effect of increasing Lm becomes
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limited as there will be a point where the release medium is orders of magnitude greater in size,
compared to the length scales of the drug and porous layers. So, when increasing Lm further, the
release time reductions will be small. There is also a limit associated with Lm such that below
this value, for a given solubility, complete release is impossible. This is evidenced by the release
profile for when Lm = 10−2, meaning that the minimum length scale for the release medium for
complete release is dependent on the drug solubility.
(a) (b)
Figure 4.12: Plots showing the release profiles obtained through varying the system parame-
ters:(a) porosity (φ) (b) solubility (S).
In Figure 4.12, plot (a) shows the effect that altering the porosity, φ, of the porous wall has
on the release profile. The trend shown is expected, that is the higher the degree of porosity,
the faster the release of drug. This change is attributed to the change in the effective diffusion
coefficient through the porous layer, which ranges from 3 × 10−11 to 2.25 × 10−10. The effect
porosity has on the release profile is less prominent than other parameters, however, this may be
due to length scale of the pin’s porous wall, which is 1.6 mm. This is a relatively small distance
for diffusion to occur and the associated diffusive timescale in the porous layer (L2p/Dp) ranges
from approximately 3 − 24 hours. When compared to the overall release times, the timescale
for diffusion in the porous wall is relatively small. This suggests that the influence that porosity
has on the release has much less variability when compared to the other parameters. This is
evidenced by the times in Table 4.5, which show that increasing the level of porosity, the release
times for 50 % and 95 % release, are reduced, albeit to a lower degree. However, these results
do not necessarily mean that the porosity parameter is not a useful design parameter, as this is
the type of parameter that could be used to fine-tune the release profile.
In Figure 4.12, plot (b) shows the effect that varying the drug solubility, S, has on the release
profile. One can see that this parameter is particularly significant, perhaps even the dominant
parameter, due to the drastic reduction in release times shown in Table 4.5 when compared to
the baseline case. The other parameter ranges required considerably longer timescales for their
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influence to be appreciable in the plots, i.e. in the region of 100 − 300 days. This contrasts
with the range of solubility values considered, in that marked differences in the release profiles
are seen in a timescale of just 20 days. Also noteworthy is that the influence of solubility on
the release profile is noticeable with less than an order of magnitude increase in the parameter.
This suggests that the release profile is especially sensitive to changes in this parameter, which
may also alter the influence that the other parameters have. Solubility having such an influential
role in the release compared to the other parameters can be explained when considering the
nondimensional solubility. With S∗ < 1 in all cases considered, i.e. the solubility is less than
the initial drug concentration, the free-drug phase is saturated immediately, specifically cd = S∗.
Therefore, excess drug must wait for drug in the solute phase to diffuse out of the system before
any more drug may dissolve. By increasing S∗, more of the drug is able to dissolve and thus
begin diffusing out of the drug layer, through the porous wall and out into the release medium,
which will take less time to occur.
Figure 4.13: Plot showing the effect of replacing the release medium with an infinite sink con-
dition.
Figure 4.13 shows the effect on the release profile when replacing the release medium with
an infinite sink condition. As expected, the sink condition generates the fastest possible release
profile when altering the length scale, Lm, of the release medium. This is because with the
sink condition in place, the concentration gradient within the drug and porous layers is at its
theoretical maximum value. This is akin to having a release medium of infinite size and so the
sink condition is the theoretical upper limit on the release time.
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Second
Damköhler number
DaII
Normalised solubility
S∗
Time for 50 %
release (Days)
Time for 95 %
release (Days)
Baseline 1.6 0.0059 23 53
Parameter
Second
Damköhler number
DaII
Normalised solubility
S∗
Time for 50 %
release (Days)
Time for 95 %
release (Days)
α = 0 0.025 0.0059 130 276
α = 1/3 0.2 0.0059 36 86
α = 1 12.5 0.0059 21 47
β = 10−7 0.016 0.0059 235 822
β = 10−6 0.16 0.0059 43 122
β = 10−4 16 0.0059 21 46
β = 10−3 157 0.0059 21 45
Df = 10
−11 157 0.0059 2088 4532
Df = 5× 10−11 31 0.0059 421 911
Df = 10
−10 16 0.0059 212 460
Df = 5× 10−10 3.1 0.0059 44 98
Lm = 10
−2 1.6 0.0059 N/A N/A
Lm = 2× 10−2 1.6 0.0059 26 79
Lm = 4× 10−2 1.6 0.0059 23 48
Lm = 10
−1 1.6 0.0059 22 45
φ = 0.1 1.6 0.0059 36 81
φ = 0.25 1.6 0.0059 17 41
φ = 0.5 1.6 0.0059 11 27
φ = 0.75 1.6 0.0059 9 23
S = 10 1.6 0.019 6 14
S = 20 1.6 0.039 3 7
S = 30 1.6 0.059 2 4
S = 40 1.6 0.079 2 3
Table 4.5: Release times for 50 % and 95 % across a variety of parameter ranges. All values are
approximate and rounded.
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4.3.4 Model calibration and validation
In the quest to produce a useful mathematical model, it must be validated against experimental
data. In an ideal situation, all of the model parameters would be known, and then validation
would be performed by solving the model with these parameters as inputs and then comparing
with the experimental data. However, not all of the parameters are known a priori and of those
whose values that are known, these are associated with some uncertainty. Therefore, in this
section an attempt is made to calibrate the model using the release profile from [11]. Even if it
is found that the model is capable of capturing the data, further experiments would be required
to fully validate the model.
Since the raw experimental drug release data was not available directly from the authors,
the data had to be extracted via other means. This was done by approximating the data point
coordinates in Figure 4.1 (b) using an online tool [68]. The basic procedure is to upload an
image of plotted data and specify the origin and the maximum and minimum values of the x
and y axes. In the case of the porous pin drug release data, the x-axis was set from 0 − 10, 000
minutes and the y-axis was set to 0−100 %, as shown in Figure 4.1 (b). This then allows the user
to approximate the position coordinates of all data points by aiming a cursor at the centre of each
data point in the image, which is recorded and may be exported as a table. Figure 4.14 shows
the approximated data points of the original release data in Figure 4.1 (b). The approximated
data used is divided by 100 to give release values in the range [0, 1], the same range as generated
by release profile equation (4.137), so that the data can be compared with the model output.
Figure 4.14: Plot showing the approximated drug release data.
Since all relevant model information is not available, it is useful to determine if the current
model can replicate the experimental data through the determination of best-fitting parameters.
A least squares approach is practical in this instance and the process involves solving the model
numerically at the N number of time points (tj) of the drug release data in Figure 4.14 and
calculating the fraction of drug released (Mfrac(tj)). The experimental data (E(tj)) can then be
subtracted from the theoretical data of the same time point, then the squared difference between
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the data points can be summed to give a measure of the error, the least squared error (LSE), for
a given parameter value:
LSE =
N∑
j=1
(Mfrac(tj)− E(tj))2 , (4.138)
with a smaller summation meaning there is a closer agreement between the model and the ex-
perimental data. Equation (4.138) is the objective function and the desire is to minimise this
function. In principle, several parameters can be fitted simultaneously. However, given the lack
of data (one release profile with no error bars) and the linearity of the release profile, it was
decided to focus instead on only two parameters, following from the results of the sensitivity
analysis. This particular objective function is quadratic and there exists a value of the parameter
of interest such that equation (4.138) is minimised. The “Parameter Sweep” functionality within
COMSOL®, version 5.3a, was used to calculate Mfrac(tj) over the range 0.04 ≤ S∗ ≤ 0.05,
divided into 101 equally spaced points. Then equation (4.138) was used to calculate the LSE.
From the results of the sensitivity analysis, drug solubility has a more significant influence on
the release profile when compared to the other parameters and since parameters are grouped
together in the nondimensional model, S∗ was the first parameter to undergo the least squares
fitting process, with the other parameters fixed at the baseline values. The results of the fitting
process are shown in Figure 4.15.
Figure 4.15: Example plot showing the output of the objective function (4.138) when determin-
ing the best fit value for S∗. The minimum shown in the plot indicates which value of S∗, in the
range of values considered, provides the best fit to the experimental data.
The value of S∗, to three significant digits, which minimises the objective function (4.138),
and hence, provides the best fit to the experimental data, was found to be 0.0468. Using this
value of S∗, the procedure was repeated to find the best fitting second Damköhler number, DaII ,
which was found to be 1.48. Using these parameter values, a release profile was generated and
the results plotted alongside the experimental data (Figure 4.16).
The results suggest that the model is broadly capable of replicating drug release profile of
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Figure 4.16: Plot showing the best fitting release profile compared to the experimental data.
the porous pin for most of the release duration, with only the end of the release process not
being captured fully. A multi-objective optimisation, where fitting is performed for several
parameters simultaneously (such as Df , b0, φe) may provide a closer fit to the data. However,
this was deemed unnecessary for the following reasons: A mathematical model can only ever be
as accurate as its inputs. There are many questions left unanswered from the work of Gimeno et
al. [11] and not all information related to the experimental protocol is given in the publication,
some of which is crucial to any mathematical modelling attempt. Arguably the most crucial
issues are the uncertain masses of drug used in the release experiments and the lack of details
of the vessel in which the release medium is contained. Without full knowledge of the mass
of drug used and of the geometry of the release medium, the accuracy of any model relative
to the experimental setup suffers. The experimental results suggest that full release was not
achieved for the porous pin. This could be due to a variety of reasons, but more likely through
a combination of drug solubility and an insufficient volume of release media. Therefore, the
mass of drug used and the geometric details of the release medium container are necessary. The
necessity of accurate geometric information is evidenced by Figure 4.11 (b), which shows that
the drug release profile may be influenced by the length scale of the release medium.
4.3.5 Discussion
The commercial Linezolid used in the experiments (Zyvox®) is composed of many other com-
ponents, not just the active ingredient, and these other components may have wildly different
diffusivities and solubilities, for example. This is highlighted by the fact that each mL of pre-
pared pharmacological solution contains just 2 mg of Linezolid, but it also contains 45.7 mg of
glucose and 0.38 mg of sodium hydroxide [11]. In other words, most of the product is in fact
glucose. This mix of different compounds makes the modelling process very challenging and
assumptions have had to be made, specifically, the drug is only composed of the active ingredi-
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ent and so the solubility refers to the Linezolid, not the Zyvox®. Another problem is the lack of
information on drug solubilities in SBF. The solubility of the commercial drug used is reported
as 3 mg/mL, however, this is the solubility of the drug in water [11]. The SBF used as the
release medium in the experiments contains a variety of ions, which of course have an electrical
charge, which may influence the solubility of a drug. Additionally, the diffusivity of the drug in
SBF is also unknown.
These issues cast unnecessary uncertainty with model parameters and so more assumptions
must be made, reducing the usefulness of the model. Thus, as much knowledge of the experi-
mental setup as possible is necessary when constructing a mathematical model and this example
serves to highlight that the research area of drug delivery should be a multidisciplinary endeav-
our. Experimentalists must be able to discuss with theorists, and vice versa, to ensure that any
mathematical model of drug release from a particular device has as few assumptions as possible
and to keep uncertainty in parameter values and model results, to a minimum.
4.3.6 Conclusions
This chapter describes the mathematical modelling procedure undertaken to model drug release
from a prototype drug-releasing porous fixation pin developed by Gimeno et al. [11]. The mod-
elling process began with an initial 3D diffusion model and through numerical testing, it was
concluded that a 1D mathematical modelling approach was sufficient. This is due to the sym-
metrical geometry of the porous pin and also due to the insignificant influence fluid flow has on
the release of drug from the pin. Due to the cylindrical shape of the porous pin, the next step in
the modelling methodology was to derive a 1D diffusion model based on the radial coordinate
and obtain a semi-analytical solution. With the solution found, it was realised that this model
would not be sufficient and that another key process in the release of drug from the porous pin
was absent. It was believed that the missing model component was the dissolution process, this
is evidenced by the fact that the drug used in the release experiments was loaded into the porous
pins as a dry powder. The constructed model was used to carry out a sensitivity analysis to deter-
mine the influence the system parameters have on the release profile. Subsequently, the model
was subjected to a least squares process to determine the values of two key nondimensional pa-
rameters that would allow the model to best replicate the experimental data. Lastly, the model
performance was discussed with reference to the details of the experiment provided by Gimeno
et al. [11].
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Chapter 5
Modelling drug release from hollow
orthopaedic pins with orifices
The previous chapter studied the theoretical release of drug from a porous pin. The device was
chosen as porosity is a popular method of controlling drug release in experiments. Since it
was concluded that fluid flow will produce an insignificant advective component to the trans-
port within and out of the pin, coupled with symmetry, drug release was described with a 1D
dissolution-diffusion model. In this chapter, a different prototype pin studied by Gimeno et
al. [12] is examined and the methodology required to model release of drug from this device is
explored.
The pin in question is a stainless steel medical grade tube of length 25 mm, an outer diameter
of 6 mm and a wall thickness of 1.6 mm, with a hollow interior to enable a reservoir of drug for
delivery. Four versions of this pin were used in the experiments, each with a differing number
(2, 4, 6 or 8) of equidistant orifices of diameter 0.5 mm (Figure 5.1). The orifices are made by
drilling the body of the pin, through to the opposite side, doubling the number of orifices. The
drug-release experiments were conducted in triplicate and the pins were loaded with commercial
linezolid (Zyvox®) or cefazolin sodium (Cefazolina Normon®) and submerged in 200 mL of
SBF, stirred at 30 RPM (pi rad/s). The aim of this chapter is to devise a mathematical model
of drug release from the orifice pin by Gimeno et al. (Figure 5.1 [12]), conduct a sensitivity
analysis on the various system parameters and how they influence the release profile.
Figure 5.1: The pins used by Gimeno et al. [12] in the drug release and bactericidal experiments.
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In chapter 4, it was initially not clear if fluid flow would have a notable impact on the release
of drug from the porous pin, due to the small pore sizes of the pin’s porous wall. However, a
thorough mathematical investigation demonstrated that fluid flow had a negligible influence on
the release of drug from the porous pin. Although in this chapter, the orifice pins have a mostly
solid wall, impervious to fluid ingress, the orifices themselves are much larger (0.5 mm) than
any pore in the wall of the porous pin (on the order of 10µm). Therefore, it is reasonable to
suspect that fluid flow may have an appreciable influence on the release of drug from the orifice
pins.
5.1 Influence of fluid flow on drug release from hollow or-
thopaedic pins with orifices
To be able to model the behaviour of the release medium fluid, important information is required,
such as the properties of the fluid and accurate geometric details. The release medium used in the
experiments is SBF, however, there is no source for parameter values of the physical properties
of SBF, such as density and kinematic viscosity. Therefore, for all simulations, the release
medium is assumed to be water. The dimensions of the orifice pins are provided within the
publication of Gimeno et al. [12]. However, the type of release medium vessel is not. Following
correspondence with the authors, it was revealed that the release medium and the drug-loaded
orifice pins were contained within 250 mL conical flasks, whose dimensions are available from
the manufacturer [69]. The experimental setups are atop rotating plates, which agitates the
release media. It would be useful to gain an understanding of how the fluid is likely to behave in
the orifice pins and to determine if fluid is able to flow in and out of the pins via the orifices or
produce a velocity field like the cavity flow problem, for example [70]. To approximate the flow
conditions, it is assumed that the outer boundary, Γ1, shown in Figure 5.2 (a), is rotating, which
will provide the driving force to the release medium such that it flows and will have velocity
field u = (ux, uy, uz). It should be noted that the θ and r shown in in Figure 5.2 (a), are not
model variables, they are separately defined within COMSOL Multiphysics®, version 5.3a, to
setup a moving wall boundary condition.
The following model is used to describe the motion of the release medium and is applied to
the geometries for the two cases considered i.e. the 2 and 8-orifice pins. Only these two orifice
configurations were investigated as they are the extreme cases and it can be reasoned that any
results from a study of the 4 and 6-orifice pins would lie somewhere between the 2 and 8-orifice
pins. Although the release medium vessel is a conical flask, only the volume occupied by the
release medium is required and so the neck of the conical flask is not present. Figure 5.2 (a)
shows the geometry used for all simulations in this chapter, albeit for a change in the number of
orifices to represent the pin configuration i.e. 2 orifices instead of 8.
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(a)
(b)
Figure 5.2: (a) Geometry of the 8-orifice pin. The release medium fluid is represented by Ω1, the
set of orifices of the pin are denoted by Ω2 and the inner drug core of the pin is designated Ω3.
The set of boundaries of the release medium are collectively represented by Γ1. Spatial variables
x and y extend outward from the central z-axis to the outer wall of the geometry. Spatial variable
z is the height from the centre of the bottom boundary to the centre of the top boundary of Γ1,
with the positive direction shown alongside. Although not variables, it is useful to define two
additional components: r is the radius from the central z-axis to the outer wall and θ is the angle
which Ω1 makes with respect to its original position as it rotates. (b) A close-up of a segment of
the 8-orifice pin to more clearly show the drug core and the orifices, which go through the casing
of the pin. Γ2 represents the entire surface area of the pin, including the cylindrical walls of the
orifices in each pin configuration. Additionally, Γ3 and Γ4 are the collection of the circular
boundaries at the endpoints of the orifices, that connect the domains Ω1 to Ω2 and Ω2 to Ω3,
respectively.
The model for describing fluid flow in the release medium is:
ν∇2u− (u · ∇)u− 1
ρ
∇p = 0, ∇ · u = 0, in Ω1,Ω2 and Ω3, (5.1)
u = (−r sin(θ), r cos(θ), 0)u, on Γ1, (5.2)
u = 0, on Γ2, (5.3)
p = 0, at an arbitrary point. (5.4)
The model consists of the stationary form of the incompressible Navier-Stokes and the con-
tinuity equations (5.1), where ρ is the fluid density, p is the pressure and ν is the kinematic
viscosity of the fluid. On the boundary Γ1, a moving wall boundary condition (5.2) is applied,
in which u is the magnitude of the angular velocity of the rotating wall in rad/s, the angular ve-
locity used in the simulations is pi rad/s. This condition ensures that the fluid at this boundary,
takes the wall’s angular velocity, this is the driving force behind the fluid flow. A no-slip/no-
penetration boundary condition (5.3) is applied to the collection of boundaries that comprise
the body of the pin, denoted by Γ2. Since pressure is not specified explicitly on a boundary, a
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pressure point constraint (5.4) is required and is applied to an arbitrary point to allow the numer-
ical scheme to find a solution. The model was solved using COMSOL Multiphysics®, version
5.3a, specifically, the GMRES method was used to obtain the stationary solution. The built-in
software meshing tools were used to create a tetrahedral element-based mesh using the “Nor-
mal” element size, calibrated for “Fluid Dynamics” physics (Figure 5.3). To determine if this
mesh was suitable, a finer mesh setting was also used, however, no appreciable difference in the
velocity field was found using this denser mesh.
Figure 5.3: FEM mesh generated for the 3D 8-orifice pin geometry for the influence of flow
study. Mesh consists of 217, 071 domain elements, 10, 434 boundary elements, and 928 edge
elements. A similar mesh for the 2-orifice pin was also created which consisted of 178, 296
domain elements, 9050 boundary elements, and 728 edge elements.
The results shown in Figure 5.4, suggest that fluid flow into the orifice pins can occur and
does not produce the velocity field pattern associated with the cavity flow problem [70]. Indeed,
flow out of the pin was also shown to be possible. Although the velocity of the fluid in the
orifices and the inner bulk domain of the pins is slow, in the order of 10−5 m/s, it is present
and it may have a significant effect on the release of a drug from these pins. Interestingly,
there is a region of recirculation in Figure 5.4 (b), which in principle, could trap drug particles
within its cycle. Although in theory the release medium is able to flow in and out of the orifice
pins, another important question is whether the flow is able to provide a significant advective
component to the transport of a drug. To determine the influence of the flowing release medium,
Péclet numbers are calculated based upon average fluid velocity magnitudes in each region:
PeΩ1 =
uΩ1Lr
Df
, P eΩ2 =
uΩ2Lo
Df
, P eΩ3 =
uΩ3Ld
Df
,
where uΩ1 , uΩ2 and uΩ3 are the average velocity magnitudes in each domain and Df is the free-
diffusion coefficient. The length scales required to compute the Péclet numbers are Lr, Lo and
Ld, which are the average radius of the release medium, the length of the orifices and the radius
of the inner drug core, respectively. Although no drug transport is present in this simulation, it
is assumed that Df = 10−9 m2/s, which is regarded as an upper limit in the range of diffusion
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(a)
(b)
Figure 5.4: (a) A horizontal cross-sectional slice through the centre of the top pair of orifices of
the 8-orifice pin. (b) Image of the velocity field within the red box region of the cross-sectional
slice.
coefficient of solutes [61]. Therefore, if the advective component of drug transport is significant
when compared to the upper limit of diffusivity of a solute, then it is likely important for all
solute diffusion coefficients.
Domain 2-Orifice Pin 8-Orifice Pin
Ω1 2.81× 106 2.81× 106
Ω2 13.75 26.37
Ω3 2.26× 10−4 0.834
Table 5.1: Average Péclet numbers within each domain for the 2 and 8-orifice pins.
Table 5.1 shows the average Péclet numbers for the different domains: the bulk release
medium (Ω1), the orifices (Ω2) and the drug core of the pin (Ω3). These Péclet numbers suggest
that with an increasing number of orifices, there is a stronger velocity field throughout the pin.
This is what one may expect to be the case since, with more open channels (orifices), the release
medium will be more freely able to penetrate the pin and thus generate a more significant veloc-
ity field. The most noticeable difference lies in the Péclet numbers for the drug cores, with the
8-orifice pin showing a three orders of magnitude increase in the Péclet number when compared
to the 2-orifice pin. Again, one can attribute this increase of Péclet number to the greater ease
of access the fluid has with the 8-orifice pin.
Since the model demonstrates that fluid flow is likely a key component to the release of drug
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from the orifice pins, due its appreciable influence compared to diffusion, it is wise to provide
evidence that this is in fact the case. The concentration of drug in the solute phase, in each
domain, is defined as ci(x, y, z, t), where i = Ω1,Ω2,Ω3. To model the potential influence of
fluid flow on the release of drug, the following model was devised:
∂cΩ1
∂t
= Df∇2cΩ1 − u · ∇cΩ1 , in Ω1, t > 0, (5.5)
∂cΩ2
∂t
= Df∇2cΩ2 − u · ∇cΩ2 , in Ω2, t > 0, (5.6)
∂cΩ3
∂t
= Df∇2cΩ3 − u · ∇cΩ3 , in Ω3, t > 0, (5.7)
∂u
∂t
= ν∇2u− (u · ∇)u− 1
ρ
∇p, ∇ · u = 0, in Ω1,Ω2 and Ω3, t > 0, (5.8)
where the free-diffusion coefficient, Df , is assumed to be constant and isotropic. These equa-
tions are coupled with the following boundary and initial conditions:
nˆ · (−Df∇cΩ3 + cΩ3u) = 0, u = (−r sin(θ), r cos(θ), 0)u, on Γ1, t > 0, (5.9)
− nˆ ·Df∇cΩ1 = 0, −nˆ ·Df∇cΩ2 = 0,
− nˆ ·Df∇cΩ3 = 0, u = 0, on Γ2, t > 0, (5.10)
cΩ1 = cΩ2 , nˆ · (−Df∇cΩ1 + cΩ1u) = nˆ · (−Df∇cΩ2 + cΩ2u) , on Γ3, t > 0, (5.11)
cΩ2 = cΩ3 , nˆ · (−Df∇cΩ2 + cΩ2u) = nˆ · (−Df∇cΩ3 + cΩ3u) , on Γ4, t > 0, (5.12)
p = 0, at an arbitrary point, t ≥ 0, (5.13)
cΩ3 = c0, in Ω3, cΩ2 = 0, in Ω2, cΩ1 = 0, in Ω1, t = 0, (5.14)
u = 0, in Ω1, Ω2 and Ω3, t = 0. (5.15)
The above model consists of advection-diffusion equations (5.5-5.7) and the incompressible
forms of the Navier-Stokes and continuity equations (5.8). In applicable boundary conditions, nˆ
is the outward facing unit normal appropriate for each of the surfaces. Zero-flux and moving wall
boundary conditions (5.9) are applied to Γ1. Zero-flux and no-slip/no-penetration conditions
(5.10) are applied to Γ2. Continuity of concentration and flux boundary conditions are applied
to Γ3 and Γ4 (5.11-5.12). A pressure point constraint (5.13) is applied to an arbitrary point
of the geometry. There is a non-uniform initial drug concentration condition set (5.14), where
cΩ3 = c0 and cΩ2 = cΩ1 = 0, initially. Additionally, the release medium fluid is at rest initially
(5.15). With a view to reduce computational cost, the impact of replacing the time-dependent
fluid equations with the corresponding steady solution was also assessed. The model can be
nondimensionalised with the following scalings:
c ′i =
ci
c0
, x ′ =
x
Ld
, y ′ =
y
Ld
, z ′ =
z
Ld
, t ′ =
D
L2d
t, u ′ =
Ld
Df
u, p ′ =
L2d
ρD2f
p,
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where i = Ω1,Ω2,Ω3. These scalings result in the following nondimensional model (dropping
the primes for clarity):
∂cΩ1
∂t
= ∇2cΩ1 − u · ∇cΩ1 , in Ω1, t > 0, (5.16)
∂cΩ2
∂t
= ∇2cΩ2 − u · ∇cΩ2 , in Ω2, t > 0, (5.17)
∂cΩ3
∂t
= ∇2cΩ3 − u · ∇cΩ3 , in Ω3, t > 0, (5.18)
∂u
∂t
= Sc∇2u− (u · ∇)u−∇p, ∇ · u = 0, in Ω1,Ω2 and Ω3, t > 0, (5.19)
where Sc is the Schmidt number and is equal to ν/Df , which is the ratio of the viscous diffu-
sion rate to mass diffusion rate. The nondimensional equations are coupled with the following
nondimensional boundary and initial conditions:
nˆ · (−∇cΩ3 + cΩ3u) = 0, u =
L2d
Df
(−r sin(θ), r cos(θ), 0)u, on Γ1, t > 0, (5.20)
nˆ · ∇cΩ1 = 0, nˆ · ∇cΩ2 = 0, nˆ · ∇cΩ3 = 0, u = 0, on Γ2, t > 0, (5.21)
cΩ1 = cΩ2 , nˆ · (−∇cΩ1 + cΩ1u) = nˆ · (−∇cΩ2 + cΩ2u) , on Γ3, t > 0, (5.22)
cΩ2 = cΩ3 , nˆ · (−∇cΩ2 + cΩ2u) = nˆ · (−∇cΩ3 + cΩ3u) , on Γ4, t > 0, (5.23)
p = 0, at an arbitrary point, t ≥ 0, (5.24)
cΩ3 = 1, in Ω3, cΩ2 = 0, in Ω2, cΩ1 = 0, in Ω1, t = 0, (5.25)
u = 0, in Ω1, Ω2 and Ω3, t = 0. (5.26)
The model (5.16-5.26) was solved using COMSOL Multiphysics®, version 5.3a. The GM-
RES method was used to obtain the solutions of the time-dependent, stationary and purely diffu-
sive models. To aid in conservation of mass, equations (5.16-5.18) were solved in conservative
form, which reduced the error in mass conservation to 1 %. The software assumes continu-
ity of concentration and flux across boundaries, therefore, boundary condition sets (5.22-5.23)
are not required to be explicitly implemented. The same meshes used to determine fluid flow
behaviour (Figure 5.3) in the 2 and 8-orifice pins were also used in this study. Preliminary
simulations demonstrated that a mesh of a density greater than these meshes had a negligible
influence on the release profile. To illustrate the results, the release profile was calculated and if
fluid flow has an appreciable effect on the release of drugs from the orifice pins, then the release
profiles for the simulations including the time-dependent and stationary velocity fields, will be
markedly different from the release profile from the diffusion-only model.
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5.1.1 Equations for mass of drug
The dimensional equations for the mass of drug in each region are:
MΩ1(t) =
∫
Ω1
cΩ1 dΩ1, MΩ2(t) =
∫
Ω2
cΩ2 dΩ2, MΩ3(t) =
∫
Ω3
cΩ3 dΩ3,
where dΩj = dxdydz, with j = 1, 2, 3. The equations for mass can be normalised with M0,
the initial drug mass. As this is a purely numerical investigation, not only are the drug masses
in each region approximated, but so too is the initial drug mass, which can be calculated via the
integral:
M0 = c0
∫
Ω3
dΩ3.
Using the nondimensional scalings, the normalised equations for mass are:
MΩ1(t)
M0
=
c0L
3
d
∫
Ω ′1
c ′Ω1 dΩ
′
1
c0L3d
∫
Ω ′3
dΩ ′3
,
MΩ2(t)
M0
=
c0L
3
d
∫
Ω ′2
c ′Ω2 dΩ
′
2
c0L3d
∫
Ω ′3
dΩ ′3
,
MΩ3(t)
M0
=
c0L
3
d
∫
Ω ′3
c ′Ω3 dΩ
′
3
c0L3d
∫
Ω ′3
dΩ ′3
.
Simplifying and dropping the primes for clarity:
MΩ1(t)
M0
=
∫
Ω1
cΩ1 dΩ1∫
Ω3
dΩ3
,
MΩ2(t)
M0
=
∫
Ω2
cΩ2 dΩ2∫
Ω3
dΩ3
,
MΩ3(t)
M0
=
∫
Ω3
cΩ3 dΩ3∫
Ω3
dΩ3
.
5.1.2 Release profile
The release profile may be calculated through the mass of drug lost from the orifice pins:
Mfrac(t) =
M0 − (MΩ2(t) +MΩ3(t))
M0
= 1− MΩ2(t) +MΩ3(t)
M0
,
= 1−
∫
Ω2
cΩ2 dΩ2 +
∫
Ω3
cΩ3 dΩ3∫
Ω3
dΩ3
.
The simpler method to calculate the release profile is to determine the mass which accumulates
in the release medium
Mfrac(t) =
MΩ1(t)
M0
=
∫
Ω1
cΩ1 dΩ1∫
Ω3
dΩ3
. (5.27)
Figure 5.5 shows the extremes of the potential influence of fluid flow on drug release from
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(a) (b)
Figure 5.5: (a) Plot showing the effect of including fluid flow for the 2-orifice pin case com-
pared to a purely diffusive problem, with Df = 10−9 m2/s. (b) Plot showing the effect of
including fluid flow for the 8-orifice pin case compared to a purely diffusive problem, with
Df = 10
−9 m2/s.
the orifice pins. The release profiles were calculated using equation (5.27). As expected, with
more orifices, fluid flow has a greater impact on the drug release. This is likely due to the fluid
having more open channels to enter the 8-orifice pin, than the more constrictive 2-orifice pin.
One can quantify this via Péclet numbers: the average Péclet number in the orifices are 13.75 and
26.37 for the 2 and 8-orifice pins, respectively. However, within the cores of the orifice pins, the
average Péclet numbers are substantially smaller: 2.26× 10−4 and 0.834 for the 2 and 8-orifice
pins, respectively. These numbers align themselves with what the expected behaviour would
be, that is that fluid flow is significantly more influential in the release of drugs from the orifice
pins as the number of orifices increases. This behaviour is also apparent from the difference in
the timescales, with the 2-orifice pin requiring days for complete release and the 8-orifice pin
only requiring hours. The results also show that using a stationary velocity field as input for
the advection-diffusion equation is sufficient and has the benefit of being less computationally
intensive.
5.1.3 Comparison with Taylor-Couette flow
There exists a potential avenue of simplification when including the effects of fluid flow on
drug release from the orifice pins and that is to consider the similarity of the flow to Taylor-
Couette (TC) flow. TC flow concerns the problem of fluid flow between two, concentric, rotating
cylinders [71, 72], as shown in Figure 5.6. The problem was investigated experimentally by
Couette [73], as a method to measure viscosity, and then mathematically by Taylor [74], who
investigated the stability of a viscous fluid between two rotating cylinders. The problem can be
solved analytically with some assumptions: the flow between the cylinders is incompressible
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and steady i.e. has no time-dependence, the flow does not change in the axial (z-axis) direction
and the flow is angularly symmetric.
Figure 5.6: Illustration of the Taylor-Couette problem.
The inner and outer cylinders have rotational velocities ω1 and ω2, respectively. The fluid in
the system is contained within the gap between the inner and outer cylinders, which have radii
R1 and R2, respectively. Defining the fluid velocity field as u = (ur, uθ, uz), after simplification
of the Navier-Stokes and continuity equations, the problem can be described by the ODE [75,
p. 44]:
r2
d2uθ
dr2
+ r
duθ
dr
− uθ = 0,
which has the solution:
uθ = Ar +
B
r
, A =
ω2R
2
2 − ω1R21
R22 −R21
, B =
(ω1 − ω2)R21R22
R22 −R21
. (5.28)
Using model equations (5.1-5.4) to compute the stationary solution for the 8-orifice pin geome-
try, the results may be compared to the velocities computed by analytical solution (5.28). Since
the analytical solution is only applicable to problems where the cylinders are of constant radius,
a compromise must be made since the geometry for the orifice pin setups feature an approxima-
tion of a conical flask. Therefore, for use in the analytical solution, the outer cylinder radius,
R2, will be the average radius of the conical flask geometry i.e. R2 = 36.25 mm. Additionally,
the radius of the inner cylinder, R1, will be the radius of the orifice pin, therefore, R1 = 3 mm.
Also, ω1 = 0 and ω2 = pi rad/s, since it is assumed that only the conical flask component of the
orifice pin setup is rotating. To compare the numerical and analytical solutions, a 1D line was
added to the geometry within COMSOL Multiphysics®, version 5.3a. These lines extend from
the outer wall of the orifice pin to the sloped wall of the release medium geometry. The velocity
magnitudes of the solution on these lines were then plotted alongside the velocity magnitudes
calculated by analytical solution (5.28).
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(a)
(b)
Figure 5.7: (a) Wireframe rendering of the geometry, with the solution line on the upper-most
boundary of the geometry. (b) Plot showing both the analytical and numerical solutions along
the red line.
(a)
(b)
Figure 5.8: (a) Wireframe rendering of the geometry, with the solution line at the centre of the
height of the geometry. (b) Plot showing both the analytical and numerical solutions along the
red line.
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(a)
(b)
Figure 5.9: (a) Wireframe rendering of the geometry, with the solution line on the base of the
geometry. (b) Plot showing both the analytical and numerical solutions along the red line.
Figures 5.7-5.9 show a not unreasonable agreement between the analytical and numerical
solutions for the velocity magnitudes on each line. The differences in the solutions are not un-
expected since the orifice pin geometries do not represent the TC problem precisely. The orifice
pins and the overall height of the release medium are not the same, for TC flow both cylinders
are of the same height. Additionally, the cylinders featured in TC flow are of constant radius,
whereas the release medium of the orifice pin geometry has sloped walls, due to the presence
of a conical flask. These differences affect the magnitude of the deviation of the solutions. It is
not surprising that both solutions take the same velocity magnitude at the outer wall/cylinder as
the no-slip/no-penetration conditions ensure that both solutions take the velocity of the moving
wall. However, when moving away from the outer wall/cylinder towards the orifice pin/inner
cylinder, the solutions begin to diverge. This is also not unexpected as part of the TC problem
includes that the rotating fluid does not penetrate the inner cylinder and thus the solution ap-
proaches zero when moving closer to the inner cylinder. However, the velocity field solution
computed in the orifice pin simulation does not approach zero and it is reasonable to conclude
that this is because the rotating fluid is able to penetrate the orifice pin. Based on the results, it
may be a possible to simplify the implementation of a velocity field in future work. If this is not
in fact possible, then perhaps a rough estimate of the influence the velocity field of the fluid has
on the release of drugs may be made.
5.2 3D advection-diffusion-dissolution model
In reality, the drug loaded would likely be in a dry, solid form, such as in the case of the exper-
iments by Gimeno et al. [12]. Their work featured two commercially available products, which
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feature the antibiotics, Cefazolin Sodium and Linezolid, which the authors state have a solubil-
ity of 50 mg/mL and 3 mg/mL, respectively. The results from their experiments suggest that
solubility plays a major role in the release of the drugs from the pins and so should be accounted
for in a proposed model. In addition to the assumption that the free-diffusion coefficient, Df ,
is constant and isotropic, it is also assumed that the orifice pins are rapidly infiltrated by the
release medium fluid and that the drug is fully wetted. This enables the dissolution process to
begin throughout the drug core immediately and allows one to describe the dissolution process
through an ODE, with the spatial dependence coming from the coupling to a PDE for dissolved
drug concentration. The equations proposed to model mass transport of a drug, of concentration
b(x, y, z, t) and which must dissolve first, are as follows:
∂b
∂t
= −βbα (S − cΩ3) , in Ω3, t > 0, (5.29)
∂cΩ1
∂t
= Df∇2cΩ1 − u · ∇cΩ1 , in Ω1, t > 0, (5.30)
∂cΩ2
∂t
= Df∇2cΩ2 − u · ∇cΩ2 , in Ω2, t > 0, (5.31)
∂cΩ3
∂t
= Df∇2cΩ3 − u · ∇cΩ3 + βbα (S − cΩ3) , in Ω3, t > 0, (5.32)
ν∇2u− (u · ∇)u− 1
ρ
∇p = 0, ∇ · u = 0, in Ω1,Ω2 and Ω3, (5.33)
with the following boundary and initial conditions:
nˆ · (−Df∇cΩ3 + cΩ3u) = 0, u = (−r sin(θ), r cos(θ), 0)u, on Γ1, t > 0, (5.34)
− nˆ ·Df∇cΩ1 = 0, −nˆ ·Df∇cΩ2 = 0,
− nˆ ·Df∇cΩ3 = 0, u = 0, on Γ2, t > 0, (5.35)
cΩ1 = cΩ2 , nˆ · (−Df∇cΩ1 + cΩ1u) = nˆ · (−Df∇cΩ2 + cΩ2u) , on Γ3, t > 0, (5.36)
cΩ2 = cΩ3 , nˆ · (−Df∇cΩ2 + cΩ2u) = nˆ · (−Df∇cΩ3 + cΩ3u) , on Γ4, t > 0, (5.37)
p = 0, at an arbitrary point, t ≥ 0, (5.38)
b = b0, in Ω3, t = 0, (5.39)
cΩ3 = 0, in Ω3, cΩ2 = 0, in Ω2, cΩ1 = 0, in Ω1, t = 0. (5.40)
Equation (5.29) is used to model the dissolution of the drug, similar to chapter 4, where S
is the solubility of the drug in the release medium, β is the dissolution rate and α is the re-
action exponent and determines the type of reaction. The advection-diffusion-reaction equation
(5.32), models the transport of newly dissolved drug within Ω3. The incompressible forms of the
Navier-Stokes and continuity equations (5.33) are used to compute the stationary velocity field,
to be used as input for the drug-transport equations of the model. Initially, b = b0 in Ω3 (5.39)
and cΩ1 = cΩ2 = cΩ3 = 0 (5.40), since no drug has dissolved initially. The remaining compo-
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nents of the model are identical to model equations (5.5-5.15), including boundary conditions.
The model equations (5.29-5.40) are nondimensionalised with the following scalings:
c ′i =
ci
S
, b ′ =
b
b0
, x ′ =
x
Ld
, y ′ =
y
Ld
z ′ =
z
Ld
,
t ′ =
D
L2d
t, u ′ =
Ld
Df
u, p ′ =
L2d
ρD2f
p,
where i = Ω1,Ω2,Ω3. These scalings result in the following nondimensional model (dropping
the primes for clarity):
∂b
∂t
= −DaIIS∗bα (1− cΩ3) , in Ω3, t > 0, (5.41)
∂cΩ1
∂t
= Df∇2cΩ1 − u · ∇cΩ1 , in Ω1, t > 0, (5.42)
∂cΩ2
∂t
= Df∇2cΩ2 − u · ∇cΩ2 , in Ω2, t > 0, (5.43)
∂cΩ3
∂t
= Df∇2cΩ3 − u · ∇cΩ3 +DaIIbα (1− cΩ3) , in Ω3, t > 0, (5.44)
Sc∇2u− (u · ∇)u−∇p = 0, ∇ · u = 0, in Ω1,Ω2 and Ω3, (5.45)
where DaII is the second Damköhler number which is equal to L2dβb
α
0/Df and S
∗ is defined
as S/b0. These equations are coupled with the following nondimensional boundary and initial
conditions:
nˆ · (−∇cΩ3 + cΩ3u) = 0, u =
L2d
Df
(−r sin(θ), r cos(θ), 0)u, on Γ1, t > 0, (5.46)
nˆ · ∇cΩ1 = 0, nˆ · ∇cΩ2 = 0, nˆ · ∇cΩ3 = 0, u = 0, on Γ2, t > 0, (5.47)
cΩ1 = cΩ2 , nˆ · (−∇cΩ1 + cΩ1u) = nˆ · (−∇cΩ2 + cΩ2u) , on Γ3, t > 0, (5.48)
cΩ2 = cΩ3 , nˆ · (−∇cΩ2 + cΩ2u) = nˆ · (−∇cΩ3 + cΩ3u) , on Γ4, t > 0, (5.49)
p = 0, at an arbitrary point, t ≥ 0, (5.50)
b = 1, in Ω3, t = 0, (5.51)
cΩ3 = 0, in Ω3, cΩ2 = 0, in Ω2, cΩ1 = 0, in Ω1, t = 0. (5.52)
5.2.1 Equations for mass of drug
The dimensional mass of drug in each region of the geometry may be found via:
MΩ1(t) =
∫
Ω1
cΩ1 dΩ1, MΩ2(t) =
∫
Ω2
cΩ2 dΩ2, MΩ3(t) =
∫
Ω3
cΩ3 dΩ3 +
∫
Ω3
b dΩ3,
where dΩj = dxdydz, with j = 1, 2, 3. The equations for mass can normalised with M0, the
initial drug mass. As this is a purely numerical investigation, not only are the drug masses in
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each region approximated, but so too is the initial drug mass, which can be calculated via the
integral:
M0 = b0
∫
Ω3
dΩ3.
Using the nondimensional scalings, the normalised equations for mass are:
MΩ1(t)
M0
=
SL3d
∫
Ω ′1
c ′Ω1 dΩ
′
1
b0L3d
∫
Ω ′3
dΩ ′3
,
MΩ2(t)
M0
=
SL3d
∫
Ω ′2
c ′Ω2 dΩ
′
2
b0L3d
∫
Ω ′3
dΩ ′3
,
MΩ3(t)
M0
=
SL3d
∫
Ω ′3
c ′Ω3 dΩ
′
3
b0L3d
∫
Ω ′3
dΩ ′3
+
b0L
3
d
∫
Ω ′3
b ′ dΩ ′3
b0L3d
∫
Ω ′3
dΩ ′3
.
Simplifying and dropping the primes for clarity:
MΩ1(t)
M0
=
S∗
∫
Ω1
cΩ1 dΩ1∫
Ω3
dΩ3
,
MΩ2(t)
M0
=
S∗
∫
Ω2
cΩ2 dΩ2∫
Ω3
dΩ3
,
MΩ3(t)
M0
=
S∗
∫
Ω3
cΩ3 dΩ3∫
Ω3
dΩ3
+
∫
Ω3
b dΩ3∫
Ω3
dΩ3
.
5.2.2 Release profile
The release profile may be obtained through the mass of drug released from the orifice pins:
Mfrac(t) =
M0 − (MΩ2(t) +MΩ3(t))
M0
= 1− MΩ2(t) +MΩ3(t)
M0
= 1−

∫
Ω3
b dΩ3 + S
∗
(∫
Ω2
cΩ2 dΩ2 +
∫
Ω3
cΩ3 dΩ3
)
∫
Ω3
dΩ3
 ,
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or by the accumulation of mass in the release medium:
Mfrac(t) =
MΩ1(t)
M0
=
S∗
∫
Ω1
cΩ1 dΩ1∫
Ω3
dΩ3
. (5.53)
5.2.3 Sensitivity analysis - parameter values
The model (5.41-5.52) was applied to the 2 and 8-orifice pin geometries and was solved us-
ing COMSOL Multiphysics®, version 5.3a, using the GMRES method, with time-advancement
being handled by the BDF with free time stepping. To aid in conservation of mass, the drug-
transport equations (5.42-5.44) were solved in conservative form. Similar meshes were used to
that shown in Figure 5.3. Preliminary modelling suggested that error in mass conservation could
be influenced by parameter values. Therefore, a suitably dense mesh was constructed for use
across all parameters considered. The final meshes created for the 2 and 8-orifice pin geometries
used the “Finer” mesh setting, calibrated for “Fluid Dynamics” problems. The need for this con-
siderably denser mesh setting, compared to previous models in the chapter, is reasoned to be due
to the inclusion of the drug dissolution process. Additionally, because multiple parameters are
varied, the release timescales can vary significantly, so a denser mesh ensures that the solution
is accurate for all timescales. Both meshes were constructed from tetrahedral elements such that
the 2-orifice pin mesh consisted of 969, 889 domain elements, 18, 094 boundary elements, and
1052 edge elements and the 8-orifice pin mesh consisted of 1, 094, 980 domain elements, 21, 520
boundary elements, and 1404 edge elements. A sampling of the data obtained from the model
for a several parameters were examined and the error in mass calculated was 1 %. Equation
(5.53) was used to calculate the release profile in each case.
With the nondimensional model introduced, baseline parameter values for use in a sensitivity
analysis can be established to determine the influence that changes in system parameters have
on the release profile. Although there are four orifice pin configurations, only the 2 and 8-orifice
pins are used in the sensitivity analysis. These are the extreme cases and so it is reasonable
to assume that the results of a sensitivity analysis involving the 4 and 6-orifice pins would lie
somewhere between the results of the 2 and 8-orifice pins. A suitable range of parameter values
are required to adequately test the sensitivity of the release profile to changes in the model
parameters. There are several model parameters identical to the parameters investigated in the
sensitivity analysis within chapter 4. Shared parameters between both analyses include: reaction
exponent, α, free-diffusion coefficient, Df , dissolution rate, β and the drug solubility, S. The
range of values considered for α, Df and β are identical to values used in chapter 4 for the
porous pin’s release profile sensitivity analysis and as such, the reasoning behind the use of these
values are also the same. Although the values used for the drug solubility, S, are different to
those values used in chapter 4, the reason for their use is the same: some preliminary modelling
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suggested that the variation of drug solubility could lead to vast changes to the release profile.
Therefore, a large interval of solubilities were selected to cover a variety of scenarios. The
reason for this is due to the appreciable effect that fluid flow has on the release of drug from the
orifice pin. Therefore, by having a varied set of drug solubilities for the sensitivity analysis, one
could gain insight into the relationship between drug release and solubility, in the presence of
fluid flow.
There are two additional parameters to be varied for the sensitivity analysis in this chapter:
the orifice diameter, d, and the magnitude of the rotational velocity, u, of the outer wall of the
release medium, Γ1. The values chosen for the orifice diameter, d, are based on the 0.5 mm
diameter used in the experiments and it was believed to be reasonable to adjust this diame-
ter by increments of 0.25 mm such that the minimum and maximum orifices diameters used
were 0.25 mm and 1 mm, respectively. The rate of stirring in the experiments were quoted as
30 RPM, therefore, the values used for the sensitivity analysis would simply be half and double
this rotational speed i.e. 15 and 60 RPM. It was reasoned that these values would be suitable
at providing insight into how the rotational velocity of a release medium would influence the
release profile. Since fluid flow is important to consider in the case of the orifice pins, in addi-
tion to the second Damköhler and Péclet numbers, the first Damköhler number is also useful.
This nondimensional number is defined as the ratio of the reaction rate to the advective transport
rate and is equal to Ldβbα0/uΩ3 , where uΩ3 is the average magnitude of the velocity field within
the inner core of the pin, and gives a useful measure of the relative importance of these pro-
cesses. Additionally, to quantify the release times and give a measure of the influence altering
of a parameter has on the release profile, the times for 50 % and 95 % release are recorded. The
baseline parameter values for the sensitivty analysis for both the 2 and 8-orifice pins are shown
in Table 5.2.
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Parameter Value
b0 775.194 kg/m
3
α 2/3 [34]
Df 10
−9 m2/s [61]
β 10−5 s−1(m−3kg)−2/3
d 0.5 mm [12]
u pi rad/s [12]
S 50 kg/m3 [12]
Table 5.2: Baseline parameter values. These values are taken from the literature or inferred from
[12]. The initial mass concentration, b0, is inferred by taking the experimental drug mass loading
of 100 mg and dividing by the interior volume of the pin [12]. The experiments featured two
drugs, Cefazolin and Linezolid, the more soluble of the two was chosen as a baseline solubility.
5.2.4 Sensitivity analysis - 2-orifice pin
(a) (b)
Figure 5.10: Plots showing the release profiles obtained through varying the system parame-
ters:(a) reaction exponent α (b) free-diffusion coefficient Df .
Figure 5.10 (a) shows the effect of changing the value of the reaction exponent, α. For the
majority of the values examined, there is little difference in most of the release profiles, which
can be seen in the release times shown in Table 5.3, particularly for when α is equal to 1/3, 2/3
or 1. At first this may seem like a strange result, however, when looking at the range of relevant
nondimensional numbers in Table 5.4, one can understand why. The first Damköhler numbers
all show that the reaction timescale is much less than the timescale for advective transport.
The second Damköhler numbers display a different trend: when α = 1, the reaction timescale
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is smaller than the diffusive timescale, however, as α is decreased, the reaction timescale is
increased and thus lowers the second Damköhler number and only when α = 0 is the reaction
rate significantly smaller than the diffusive rate and so the drug transport process is quicker than
the dissolution of the drug. In the other scenarios, because the rates of the transport processes of
diffusion and advection are small when compared to the reaction rate, there is an excess of drug
available for release out of the pin and thus the release profiles are very similar.
In Figure 5.10 (b) the effect of varying the free-diffusion coefficient Df , is shown. The plot
displays the general behaviour one would expect from the release profile, that is the lower the
diffusion coefficient, the slower the release. Since the 2-orifice pin is much less permeable to
fluid flow than the 8-orifice pin, any change to the diffusion coefficient produces a more marked
difference in the release profiles. Hence the wide range of release times shown in Table 5.3.
This is demonstrated through examination of the Péclet numbers in Table 5.4: in Ω3 (the inner
portion of the pin), when Df is decreased to 10−11, the diffusive rate is still much greater than
the advective rate and only when the diffusing drug reaches Ω2 (the orifices) is advection able
to significantly impact the transport of the drug. The Péclet number in Ω2 acts as expected,
in that when Df = 10−9, the timescale for advection is smaller than that of diffusion, which
becomes greater as Df is decreased further. It should be noted that the small differences in the
first Damköhler numbers is due to the numerical solution, in reality these values are identical.
(a) (b)
Figure 5.11: Plots showing the release profiles obtained through varying the system parame-
ters:(a) reaction exponent β (b) orifice diameter d.
Figure 5.11 (a) shows the effect of altering the dissolution rate β. For the majority of the
values examined, there is little difference in most of the release profiles, which can be seen in
the release times shown in Table 5.3, the only markedly different release profile is for when
β = 10−7. The trends shown by the release profiles are similar to that of the plots generated by
varying α and for similar reasons. The first Damköhler numbers shown in Table 5.4, indicate
that the advective timescale is considerably greater than the reaction timescale for all values of
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β considered. The second Damköhler numbers shown in Table 5.4, suggest that the diffusive
timescale is also larger than the reaction timescale, until β = 10−7, at which point the diffusive
timescale is much smaller than the reaction timescale. Up to this point dissolution is relatively
fast and it is almost insignificant, hence the similarities between most of the release profiles.
Figure 5.11 (b) shows the effect of altering the orifice diameter, d. The trend shown in the
release profiles is as one would expect, that is that making the orifice diameters larger, there
is more available volume for the fluid medium to pass through the orifices, thus drug release
is quicker. On the other hand, decreasing the orifice diameter, constricts the flow of fluid and
thus release is slowed down. This behaviour can be clearly seen from the release times shown
in Table 5.3. The nondimensional numbers of Table 5.4, show that the Péclet numbers in the
orifices range from 0.138 to 65.1. Although there is a two orders of magnitude increase to
the Péclet number as d is increased, the first and second Damköhler numbers remain such that
the advective timescale is still much greater than the reaction and diffusive timescales. This
illustrates how little fluid penetration exists in the case of the 2-orifice pin.
(a) (b)
Figure 5.12: Plots showing the release profiles obtained through varying the system parame-
ters:(a) conical flask rotational velocity u (b) drug solubility S.
Figure 5.12 (a) shows the effect that altering the rotational velocity the release medium is
subject to. The trend shown in is what one would expect, that is, the greater the rotational
velocity the faster the drug is released, this is also shown in Table 5.3. The effect of flow in the
2-orifice pin is very small when compared to diffusion in the inner core of the pin, which is likely
due to the restrictive nature of there being only two orifices and both of them having a diameter
of 0.5 mm. When considering the geometrical features of this pin and the first Damköhler and
Péclet numbers shown in Table 5.4, it is clear why there is no large change to the release profile
when varying the rotational velocity. Ultimately, as the magnitude of the rotational velocity is
increased, the first Damköhler is greatly reduced, however, the timescale for advection is still
much larger than the reaction timescale, thus the effect is minimal. The Péclet numbers in the
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inner portion of the pin remain small and range from 1.9 × 10−5 to 4.75 × 10−3, meaning that
although the magnitude of velocity may be larger, the diffusive rate is still the greater of the two.
However, the relatively small changes in the release profiles can be attributed to the increase in
the Péclet number in the orifices, which ranges from 6.36 to 31.2. Therefore, suggesting that
the release is diffusion dominated within the inner core of the pin, but once a drug particle has
reached the orifices, then the combination of advection and diffusion act together to transport
the drug and by increasing the magnitude of advection, the release is faster.
Figure 5.12 (b) shows the effect that varying the drug solubility, S, has on the release profile.
One can see that this parameter is particularly significant, due to the noteworthy spread of release
times shown in Table 5.3. Also noteworthy is that the influence solubility has, is appreciable
from minor changes to the value of solubility. These points suggest that the release profile is
especially sensitive to changes in this parameter, which may also alter the influence that the other
parameters have. Solubility having such an influential role in the release compared to the other
parameters can be explained when considering the nondimensional solubility. Since S∗ < 1
in all cases considered, i.e. the solubility is less than the initial drug mass concentration, the
free-drug phase is saturated immediately, i.e. c = S∗. By increasing S∗, more of the drug is
permitted to dissolve and thus begin diffusing from the inner portion of the pin, to the orifices
where advection is able to play a more significant role in its transport.
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2-Orifice Pin Time for 50 %
release (Days)
Time for 95 %
release (Days)
Baseline 52 107
Parameter Time for 50 %
release (Days)
Time for 95 %
release (Days)
α = 0 62 118
α = 1/3 53 109
α = 1 52 107
Df = 10
−11 1958 4241
Df = 5× 10−11 810 1707
Df = 10
−10 441 923
Df = 5× 10−10 99 205
β = 10−7 68 147
β = 10−6 54 111
β = 10−4 52 107
β = 10−3 52 103
d = 0.25× 10−3 289 560
d = 0.75× 10−3 21 48
d = 1× 10−3 11 29
u = 15 56 114
u = 60 45 94
S = 5 537 1140
S = 100 26 56
S = 250 11 28
S = 500 6 22
Table 5.3: Release times for 50 % and 95 % across a variety of parameter ranges for the 2-orifice
pin. All values are approximate and rounded. Parameter units are shown in Table 5.2.
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2-Orifice Pin
First
Damköhler
number
DaI
Second
Damköhler
number
DaII
Normalised
solubility
S∗
Péclet
number
Pe
Ω1
Péclet
number
Pe
Ω2
Péclet
number
Pe
Ω3
Baseline 7325.9 1.654 0.0645 2.81× 106 13.75 2.26× 10−4
Parameter
First
Damköhler
number
DaI
Second
Damköhler
number
DaII
Normalised
solubility
S∗
Péclet
number
Pe
Ω1
Péclet
number
Pe
Ω2
Péclet
number
Pe
Ω3
α = 0 86.8 0.0196 0.0645 2.81× 106 13.75 2.26× 10−4
α = 1/3 797.5 0.18 0.0645 2.81× 106 13.75 2.26× 10−4
α = 1 67298 15.19 0.0645 2.81× 106 13.75 2.26× 10−4
Df = 10
−11 7445 165.4 0.0645 2.81× 108 1375 2.22× 10−2
Df = 5× 10−11 7086 33.1 0.0645 5.62× 107 275 4.67× 10−3
Df = 10
−10 7100 16.54 0.0645 2.81× 107 137.5 2.33× 10−3
Df = 5× 10−10 7106 3.31 0.0645 5.62× 106 27.5 4.66× 10−4
β = 10−7 73.3 0.01654 0.0645 2.81× 106 13.75 2.26× 10−4
β = 10−6 732.6 0.1654 0.0645 2.81× 106 13.75 2.26× 10−4
β = 10−4 73259 16.54 0.0645 2.81× 106 13.75 2.26× 10−4
β = 10−3 732590 165.4 0.0645 2.81× 106 13.75 2.26× 10−4
d = 0.25× 10−3 34478 1.654 0.0645 2.81× 106 0.138 4.8× 10−5
d = 0.75× 10−3 11717 1.654 0.0645 2.81× 106 35.4 1.41× 10−4
d = 1× 10−3 1029 1.654 0.0645 2.81× 106 65.1 1.61× 10−3
u = 15 87235 1.654 0.0645 1.4× 106 6.36 1.9× 10−5
u = 60 348 1.654 0.0645 5.62× 106 31.2 4.75× 10−3
S = 5 7326 1.654 0.00645 2.81× 106 13.75 2.26× 10−4
S = 100 7326 1.654 0.129 2.81× 106 13.75 2.26× 10−4
S = 250 7326 1.654 0.323 2.81× 106 13.75 2.26× 10−4
S = 500 7326 1.654 0.645 2.81× 106 13.75 2.26× 10−4
Table 5.4: Release times for 50 % and 95 % across a variety of parameter ranges for the 2-orifice
pin. All values are approximate and rounded. Parameter units are shown in Table 5.2.
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5.2.5 Sensitivity analysis - 8-orifice pin
(a) (b)
Figure 5.13: Plots showing the release profiles obtained through varying the system parame-
ters:(a) reaction exponent α (b) free-diffusion coefficient Df .
Figure 5.13 (a) shows the effect of changing the value of the reaction exponent, α. In contrast
to the 2-orifcie pin, there is more of a spread in the release profiles and hence, the release times
shown in Table 5.5 are also more spread out. This is helped in no small way thanks to the
increase in the number of orifices and as a result the baseline Péclet number in Ω3 (the pin core)
increasing from 2.26 × 10−4 in the 2-orifice case to 0.834 in the 8-orifice case. This explains
why for the lower values of α there is more of a difference in the release profiles. The other two
release profiles are very similar, this is due to the reaction timescale being smaller than either of
the transport processes, which is suggested by the first and second Damköhler numbers, shown
in Table 5.6. The sharp change in the plot for when α = 1, may be present due to the fact that this
is the fastest reaction exponent considered and so when approaching the time for complete drug
dissolution, there is an immediate stop in the dissolving of drug and so advective and diffusive
transport are the only processes continuing. The more gentle curve shown at approximately the
same part of the curve for when α = 2/3, may be more smooth since the reaction is not as
vigorous and hence there is a gentler approach to the time the dissolution process finishes.
Figure 5.13 (b) shows the effect of varying the free-diffusion coefficient Df . The plot dis-
plays the overall behaviour one would expect from the release profile, that is the lower the diffu-
sion coefficient, the slower the release and this behaviour is displayed in the release times shown
in Table 5.5. However, initially the release profiles are near-identical, but when approximately
40 % of the drug is released, the plots begin to diverge. The differences shown in the shapes of
the release profiles may be due to the combination of two factors. Firstly, as the free-diffusion
coefficient decreases, the Péclet numbers, shown in Table 5.6, in each region of the pin increase,
thus the advective timescale relative to the diffusive timescale is decreasing and so advection
becomes the more dominant transport mechanism. Secondly, throughout the variation of Df ,
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the reaction timescale is always smaller than the timescales of the transport processes. There-
fore, it is reasonable to conclude that despite a decreasing free-diffusion coefficient, the reaction
occurs within a smaller timescale compared to the transport timescales. Although this suggests
that the transport processes are the rate-limiting processes of the release, the similar plots may
be due to the fact that even though the diffusive transport rate decreases, the advective transport
rate is always significant, therefore, the reaction does not need to slow down to accommodate
slower drug transport out of the orifice pin. The point where the plots begin to diverge is likely
the point where the drug has completely dissolved. The difference in the overall shapes of the
release profiles, after this point, is likely due to the nonlinear nature of the advective transport
provided by the rotating release medium fluid.
(a) (b)
Figure 5.14: Plots showing the release profiles obtained through varying the system parame-
ters:(a) reaction exponent β (b) orifice diameter d.
Figure 5.14 (a) shows the effect of altering the dissolution rate β. The trend shown is as one
would expect, that is that as the dissolution rate is decreased, the release of drug is also decreased
and the release times in Table 5.5 show this trend too. The behaviour shown by the release
profiles are similar to that of the plots generated by varying α and for very similar reasons.
The first and second Damköhler numbers, shown in Table 5.6, indicate that the advective and
diffusive timescale is considerably greater than the reaction timescale for β values in the range
103 − 105. However, once β reaches the range 10−6 − 10−7, the opposite is true, that is, both
transport mechanisms have a lower time scale than the reaction time scale. The influence that
advection has is much greater than in the 2-orifice pin, this is likely the reason why there is more
of a spread between the individual plots for the different values of β. Three of the plots are very
similar during early times, namely when the value of β is in the range 103−105. This behaviour
is likely due to the first and second Damköhler numbers showing that the reaction timescale
is lower than the processes of diffusion and advection. However, these plots begin to diverge
around the 70 hour mark, with some sharp turning points in the plots when β = 10−3 or 10−4.
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The plots suggest that these higher dissolution rates are the reason for the sharp transitions, in
that the reaction experiences a “sudden stop”.
Figure 5.14 (b) shows the effect of altering the orifice diameter, d. The behaviour shown
in the release profiles is as one would expect, that is that making the orifice diameters larger,
there is more available volume for the fluid medium to pass through the orifices, thus release is
quicker. On the other hand, decreasing the orifice diameter, constricts the flow of fluid and thus
release is slowed down. These trends are quantified by the release times shown in Table 5.5.
By examining the nondimensional numbers of Table 5.6, what is happening to the release can
be deduced. The Péclet numbers in the orifices range from 2.52 to 104.2 and with an increase
to the orifice diameters, the first Damköhler number changes so that the timescale for advection
is less than the timescale for the reaction. One particularly noteworthy feature of this plot is
the relatively small difference between the release profiles for the 1 mm and 0.75 mm diameter
orifices. This may be due to the combination of the first Damköhler number being small, whilst
the Péclet number is quite large and perhaps this suggests that there is a theoretical upper limit
to the velocity magnitude that is possible in the pin.
(a) (b)
Figure 5.15: Plots showing the release profiles obtained through varying the system parame-
ters:(a) conical flask rotational velocity u (b) drug solubility S.
Figure 5.15 (a) shows the effect that altering the rotational velocity of the release medium
is subject to. The trend shown is what one would expect, that is, the greater the rotational
velocity the faster the drug is released. Since the 8-orifice pin is more permeable to the rotating
fluid, advection, when compared to diffusion, is fairly influential for all rotational velocities
in the inner core of the pin. When considering the geometrical features of this pin and the
Péclet numbers, it can be seen why there are sizable reductions in release times as the rotational
velocity is increased. The Péclet numbers in the inner portion of the pin remain small and range
from 0.26 to 2.71, which shows there is a transition in which advective timescale goes from
being greater to lower than the timescale for diffusion. The transition in transport mechanism
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dominance highlights the much greater influence fluid flow has on the release of drug from the
8-orifice pin.
Figure 5.15 (b) shows the effect that varying the drug solubility, S, has on the release profile.
One can see that this parameter is particularly significant, due to the noteworthy spread of release
times shown in Table 5.5. Also noteworthy is that the influence solubility has, is appreciable
from minor changes to the value of solubility. These points suggest that the release profile is
especially sensitive to changes in this parameter, which may also alter the influence that the other
parameters have. Solubility having such an influential role in the release compared to the other
parameters can be explained when considering the nondimensional solubility. Since S∗ < 1
in all cases considered, i.e. the solubility is less than the initial drug mass concentration, the
free-drug phase is saturated immediately, i.e. c = S∗. By increasing S∗, more of the drug is able
to dissolve and thus begin the transporting processes.
126
8-Orifice Pin Time for 50 %
release (Hours)
Time for 95 %
release (Hours)
Baseline 42 136
Parameter Time for 50 %
release (Hours)
Time for 95 %
release (Hours)
α = 0 265 501
α = 1/3 68 174
α = 1 41 130
Df = 10
−11 47 2239
Df = 5× 10−11 43 725
Df = 10
−10 42 418
Df = 5× 10−10 41 173
β = 10−7 372 1083
β = 10−6 75 202
β = 10−4 41 127
β = 10−3 42 85
d = 0.25× 10−3 1092 2105
d = 0.75× 10−3 11 56
d = 1× 10−3 7 43
u = 15 125 279
u = 60 15 67
S = 5 426 1398
S = 100 21 71
S = 250 9 35
S = 500 5 24
Table 5.5: Release times for 50 % and 95 % across a variety of parameter ranges for the 8-orifice
pin. All values are approximate and rounded. Parameter units are shown in Table 5.2.
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8-Orifice Pin
First
Damköhler
number
DaI
Second
Damköhler
number
DaII
Normalised
solubility
S∗
Péclet
number
Pe
Ω1
Péclet
number
Pe
Ω2
Péclet
number
Pe
Ω3
Baseline 1.98 1.654 0.0645 2.81× 106 26.37 0.834
Parameter
First
Damköhler
number
DaI
Second
Damköhler
number
DaII
Normalised
solubility
S∗
Péclet
number
Pe
Ω1
Péclet
number
Pe
Ω2
Péclet
number
Pe
Ω3
α = 0 0.0235 0.0196 0.0645 2.81× 106 26.37 0.834
α = 1/3 0.216 0.18 0.0645 2.81× 106 26.37 0.834
α = 1 18.22 15.19 0.0645 2.81× 106 26.37 0.834
Df = 10
−11 1.98 165.4 0.0645 2.81× 108 2636.6 83.4
Df = 5× 10−11 1.98 33.1 0.0645 5.62× 107 527.3 16.7
Df = 10
−10 1.98 16.54 0.0645 2.81× 107 263.66 8.34
Df = 5× 10−10 1.98 3.31 0.0645 5.62× 106 52.73 1.67
β = 10−7 0.0198 0.0165 0.0645 2.81× 106 26.37 0.834
β = 10−6 0.198 0.165 0.0645 2.81× 106 26.37 0.834
β = 10−4 19.8 16.54 0.0645 2.81× 106 26.37 0.834
β = 10−3 198.3 165.4 0.0645 2.81× 106 26.365 0.834
d = 0.25× 10−3 62.4 1.654 0.0645 2.81× 106 2.52 0.0265
d = 0.75× 10−3 0.367 1.654 0.0645 2.81× 106 62.04 4.5
d = 1× 10−3 0.13 1.654 0.0645 2.81× 106 104.2 12.74
u = 15 6.39 1.654 0.0645 1.40× 106 10.25 0.26
u = 60 0.611 1.654 0.0645 5.62× 106 72.13 2.71
S = 5 1.98 1.654 0.00645 2.81× 106 26.37 0.834
S = 100 1.98 1.654 0.129 2.81× 106 26.37 0.834
S = 250 1.98 1.654 0.3225 2.81× 106 26.37 0.834
S = 500 1.98 1.654 0.645 2.81× 106 26.37 0.834
Table 5.6: Release times for 50 % and 95 % across a variety of parameter ranges for the 8-orifice
pin. All values are approximate and rounded. Parameter units are shown in Table 5.2.
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5.2.6 Discussion
There are notable differences in the sensitivity analyses of the 2 and 8-orifice pins and it is rea-
sonable to conclude that the main contributing factor to the differing results is the contrasting
extent that the rotating release medium fluid is able to penetrate either orifice pin. When exam-
ining the baseline Péclet numbers (Tables 5.4 and 5.6) within the orifices of the 2 and 8-orifice
pins, the numbers are comparable: 13.75 and 26.37, respectively. However, there is a large dis-
crepancy in the baseline Péclet numbers for the drug cores of the 2 and 8-orifice pins: 2.26×10−4
and 0.834, respectively. Although expected, this difference of three orders of magnitude in the
Péclet numbers in the inner cores of the 2 and 8-orifice pins demonstrate that the rotating release
medium fluid is more capable of entering the 8-orifice pin and is also able to generate a more
significant advective transport component within the pin. This increased advective component
has an effect in the release of the drug from the 8-orifice pin in particular and a good measure
of this the difference between the baseline first Damköhler numbers (Tables 5.4 and 5.6) of the
2 and 8-orifice pins: 7325.9 and 1.98, respectively. These numbers indicate that the timescale
for the dissolution process is far shorter than the timescale for advection in the case of the 2-
orifice pin. Whereas, the timescale for both of these processes are comparable in the case of the
8-orifice pin.
The ease at which the release medium fluid is able to penetrate the 8-orifice pin goes a
long way to explain the large differences in the sensitivity analyses between the orifice pins.
For instance, when varying α, β and u, the release profiles for the 2-orifice pin do not differ
tremendously. In contrast, there is a considerably greater spread in the release profiles for the 8-
orifice pin when varying these parameters, which can be reasonably attributed to the greater drug
transport provided by advection since the flowing release medium can enter the 8-orifice pin far
more easily. Other parameters can produce release profiles that vary significantly for the both the
2 and 8-orifice pins, specifically d and S, which suggest that these parameters are particularly
influential in the release of drugs from the orifice pins. Changes to the orifice diameter, d, can
be reasoned to have such an effect as with wider orifices comes greater ease for release medium
fluid penetration of the orifice pins. Drug solubility, S, can give rise to such varied results as
the greater the solubility, more particles are able to begin transporting out of the orifice pins.
The free-diffusion coefficient, Df , produces an almost reversed scenario: the release profiles
vary more considerably in the case of the 2-orifice pin than the 8-orifice pin. Although at first a
strange result, it is not unreasonable to conclude that the greater advective transport component
within the 8-orifice pin is the cause. In the 2-orifice pin case, the Péclet number (5.4) in the core
of the pin is always small, meaning that the timescale for diffusion is always much smaller than
the timescale for advection. As transport is diffusion dominated within the core of the 2-orifice
pin, it would be expected that variation of the free-diffusion coefficient would produce such
varied release profiles. On the other hand, in the case of the 8-orifice pin, despite the decrease in
the free-diffusion coefficient, there is still an appreciable advective transport component within
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the core of the pin.
There are many conclusions that can be drawn from the sensitivity analysis of the orifice pins,
however, there is one in particular that relates strongly to experiments: the rotational velocity
applied from the stirring of the release medium can greatly influence the release of drug from
the orifice pins. In other words, the experimental setup itself can be influential in the release of
drug from the pins. This is in stark contrast to the porous pin of chapter 4, in which fluid flow
had a negligible influence on the release of drug.
The orifice pins studied by Gimeno et al. [12] are a fine example of the current research into
the exploration of prototype OI device designs, with a view for such devices to release drugs. It is
for this reason and the foresight that these pins would be an interesting mathematical modelling
challenge, that they were chosen for the theoretical study. However, there are some drawbacks
from this choice: although it was found that fluid flow is likely very influential in the release
rate of drugs from the orifice pins, the current model is unlikely to be able to capture the data.
There are a variety of factors which contribute to this and one important issue, which was also
discussed in chapter 4, is that of the solubility of the drugs in SBF. In the publication of Gimeno
et al. it is stated that the solubility of the drugs in water for Cefazolin Sodium (Cefazolina
Normon®) and Linezolid (Zyvox®) are 50 mg/mL and 3 mg/mL in water [12], respectively.
However, the release medium used in the drug release experiments was SBF and the solubilities
of these drugs are unknown and, as noted in chapter 4, SBF contains a variety of ions (charged
particles), which may have a significant effect on the drug solubility. Additionally, since it was
discovered that fluid flow can have a noteworthy influence on the release of drugs from the
orifice pins, it is important to the relevant physical properties of SBF, such as dynamic viscosity
and density. The values of these physical parameters may be noticeably different to the values
of water and so may influence the resultant velocity field that develops due to the stirring of
the release medium, which may have a knock-on effect on the release of drugs from the orifice
pins. Therefore, it is reasonable to conclude that the assumption that the release medium, for the
purposes of the mathematical model, is water, is inaccurate and in fact may hamper the model
output.
Another reason why the current model is not likely to be able to replicate the release data
of Gimeno et al. [12], is due to the apparent stop-start release of Linezolid from the orifice
pins, which may be seen from the release data in Figure 5.16. This plateauing effect is more
pronounced as the number of orifices increases. From the theoretical study into drug release
from the orifice pins, it is reasonable to propose the following hypothesis: since most of the
commercial Linezolid used in the experiments is in fact mostly glucose (per mL of prepared
solution contains 45.7 mg of glucose and 2 mg of Linezolid [12]), the release of this glucose
inhibits the release of the Linezolid component. There are two key reasons for this, depending
on temperature, the solubility of glucose may be as high as 1200 mg/mL [76], compared to
the stated solubility of 3 mg/mL of the Linezolid component. Also, the molecular weights of
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these components are noticeably different: 180.16 g/mol for glucose [76] and 337.35 g/mol for
Linezolid [77]. This difference in weight may allow the slower flow inside the pin to have an
increased effect in moving glucose particles compared with Linezolid particles. The restriction
in Linezolid release is more noticeable as the number of orifices increases, and this may be due
to the increasing ease at which the flowing release medium may enter the pin and thus wash
away the lighter, and more soluble, glucose. These two factors may be why the Linezolid is
restricted in its release initially and after the glucose has left the orifice pins, the release of the
Linezolid can resume. This is not a simple problem to tackle mathematically, to begin with
the motion of the release medium and the dissolution process must be accounted for, however,
adding multi-component diffusion to the model adds severe levels of complexity, which is likely
to reduce the appeal of a mathematical approach to the understanding of drug release from the
orifice pins from an experimentalist’s point of view.
In addition to the oddly shaped release profiles for Linezolid in the case of the 4, 6 and
8-orifice pins, the release profiles for Cefazolin Sodium and Linezolid in the 2-orifice pin are
remarkably similar, despite an order of magnitude difference in solubility (Figure 5.16). This
result is very unlikely to be captured by the current model as both drugs, in theory, would
experience the same velocity field, with the only immediate difference being the solubilities of
each drug. However, the answer may lie within the murky cloud of unknown parameter values,
such as the free-diffusion coefficient. This parameter, in principle, may be sufficiently different
to give rise to these similar release profiles for the 2-orifice pin case. This is evidenced from
the theoretical results from the sensitivity analyses, which show that fluid flow within the core
of the 2-orifice pin is almost negligible. This means that mass transport is diffusion-driven
initially, then once drug particles reach the orifices, advective transport becomes appreciably
more influential. Therefore, a large difference in the free-diffusion coefficient may explain why
the release profiles are similar. The trend shown in the release profiles for the 4, 6 and 8-orifice
pin cases are what one would expect for an increasing number of orifices: release is faster for
the more soluble Cefazolin Sodium.
Another reason why the current model is not likely to be able to capture the release data is
due to the nature of the stirring method. In correspondence with the authors, the conical flasks,
which contain the release medium and an orifice pin, are on a rotating plate. The way in which
the rotational force is applied may well introduce sloshing effects and perhaps create turbulence
in the release medium. Additionally, the orifice pins are suspended in the release medium via a
piece of string, which may result in the pin moving like a pendulum, in a libration sense, within
the release medium. It is very reasonable to conclude that the combination of the sloshing release
medium and the orifice pin moving, is likely to influence the release of drugs from the orifice
pins. The incorporation of a sloshing release medium coupled to the release of a dissolving
drug would require exceptionally powerful computational muscle and time to simulate. Such
an inclusion is very likely to dissuade experimentalists from seeking mathematical assistance in
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Figure 5.16: Release profiles for drug-filled tubes with varied numbers of orifices. Reproduced
from [12].
future research.
Figure 5.17: Images showing the grain sizes of the two drugs used by Gimenoo et al.. Repro-
duced from from the supplementary material of [12].
In the case of the orifice pins a reasonable conclusion is that fluid flow matters. However,
there is a limitation with the current model: the computed stationary velocity field penetrates
the undissolved drug. In reality, the “solid” drug is a porous structure (Figure 5.17) and would
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allow for the penetration of release medium fluid. However, the speed of this penetration is finite.
One approach to tackle this may be to adopt a moving boundary approach to the dissolution of
the drugs, in which the flowing release medium fluid would transport dissolved drug particles
on one side of the boundary and on the other side is solid, undissolved drug, thus eliminating
the apparent contradiction of the release medium fluid flowing through solid, undissolved drug.
However, it may be argued that this is potentially not a big issue as although the velocity field of
the flowing release medium is penetrating solid drug, the drug does not move until it dissolves.
Therefore, it may be the case that the inclusion of a moving boundary is an unnecessary, and
complex, addition. However, evidence in the form of a comparison between such mathematical
models would be required.
These issues highlight the main reason for choosing to model the release of drug from the
orifice pins, that experimentalists and theorists should conduct research in tandem, not separately
[28, 78]. Experimentation can provide the necessary raw data of drug release from a device and
then theory may be applied to determine key drug release features and parameters [28, 79].
Even before experiments take place, sound theory may be used to advise on the experimental
setup to reduce the number of simplifications and assumptions within the model, potentially
increasing model usefulness. A validated mathematical model may also reduce the number of
costly experiments required when seeking to evaluate changes to experimental setups, such as
drug solubility.
5.3 Conclusions
This chapter details the process of mathematically modelling drug release from orifice pins by
Gimeno et al. [12]. From the outset, it was realised that the model must be 3D in nature, due
to the inability to reduce the model via symmetry. In comparison to the porous pin of chapter
4, it is not immediately clear if the stirring of the release medium would have a significant
influence on the release of drug from the orifice pins. Therefore, a study to determine the
influence of fluid flow was conducted. The results showed that fluid flow may have a significant
effect on the release of drug from the orifice pins, with more orifices providing a stronger effect.
Although this added source of model complexity would incur additional computational cost,
it was found that that a stationary velocity field in place of a time-dependent velocity field,
produced near-identical results. Although not precisely the same, an interesting comparison
between the stationary velocity field and the Taylor-Couette flow solution was made. The results
of which showed that the stationary velocity field only differed significantly from the Taylor-
Couette solution close to the orifice pins, where the geometries of the orifice pin experimental
setup and Taylor-Couette problem breaks down. In light of the modelling of chapter 4, the
dissolution process was accounted for immediately after determining that the stirring of the
release medium influenced the release of drug. A sensitivity analysis was conducted to ascertain
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the effect that altering key system parameters would have on the release profile produced by
the model. It was found that the diameter of the orifices, the rotational velocity of the release
medium and the drug solubility were particularly influential in the release of drug from the
orifice pins. This is because these parameters relate heavily to the experimental setup and thus
changes to them will likely affect the results from experiments. Lastly, an in-depth discussion
on the reasons why future cooperation between experimentalists and theorists is paramount to
drug-releasing OI design.
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Chapter 6
Coupling drug release from orthopaedic
pins with bacterial inhibition
In chapters 4 and 5, the release of drug from prototype orthopaedic devices was studied in
detail. These investigations were of drug release in vitro and serve to present models that aid in
identifying key drug-release mechanisms and may be built upon in future research. However, it
is sensible to wonder what happens to the drug once it is released in vivo. The literature shows
a wide variety of experiments which feature prototype orthopaedic devices and materials with
a view for each to hold and release drugs, with a particular emphasis on antibiotics. Although
chapter 2 details a small proportion of this ongoing research, it does highlight that bacterial
infection due to orthopaedic surgery is a tremendous issue. If infection is able to take hold
and the bacteria are able to form a biofilm, an implant can fail [80, 81]. The need for revision
surgeries, including implant failure due to infection, is very costly. For example, of the 6009
total knee arthroplasty revision surgeries carried out in 2012 in the UK, 23 % was due to infection
[82]. If infections could be prevented, there would be an appreciable economic benefit as the
cost of some procedures may be as high as £75,000 per patient [82].
Prevention is the best medicine and this ideology may be applied to the problem of or-
thopaedic associated infection. To begin to tackle this challenge, where infecting bacteria come
from would give an indication of where efforts should be focused. The skin of humans is
colonised with a variety of microorganisms [85] and potentially amongst them is the bacteria
Staphylococcus aureus [86, 87], one of the most common microorganisms associated with or-
thopaedic infections [81, 88–91]. Most infections arise from microbial contamination of a pros-
thesis during surgery [81] and despite extensive preoperative procedures to cleanse the surgical
site before an incision is made [87], bacteria, such as S. aureus, may not be fully eradicated.
This is not only due to the sheer number of sources, such as the surgical equipment used and
even the clothing worn by medical staff [86], but also because bacteria may be protected from
sterilisation efforts, for example, by residing within hair follicles [87]. If some bacteria survive
the decontamination process, they may be able to enter the body via open skin, into vulnerable
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(a) (b)
Figure 6.1: Scanning electron microscope images. (a) A S. aureus colony visible on a smooth
polished titanium sample. Reproduced from [83]. (b). S. aureus cells adhering to a titanium
orthopaedic screw. Reproduced from [84].
regions once surgery begins [86,87]. Another risk factor which is particularly noteworthy, where
orthopaedic surgery is concerned, is the ability of infectious bacteria to adhere and colonise a
prosthesis [87, 92] (Figure 6.1), and these bacteria may come from the patient or from medical
staff [88]. Upon insertion of the implant, bacteria may now be in close proximity to vital regions
of the body, for example, within bone marrow. Worsening matters is the fact that the number of
bacteria required to cause infection in this case is decreased [87]. Additionally, bacteria present
on the implant are likely to develop a biofilm as most microorganisms live in such communities
(Figure 6.2) [88]. Perhaps most disturbing about biofilms is the level of protection it offers to
the infecting bacteria. Whilst in the biofilm, bacteria are much more resistant to antibiotics,
reportedly as high as a factor of 1000 times more resistant [88, 90].
(a) (b)
Figure 6.2: (a) Biofilm visible on the titanium surface of the acetabular component of a failed
hip implant. Reproduced from [80]. (b) Biofilm present in the femoral notch of a failed total
knee arthroplasty. Reproduced from [93].
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It is clear from the literature that OI associated infection is a problem and to begin tackling
it mathematically, a suitable mathematical description of bacterial growth is required. Bacterial
growth can be thought of as part of the wider field of population dynamics, which garnered some
attention as far back as the time of Leonardo of Pisa, known today as Fibonacci. He considered
the problem of an increasing population of rabbits and through this he discovered the famous
Fibonacci sequence [94]. Many other famous names took an interest in population dynamics,
such as Leonhard Euler and Pierre-François Verhulst [94]. Much of the work on population
dynamics at the time had considered a continuously growing population, and in some cases,
exponentially. The simplest growth model, known as the “Malthusian growth model”, is an
ODE in time, t, which describes the rate of change of a population, P , subject to a growth rate,
r:
dP (t)
dt
= rP, P (0) = P0.
where P0 is the initial population size. This ODE has the general solution:
P (t) = P0e
rt.
From this solution there are three possible outcomes: the population increases or decreases
exponentially (r > 0 and r < 0, respectively) or remains constant (r = 0). This is not a realistic
situation in most circumstances, however, bacteria can experience a phase of exponential growth
in optimal conditions [95]. Verhulst introduced what is known as the “logistic equation”, which
is an ODE that describes a growing population, limited by a “carrying capacity”, K:
dP (t)
dt
= rP
(
1− P
K
)
, P (0) = P0.
The logistic equation has the general solution [94]:
P (t) =
KP0e
rt
K + P0 (ert − 1) =
K
1 +
(
K − P0
P0
)
e−rt
.
From the solution of the logistic equation, it can be seen that for a for an initial population size,
such that P0 < K, the population will asymptote towards the carrying capacity. On the other
hand, should P0 > K, the population will steadily decrease until reaching the carrying capacity.
This is a more realistic description of population growth as it applies a limit to the population
size in the form of parameter K, which may be a combination of several important factors, such
as food supply and available space for inhabitation.
There exists several models which only describe bacterial growth [96], however, in the con-
text of bacterial infection the desire is to eradicate the bacteria before infection can take hold.
For the mathematical study in this chapter, the differential form of the logistic equation will be
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used to model bacterial growth and modifications will be applied to account for additional pro-
cesses which may influence the growth of infecting bacteria. In the following sections several
mathematical models of bacterial growth are derived. Each subsequent model adds an extra level
of complexity as new processes are considered and the limitations of the models are discussed.
6.1 Single ODE with a constant antibiotic source
There are various ways to express the number of individuals within a bacterial population, for ex-
ample, the number of colony-forming-units per millilitre of diluting solution (CFU/mL) [97].
However, since the mathematical modelling within this chapter will include the action of an
antibiotic on a bacterial population, the units must balance. Therefore, for the bacterial popu-
lation variable, B, the units are kg/m3, essentially a “concentration” of bacteria. The proposed
simplest mathematical model of the growth of a bacterial population, B, subject to a constant
antibiotic source, would be the ODE:
dB
dt
= gB
(
1− B
Bmax
)
− kmaxB, B(0) = B0, (6.1)
where g and kmax are the growth and maximal killing rates, respectively, Bmax is the carrying
capacity and B0 is the initial bacterial concentration. ODE (6.1) may be solved analytically and
the following identity will be useful [66, p. 12]:
∫
dB
A3B2 + 2A2B + A1
=
1
2
√
A22 − A1A3
ln
(
A3B + A2 −
√
A22 − A1A3
A3B + A2 +
√
A22 − A1A3
)
, ifA1A3 < A22,
(6.2)
where A1, A2 and A3 are positive constants. Rearranging (6.1) and using (6.2), constants A1,
A2 and A3 can be identified:∫
dB
g
Bmax
B2 + (kmax − g)B
= −
∫
dt,
thus, A1 = 0, A2 = (kmax − g)/2 and A3 = g/Bmax and so the solution has the form:
1
kmax − g ln
(
gB
gB +Bmax (kmax − g)
)
= −t+ C. (6.3)
Applying the initial condition, the value of the constant of integration, C, may be determined:
C =
1
kmax − g ln
(
gB0
gB0 +Bmax (kmax − g)
)
. (6.4)
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Combining (6.3) and (6.4) and simplifying:
B(t) =
Bmax (kmax − g) exp ((g − kmax) t)
g
(
gB0 +Bmax (kmax − g)
gB0
− exp ((g − kmax) t)
) . (6.5)
Depending on the values of g and kmax, solution (6.5) changes form, specifically the exponent of
the exponential function can be equal to zero or either positive or negative, suggesting bacterial
growth and decay, respectively. In the case where the exponent is equal to zero (kmax = g),
solution (6.5) is equal to zero. This scenario may be considered the critical case, in that should
kmax < g, the bacteria will not be eradicated. By taking the limit of (6.5) as t tends to infinity,
the steady states of the model may be determined. Starting with the case where kmax < g, the
limit is of an indeterminant form, therefore, L’Hôpital’s rule may be used to determine the limit:
lim
t→∞
B(t) =
Bmax (kmax − g)
−g = Bmax
(
1− kmax
g
)
. (6.6)
For the case where kmax > g, it is clear from solution (6.5) that the limit is zero. These steady
states illustrate the expected behaviour of ODE (6.1): if the growth rate of a bacterial population
is greater than the killing rate due to the antibiotic, then the population will grow till it reaches
steady state (6.6). Otherwise, if the growth rate is less than the killing rate, the population will
decay to the zero steady state, the ideal outcome in this scenario. Solution (6.5) was evaluated
using MATLAB®R2019a via a for loop in time, t, which was discretised into 100 equally spaced
timesteps. Figure 6.3 illustrates the steady states of the model.
Figure 6.3: Plot showing the two possible outcomes of the model: either the bacterial population
reaches a non-zero steady state or the population is eradicated. Parameter values used in the case
where kmax < g: B0 = 1; Bmax = 10; g = 1 and; kmax = 1/2. Parameter values used in the
case where kmax > g were the same as in the previous case, however, kmax was increased from
1/2 to 3/2.
A constant source of antibiotic is, of course, unrealistic, as drugs are given in the form of
139
doses and an antibiotic will not provide its maximal killing effect indefinitely as the concentra-
tion will reduce over time and thus the antibiotic’s effectiveness will also decrease. However,
this simple starting point allows for initial model assessment to determine if the model performs
as expected and allows one to make alterations to increase model realism and hence, applica-
bility. Although simplistic, ODE (6.1) offers a platform for model enhancement and a sensible
addition is the inclusion of antibiotic depletion.
6.2 Coupled ODEs with finite antibiotic
In reference to the prototype orthopaedic pins explored in previous chapters, drug-releasing OIs
would have a finite amount of drug loaded, which must be able to prevent the growth of, and kill
any bacteria which may be present on the OI or within the site of surgery. Therefore, the next
step in modelling bacterial growth subject to an antibiotic, is to include the process of antibiotic
consumption. As an antibiotic is used, its concentration will decrease and thus, its effect on
a local bacterial population will begin to lessen, effectively reducing the maximal killing rate,
kmax. Therefore, in place of a constant consumption rate, Michaelis–Menten reaction kinetics
[98, p. 759] will be used to determine the effective killing rate of an antibiotic, ke, and hence, its
consumption rate. The form chosen for this term in the mathematical model is:
ke =
kmaxc
c+ c50
, (6.7)
where c is the concentration of antibiotic and c50 is the concentration of antibiotic that corre-
sponds to a 50 % killing rate i.e. kmax/2. This value is also known as the EC50 value [99].
This expression for the effective killing rate is nonlinear and the general shape of the function is
shown in Figure 6.4.
Figure 6.4: Plot showing the general behaviour of the Michaelis-Menten reaction term (6.7), pro-
duced by evaluating (6.7) within MATLAB®R2019a via a for loop in antibiotic concentration,
c, whose values were in the range [0, 100], discretised into 1000 equally spaced steps. Parameter
values used were kmax = 10 and c50 = 20.
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As can be seen from Figure 6.4, the effective killing rate of the antibiotic is dependent on
the value of c50 and the concentration, c. As the antibiotic concentration increases, the effective
killing rate, ke, increases and asymptotically approaches the maximal killing rate, kmax. The
behaviour of equation (6.7) can be further explored by dividing top and bottom of the expression
by c50:
ke =
kmax
c
c50
c
c50
+ 1
, and if
c
c50
 1, then ke ≈ kmax
c50
c.
In other words, the plot is approximately linear for c sufficiently small. Similarly, dividing top
and bottom of (6.7) by c:
ke =
kmax
1 +
c50
c
, and if
c50
c
 1, then ke ≈ kmax,
meaning that for high values of c, relative to c50, the effective killing rate is approximately equal
to the maximal killing rate, which can be seen in Figure 6.4.
The proposed model of bacterial growth subject to a finite source of antibiotic is:
dB
dt
= gB
(
1− B
Bmax
)
−B kmaxc
c+ c50
, B(0) = B0, (6.8)
dc
dt
= −B kmaxc
c+ c50
, c(0) = c0, (6.9)
where c0 is the initial antibiotic concentration. Examination of model equations (6.8-6.9) re-
veals that there are three potential outcomes (steady states) from the model, depending on the
parameter values chosen. The two expected results are the situations where the antibiotic has
been depleted and the bacteria have been able to grow in population size to the carrying ca-
pacity, Bmax. Alternatively, the more desirable case may arise in which the bacteria have been
eradicated and some residual antibiotic is left over. These two outcomes are shown in Figure
6.5. The third potential outcome is the situation where both the bacterial population and the
antibiotic are depleted simultaneously. This steady state is possible in theory, however, in re-
ality, it would be considerably more likely for one of either the bacteria or the antibiotic to be
consumed more quickly than the other. Model equations (6.8-6.9) were solved numerically us-
ing MATLAB®R2019a via the “ode45” solver. This solver is based on the explicit Runge-Kutta
method, specifically the Dormand-Prince (4,5) pair [100]. Additionally, the default values for
relative and absolute tolerances for ODE solvers were used (10−3 and 10−6, respectively [101]).
The parameter values, although not necessarily representative of reality, are chosen to demon-
strate the two most likely outcomes of the model. The model results displayed in Figure 6.5 (a)
show the worst outcome: despite the presence of an antibiotic, the bacteria are able to recover
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(a) (b)
Figure 6.5: Plots showing the interaction between antibiotic (c) and bacteria (B). (a) The
antibiotic is killing off the bacteria, however, antibiotic concentrations drop to levels that are
no longer effective and so the bacteria recover, grow and reach the maximum population size.
Parameter values used were kmax = 3, g = 1, Bmax = 50, c0 = 20, c50 = 5 and B0 =
10. (b) The antibiotic succeeds in eradicating the bacteria, which leaves behind an excess of
unused antibiotic. Parameter values are the same in case (a), however, the initial antibiotic
concentration, c0, was increased from 20 to 25.
from near-eradication and grow. The desired outcome is shown in Figure 6.5 (b), where the
bacteria have been completely removed, leaving behind some residual drug. This leftover drug
can then be removed from the body [102, p. 17]. The third, albeit, unlikely scenario is where
both the bacterial population and the antibiotic are reduced to zero simultaneously. This is the-
oretically possible from model equations (6.8-6.9) and may be thought of as the critical case
in which any less antibiotic would eventually lead to the bacteria recovering and being able to
grow.
The inclusion of a finite initial concentration of antibiotic whose killing rate is dependent
on the concentration and EC50 value is considerably more realistic than the previous case con-
sidered where there was a constant supply of antibiotic with a maximal killing rate. However,
there are further modelling considerations which are likely to have an influence on the behaviour
and hence the outcome: bacterial eradication or proliferation. One such consideration is that an
antibiotic would be delivered and not already present and mixed with infecting bacteria, which
is what model equations (6.8-6.9) suggest.
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6.3 Spatially varying antibiotic
6.3.1 Constant drug delivery
The mathematical modelling investigation thus far has resulted in a pair of coupled ODEs to
describe bacterial growth subject to the killing effect of an antibiotic. The previous model con-
sidered the case of a finite amount of antibiotic, which performed as expected: if the antibiotic
is not given in a high enough dose and/or it is not potent enough, the bacteria will prevail. How-
ever, the immediately noticeable limitation of such a model is that it assumes that the drug is
already in the presence of the bacteria. In reality, the antibiotic would be delivered in some way
and would have to build in concentration to have a meaningful effect on the bacteria. With a
view to incorporate the prototype pins, examined in chapters 4 and 5, a radial coordinate system
is used for all of the following models.
Consider now a 1D radial domain of thickness L, which is contaminated with an initial
bacterial population, B0. Assume that an antibiotic, c, is supplied at a constant rate, cin, via a
device of radius Ld, at r = Ld. The antibiotic must then diffuse throughout the bacteria-laden
domain, building up in concentration, to eradicate the bacteria. At r = Ld + L, a zero-flux
boundary condition is applied such that the antibiotic is confined to the domain. This setup is
illustrated in Figure 6.6.
Figure 6.6: Illustration of the 1D domain, of length L, with an initial bacterial population B0.
At r = Ld there is a constant concentration boundary condition and at r = Ld + L there is a
zero-flux boundary condition.
The proposed model which describes a diffusing antibiotic supplied at a constant rate is:
∂B
∂t
= gB
(
1− B
Bmax
)
−B kmaxc
c+ c50
, Ld < r < Ld + L, t > 0, (6.10)
∂c
∂t
= Df
(
1
r
∂c
∂r
+
∂2c
∂r2
)
−B kmaxc
c+ c50
, Ld < r < Ld + L, t > 0, (6.11)
c = cin, r = Ld, t > 0, (6.12)
−Df ∂c
∂r
= 0, r = Ld + L, t > 0, (6.13)
B = B0, Ld ≤ r ≤ Ld + L, t = 0, (6.14)
c = 0, Ld ≤ r ≤ Ld + L, t = 0. (6.15)
The model equations are based upon the previous ODE model (6.8-6.9). However, a diffusive
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component, with associated free-diffusion coefficient Df , has been added to the equation for c,
which results in nonlinear coupled PDEs. Although it was noted earlier in the chapter that a con-
stant source of antibiotic is unrealistic, it will be useful in this scenario to assess the behaviour
of the PDE model and make adjustments where applicable. The model is nondimensionalised
with the following scalings:
B ′ =
B
Bmax
, c ′ =
c
c50
, t ′ = kmaxt, r ′ =
r
L
.
For simplicity the following constants are defined: α = g/kmax; β = Df/kmaxL2; γ =
Bmax/c50; c∗ = cin/c50 and; B∗ = B0/Bmax. Additionally, the scaled position of the boundary
conditions are defined r1 = Ld/L and r2 = (Ld+L)/L. From the scalings, and dropping primes
for clarity, the following nondimensional model is derived:
∂B
∂t
= αB (1−B)−B c
c+ 1
, r1 < r < r2, t > 0, (6.16)
∂c
∂t
= β
(
1
r
∂c
∂r
+
∂2c
∂r2
)
− γB c
c+ 1
, r1 < r < r2, t > 0, (6.17)
c = c∗, r = r1, t > 0, (6.18)
∂c
∂r
= 0, r = r2, t > 0, (6.19)
B = B∗, r1 ≤ r ≤ r2, t = 0, (6.20)
c = 0, r1 ≤ r ≤ r2, t = 0. (6.21)
Model equations (6.16-6.21) were solved numerically in MATLAB®R2019a using the Meth-
od of Lines (MOL). MOL involves replacing the spatial derivatives of a PDE with an algebraic
approximation such as a finite difference approximation. This results in only the time variable
remaining and thus, the PDE is approximated by a system of ODEs [103, p. 6]. Once this system
of ODEs has been formulated, accounting for boundary and initial conditions, it may be solved
using existing numerical solution methods for ODEs [103, p. 7]. Specifically, the “ode23t”
solver was used, which is an implementation of the trapezoidal rule [104], a second order and
implicit method [105, p. 8,10]. The default relative and absolute tolerance values were also used.
Since the model is nondimensional, the 1D geometry is the interval [r1, r2], which was di-
vided into Nr equally spaced points, giving a spatial step-size of δr = (r2 − r1)/(Nr − 1).
This spatial vector has Nr elements and the position of each element in this vector is identified
with i, such that 1 ≤ i ≤ Nr. The time interval considered was divided into Nt equally spaced
time points. The model equations (6.16-6.21) were then rewritten to form a system of coupled
ODEs, which depending on the location within the 1D geometry, will have a different form. The
first and second spatial derivatives are approximated using the second order central difference
approximation. This method of derivative approximation was chosen as it is a more accurate
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method than forward or backward approximations, since the error is proportional to the square
of the spatial step size [106, p. 184-185]. At the point r = r1 i.e. i = 1, the first entry in the
spatial vector, the coupled equations are:
dB
dt
= αB(1) (1−B(1))−B(1) c(1)
c(1) + 1
,
dc
dt
= 0.
The ODE for c is equal to zero as c = c∗, a constant, and therefore does not change with time.
Within the domain, where 2 ≤ i ≤ Nr − 1, the coupled equations are:
dB
dt
= αB(i) (1−B(i))−B(i) c(i)
c(i) + 1
,
dc
dt
= β
(
1
r(i)
c(i+ 1)− c(i− 1)
2δr
+
c(i+ 1)− 2c(i) + c(i− 1)
δr2
)
− γB(i) c(i)
c(i) + 1
,
At the point r = r2 i.e. i = Nr, the coupled equations are:
dB
dt
= αB(Nr) (1−B(Nr))−B(Nr) c(Nr)
c(Nr) + 1
,
dc
dt
=
2β
δr2
(c(Nr − 1)− c(Nr))− γB(Nr) c(Nr)
c(Nr) + 1
,
where the zero-flux boundary condition (6.19) has been incorporated into the second spatial
derivative approximation by using the central difference approximation, to remove the fictitious
node Nr + 1:
∂c
∂r
≈ c(Nr + 1)− c(Nr − 1)
2δr
= 0 ⇒ c(Nr + 1) = c(Nr − 1).
Figure 6.7 shows the results of the model. It performs as expected: the constant concentra-
tion boundary condition permits drug to enter the domain and begin interacting with the bacteria.
However, once all local bacteria have been killed, the drug must diffuse and attain an appropriate
concentration to continue killing the bacteria. Although the bacterial concentration is relatively
low initially, bacteria further to the right of the domain are able to grow and have managed
to reach a normalised population size of B ≈ 0.8 as shown in Figure 6.7 (a). The constant
antibiotic supply then continues diffusing and killing the bacteria until the bacteria have been
eradicated, i.e B = 0. Once the bacteria have been eliminated, the drug continues to diffuse
into the domain, as shown in Figure 6.7 (b), until there is no longer a concentration gradient
i.e. c = c∗. Since there is now a spatial component to the concentration of the antibiotic, the
antibiotic must be especially potent as at the interface where the antibiotic and bacteria meet,
there is a relatively low concentration of antibiotic. This is because newly delivered antibiotic
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(a) (b)
Figure 6.7: Plots showing the nondimensional concentrations of antibiotic (c) and bacteria (B)
versus nondimensional space. The nondimensional parameter values used were: α = 10−2;
β = 10−3; γ = 10; c∗ = 5; B∗ = 10−1; r1 = 1 and; r2 = 2. These parameter values
were arbitrarily chosen to demonstrate how the model works. The discretisation values used
were Nr = 600 and Nt = 1000. These values of Nr and Nt were found to produce an accurate
solution and further discretisation did not produce a noticeable change to the concentration plots.
(a) After 1 hour of simulated time, most of the bacteria have been eliminated. (b) After 7 hours
of simulated time, all the bacteria have been eradicated.
must diffuse to the constantly shifting bacteria/antibiotic interface. Although a constant source
of drug is not realistic, it does demonstrate that the model works correctly, and the next step is
to modify the model such that only a finite amount of antibiotic is delivered.
6.3.2 Finite drug delivery
There are a variety of ways to modify model boundary condition (6.18) such that only a finite
amount of antibiotic is delivered. However, in the context of drug delivery, the most pertinent ap-
proach is via a release profile. Therefore, the new boundary condition will be a time-dependent
boundary condition which will replicate the release profile of an antibiotic from a given device.
The new boundary condition at r = Ld involves M(t), the mass of antibiotic still to be eluted
from the device. This may be calculated analytically: here it is assumed that the antibiotic layer
within the device is cylindrical in shape, with radius Ld and therefore, via symmetry, can be as-
sumed to be 1D. The antibiotic is loaded with an initial concentration of c0, and the transport of
drug is a diffusion dominated process (Figure 6.8). With the assumption of a zero-flux boundary
condition at r = 0 and and infinite sink condition at r = Ld, c(x, t) and M(t) may be readily
calculated analytically. It should be noted that, for this approach to be valid, the timescale of dif-
fusive transport in the domain must be much smaller than the release timescale [107]. Otherwise
the problem will have to be fully coupled to the release equations.
Redefining c∗ to be c∗ = c0/c50, the calculated semi-analytical solution, via Separation of
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Figure 6.8: Illustration of the 1D domain of length Ld, which supplies the finite antibiotic, with
initial concentration c0, as a time-dependent mass-flux boundary condition, as shown in Figure
6.9.
Variables, of the model illustrated by Figure 6.8 is:
c(r, t) =
2c∗
r1
∞∑
n=1
J1(λnr1)
λn (J1(λnr1)2 + J0(λnr1)2)
J0(λnr) exp
(−λ2nβt) (6.22)
where λn are the numerically computed solutions of:
J0(λnr1) = 0. (6.23)
From solution (6.22), the mass function, M(t), normalised with the initial mass of antibiotic,
M0, may be determined:
M(t)
M0
= M ′(t) =
4
r21
∞∑
n=1
J1(λnr1)
2
λ2n (J1(λnr1)
2 + J0(λnr1)2)
exp
(−λ2nβt) , (6.24)
where M0 = piL2dzc0, with z denoting the height of the device supplying the antibiotic.
The geometry for the bacterial study (Figure 6.9) is the same as the one shown in Figure 6.6,
albeit for a change in boundary condition at r = Ld.
Figure 6.9: Illustration of the 1D domain with the time-dependent mass-flux boundary condition.
M(t) here is the mass remaining on the device, i.e. the mass of drug still to be eluted. An area
factor, A, is required to balance the units.
The area factor, A, is the surface area of the device releasing the antibiotic and has the value
A = 2pizLd. Dimensionally, the time-dependent mass-flux boundary condition, at r = Ld, is:
−Df ∂c
∂r
= − 1
2pizLd
dM(t)
dt
.
This expression can be transformed into the nondimensional form (omitting the primes for clar-
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ity) using the previous scalings:
∂c
∂r
=
kmaxLdLc
∗
2Df
dM(t)
dt
. (6.25)
By computing the first time derivative of (6.24), the full expression for the time-dependent mass-
flux boundary condition is found to be:
∂c
∂r
= −2c
∗
r1
f(t). (6.26)
where
f(t) =
∞∑
n=1
J1(λnr1)
2
J1(λnr1)2 + J0(λnr1)2
exp
(−λ2nβt) .
The proposed nondimensional model of bacterial growth subject to a diffusing, and finite, an-
tibiotic is broadly the same as the constant source model (6.16-6.21), except for a change in
boundary condition (6.18), which is replaced with the time-dependent mass-flux boundary con-
dition (6.25):
∂B
∂t
= αB (1−B)−B c
c+ 1
, r1 < r < r2, t > 0, (6.27)
∂c
∂t
= β
(
1
r
∂c
∂r
+
∂2c
∂r2
)
− γB c
c+ 1
, r1 < r < r2, t > 0, (6.28)
∂c
∂r
= −2c
∗
r1
f(t), r = r1, t > 0, (6.29)
∂c
∂r
= 0, r = r2, t > 0, (6.30)
B = B∗, r1 ≤ r ≤ r2, t = 0, (6.31)
c = 0, r1 ≤ r ≤ r2, t = 0. (6.32)
Model equations (6.27-6.32) were solved numerically in MATLAB®R2019a using MOL,
with the system of ODEs being solved using “ode23t”, in much the same way as model equations
(6.16-6.21) were solved, including the use of the default relative and absolute tolerance levels.
The ODEs that arise from this application of MOL are largely identical to the ODE system
derived from the application of MOL to model equations (6.16-6.21). However, the ODE for
c, at r = r1 (i = 1), is very different as it is no longer a constant, it is now a time-dependent
function. The mass-flux boundary condition (6.29) may be approximated using a first order
central difference approximation:
∂c
∂r
≈ c(2)− c(0)
2δr
= −2c
∗
r1
f(t),
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from which an expression for the ficticious node, i = 0, may be derived:
c(0) = c(2) +
4δrc∗
r1
f(t).
This expression may then be inserted into the second order central difference approximation to
give the required ODE at r = r1 (i = 1):
dc
dt
= 2β
(
1
δr2
(c(2)− c(1)) +
(
2
δr
− 1
r1
)
c∗
r1
f(t)
)
− γB(1) c(1)
c(1) + 1
. (6.33)
The infinite sum, f(t), in the ODE (6.33), has a unknown summation and is dependent on
the numerically derived roots of equation (6.23). Therefore, f(t) must be truncated and to do so,
a sufficient number of roots of equation (6.23) must be included. It was found that collecting the
roots within the interval [0, 103], was sufficiently accurate and taking more roots did not yield
improved results. To check if the correct amount of nondimensional mass was being delivered by
boundary condition (6.29), it was assumed that the initial nondimensional bacterial population
was zero i.e. B∗ = 0. Therefore, the delivered antibiotic would not be consumed and would
gradually fill the domain, with the steady state concentration (css) computed to be:
css =
r21c
∗
2r1 + 1
.
The results shown in Figure 6.10 demonstrate that the antibiotic supply must be sufficient to
kill the infecting bacteria, lest they recover, grow in number and cause a serious infection. The
insufficient antibiotic outcome is shown in Figure 6.10 (a), in which most of the bacteria have
been killed. The remaining individuals may be able to grow unhindered, cause infection and
possibly lead to implant failure. The desirable outcome is shown in Figure 6.10 (b), in which
the infecting bacteria have been eradicated and although there is unused antibiotic released,
this remaining antibiotic, although unaccounted for in this model, may then be disposed of
by the body [102, p. 17]. This model is considerably more realistic than the previous models
examined. An antibiotic must travel to the site of infection to carry out its function. However,
further improvements may be made, for example, it was assumed that the release of process
of the antibiotic and its action on the bacteria may be uncoupled and this may not always be
appropriate. Additionally, as a consequence of the model equations, the bacteria are unable
to move throughout the domain, which is not likely to be realistic. Bacteria are able to move
through their immediate surroundings, in search of nutrients, for example. Therefore, the next
step in the mathematical investigation of bacterial growth subject to an antibiotic, will account
for the potential that the release of the antibiotic will be affected by the action of the antibiotic
on motile bacteria.
Should the situation arise in which an analytical/semi-analytical expression cannot be de-
rived for the mass-flux boundary condition, it is possible to use the numerical solution of the
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Figure 6.10: Plots showing the nondimensional concentrations of antibiotic (c) and bacteria (B)
versus nondimensional space. The nondimensional parameter values used were: α = 10−2;
β = 10−3; γ = 10; B∗ = 10−1; r1 = 1 and; r2 = 2. These parameter values were arbitrarily
chosen to demonstrate how the model works. The discretisation values used were Nr = 600 and
Nt = 1000. These values of Nr and Nt were found to produce an accurate solution and further
discretisation did not produce a noticeable change to the concentration plots. (a) After 5 hours
of simulated time and with c∗ = 10, almost all of the antibiotic has been consumed. (b) After 3
hours of simulated time and with c∗ = 15, all the bacteria have been eradicated.
release of an antibiotic instead. The time derivative of mass, M(t), within equation (6.25), may
be thought of as the numerical gradient of the release data. However, the number of entries
within this numerical release vector must be identical to the number of time points where the
solution is computed by the ODE solver. The ODE solvers within MATLAB®R2019a, use time
stepping that satisfies the required tolerance levels and so to supply these timesteps with the cor-
rect mass-flux value, the numerical release data may be linearly interpolated at these timesteps.
In the case where numerical release data is used, the required ODE at r = r1 (i = 1) is:
dc
dt
= β
(
2
δr2
(c(2)− c(1)) +
(
1
2r1
− 1
δr
)
LdLkmaxc
∗
Df
dM(t)
dt
)
− γB(1) c(1)
c(1) + 1
.
6.4 Fully coupled model with bacterial diffusion
Model equations (6.27-6.32) considered the case where the release process could be uncou-
pled from the reaction of the antibiotic on the bacteria. However, this may not be applicable
and so it may be the case that the two processes must be coupled for a more realistic model.
Additionally, it was assumed that the bacteria were static, merely growing in place until the
maximum population size was achieved. This is also not realistic as the invading bacteria may
be able to move. There are many reasons why the bacteria may move away from their imme-
diate surroundings, one main reason is via chemotaxis, in which the bacteria may move up a
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concentration gradient towards nutrients or down a concentration gradient to move away from
harmful substances [108]. Most bacteria are considered motile and have a variety of means to
swim through liquid environments or move over surfaces [108]. This is an active process in
which the bacteria use energy to control their movement. There are also bacteria which are con-
sidered nonmotile and these bacteria must rely on passive influences to be able to move [109],
for example, via a flowing fluid. Bacteria are very small and an averaged sized bacterium is con-
sidered to be the rod-shaped Escherichia coli, which is approximately 0.5µm in diameter and
2µm in length [110]. Previously mentioned in the chapter, S. aureus, one of the most common
causes of implant-associated infection, is spherical in shape and has a approximate diameter of
1µm [110].
Although there are bacteria which are motile and nonmotile, it may be sufficient to model
their spreading behaviour as a diffusive transport mechanism. This is not unreasonable as bac-
teria are small and so may be considered particles, which can undergo diffusion. Addition-
ally, there exists research on the subject of the diffusivity of bacteria, where efforts were made
to experimentally measure the diffusion coefficients of several bacteria species. One particu-
larly noteworthy conclusion, was that motile cells were able to move three orders of magnitude
quicker than nonmotile cells [111].
Consider a 1D radial domain (Figure 6.11), subdivided into three regions of thicknesses
Ld, LB and Lm. The subscripts indicate which region the thicknesses are associated with: d
indicates the region containing the initial concentration of antibiotic, c0; B indicates the region
containing the initial population of bacteria, B0, and; m indicates the region which, although
initially empty, the bacteria are able to move into and colonise. The interfaces between these
regions are marked r = L1 and r = L2, which are defined L1 = Ld and L2 = Ld + LB. The
endpoints are marked r = 0 and r = L3, which is defined L3 = Ld + LB + Lm.
Figure 6.11: Illustration of the 1D domain comprised of three layers: The first layer, with radius
Ld, contains the initial drug concentration, c0; the second layer, with thickness LB, contains
the initial concentration of bacteria, B0 and; the third layer, of thickness Lm, although initially
empty, is able to be occupied by the antibiotic or colonised by the moving, and growing, bacteria.
Additionally, the endpoints, r = 0 and r = L3 and the position of the layer interfaces, r = L1,
r = L2 and r = L3, are shown.
Antibiotic and bacterial concentrations are defined ci(r, t) and Bi(r, t), respectively, where i =
d,B,m. The subscript d,B andm indicate the which region within the 1D domain each variable
is associated with. Expanding upon the previous PDE model (6.27-6.32), the proposed model to
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describe a diffusing, and growing, bacterial population, subject to a releasing antibiotic is:
∂ci
∂t
= Df
(
1
r
∂ci
∂r
+
∂2ci
∂r2
)
−Bi kmaxci
ci + c50
, t > 0, (6.34)
∂Bi
∂t
= DB
(
1
r
∂Bi
∂r
+
∂2Bi
∂r2
)
+ gBi
(
1− Bi
Bmax
)
−Bi kmaxci
ci + c50
, t > 0, (6.35)
i = d : 0 < r < L1, i = B : L1 < r < L2, i = m : L2 < r < L3.
The governing equations (6.34-6.35) are coupled with the following set of boundary and initial
conditions:
−Df ∂cd
∂r
= 0, −DB ∂Bd
∂r
= 0 r = 0, t > 0, (6.36)
cd = cB, −Df ∂cd
∂r
= −Df ∂cB
∂r
, r = L1, t > 0, (6.37)
Bd = BB, −DB ∂Bd
∂r
= −DB ∂BB
∂r
, r = L1, t > 0, (6.38)
cB = cm, −Df ∂cB
∂r
= −Df ∂cm
∂r
, r = L2, t > 0, (6.39)
BB = Bm, −DB ∂BB
∂r
= −DB ∂Bm
∂r
, r = L2, t > 0, (6.40)
−Df ∂cm
∂r
= 0, −DB ∂Bm
∂r
= 0 r = L3, t > 0, (6.41)
cd = c0, 0 ≤ r ≤ L1, cB = 0, L1 < r ≤ L2,
cm = 0, L2 < r ≤ L3, t = 0, (6.42)
Bd = 0, 0 ≤ r ≤ L1, BB = B0, L1 < r ≤ L2,
Bm = 0, L2 < r ≤ L3, t = 0. (6.43)
The major addition to this model, compared to previous models, is the inclusion of the bacte-
rial diffusive transport component in the equations governing bacterial growth, with associated
constant bacterial diffusion coefficient, DB. The model equations (6.34-6.43) are nondimen-
sionalised with the following scalings:
B ′i =
B
Bmax
, c ′i =
c
c50
, t ′ = kmaxt, r ′ =
r
Ld
,
For simplicity, the following constants are defined: β1 = Df/kmaxL2d; β2 = DB/kmaxL
2
d;
α = g/kmax; γ = Bmax/c50; B∗ = B0/Bmax; c∗ = c0/c50; r1 = L1/Ld, which by definition
means that r1 = 1; r2 = L2/Ld and; r3 = L3/Ld. These scalings and simplifications give rise
to the following nondimensional model (omitting the primes for clarity):
∂ci
∂t
= β1
(
1
r
∂ci
∂r
+
∂2ci
∂r2
)
− γBi ci
ci + 1
, t > 0, (6.44)
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∂Bi
∂t
= β2
(
1
r
∂Bi
∂r
+
∂2Bi
∂r2
)
+ αBi (1−Bi)−Bi ci
ci + 1
, t > 0, (6.45)
i = d : 0 < r < 1, i = B : 1 < r < r2, i = m : r2 < r < r3.
The nondimensional governing equations (6.44-6.45) are coupled with the following set of
nondimensional boundary and initial conditions:
∂cd
∂r
= 0,
∂Bd
∂r
= 0 r = 0, t > 0, (6.46)
cd = cB,
∂cd
∂r
=
∂cB
∂r
, r = 1, t > 0, (6.47)
Bd = BB,
∂Bd
∂r
=
∂BB
∂r
, r = 1, t > 0, (6.48)
cB = cm,
∂cB
∂r
=
∂cm
∂r
, r = r2, t > 0, (6.49)
BB = Bm,
∂BB
∂r
=
∂Bm
∂r
, r = r2, t > 0, (6.50)
∂cm
∂r
= 0,
∂Bm
∂r
= 0 r = r3, t > 0, (6.51)
cd = c
∗, 0 ≤ r ≤ 1, cB = 0, 1 < r ≤ r2,
cm = 0, r2 < r ≤ r3, t = 0, (6.52)
Bd = 0, 0 ≤ r ≤ 1, BB = B∗, 1 < r ≤ r2,
Bm = 0, r2 < r ≤ r3, t = 0. (6.53)
Model equations (6.44-6.53) were solved numerically using COMSOL®, version 5.3a, using the
PARDISO method, with the BDF to handle time advancement and using the physics-based de-
fault relative and absolute tolerance levels. The 1D geometry was discretised using the densest
built-in mesh settings, giving 2500 spatial points, which provided negligible error in the nu-
merical solution at no appreciable increase in computational cost. The numerical concentration
solutions were then exported and plotted using MATLAB®R2019a.
The results shown in Figures 6.12 and 6.13, again, demonstrate that the initial concentration
of antibiotic must be sufficient to kill the infecting bacteria, otherwise they will be permitted
to recover, grow in number and potentially cause a serious infection. The case of insufficient
antibiotic is shown in Figure 6.12. Although most of the initial infecting bacteria, B∗, in the
region r1 ≤ r ≤ r2, are killed, the bacteria have been able to move into the region r2 ≤ r ≤
r3 and continue growing. Whilst the bacteria at the antibiotic/bacteria interface are are being
destroyed by the antibiotic, the bacteria further to the right of the interface are able to grow
freely, as shown in Figure 6.12 (a). As time advances, it is clear from Figure 6.12 (b), that
the initial drug loading, c∗, was insufficient to deal with the bacteria. Thus, the bacteria are
able to grow in number and, with adequate time, spread throughout the entire domain. This
scenario is clearly the least desirable outcome as potential failure of an implant may occur due
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(a) (b)
Figure 6.12: Plots showing the nondimensional concentrations of antibiotic (c) and bacteria (B)
versus nondimensional space, where the dash-dotted lines indicate the position of the interfaces
between the regions. The nondimensional parameter values used were: α = 10−2; β1 = 10−4;
β2 = 10
−3; γ = 10; c∗ = 30; B∗ = 10−1; r2 = 2 and; r3 = 3. These parameter values were
arbitrarily chosen to demonstrate how the model works. (a) After 30 minutes of simulated time
most of the antibiotic has been consumed, but the bacteria have been mostly removed from the
second layer (the B region). (b) After 45 minutes of simulated time, almost all of the antibiotic
has been consumed and the bacteria have flourished.
to the likely infection caused by bacteria growing and spreading, with impunity. The preferable
outcome is shown in Figure 6.13, in which the infecting bacteria have been eliminated. The
residual antibiotic, although unaccounted for in this model, may then be disposed of by the
body [102, p. 17]. Despite increasing c∗ = 30 to c∗ = 35, a relatively small amount, the
outcome is drastically different to that shown in Figure 6.12. The bacteria, shown in Figure 6.13
(a), have managed to move to the right-most boundary of the geometry, whilst being subjected
to the antibiotic, and attained a normalised bacterial concentration of B ≈ 0.2. However, this
population size is not enough to thwart the onslaught of the antibiotic, which eventually, kills all
of the bacteria, as shown in Figure 6.13 (b).
This model is considerably more realistic than the previous models investigated. The diffu-
sive transport component is a reasonable inclusion, since bacteria are not necessarily confined to
a single location to grow. The diffusing bacteria may be thought of as seeking nutrients within
the body to grow or to evade the antibiotic. This leads to the scenario of the antibiotic essentially
“chasing” the bacteria until they have been eliminated. The mathematical investigation thus far
has led to a core mathematical model of bacterial growth subject to an antibiotic in the form of
nonlinear coupled PDEs. These PDEs account for the movement, growth and killing effect of
an antibiotic on a bacterial population. The transport and consumption of the antibiotic is also
modelled. It is possible to make further additions to the model to enhance its ability at capturing
realistic processes, for example, the inclusion of the drug elimination process. However, it is
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(a) (b)
Figure 6.13: Plots showing the nondimensional concentrations of antibiotic (c) and bacteria (B)
versus nondimensional space, where the dash-dotted lines indicate the position of the interfaces
between the regions. The nondimensional parameter values used were identical to those used to
generate the plots in Figure 6.12, except for the nondimensional initial antibiotic concentration,
which was increased to c∗ = 35. (a) After 15 minutes of simulated time, almost all of the
bacteria have been eliminated. (b) After 30 minutes of simulated time, all the bacteria have been
eradicated.
assumed that this process occurs on a much longer timescale to that of the action of an antibiotic
on bacteria and is omitted. Therefore, the next step is to apply the current model to the prototype
pins investigated in chapters 4 and 5.
6.5 Antibiotic release from the porous pin
The porous pin, investigated experimentally by Gimeno et al. [11], was examined mathemat-
ically in chapter 4. One of the key findings from the chapter was that drug-release could be
modelled via a 1D mathematical model. This was the case as the pin is symmetric and the
stirred release medium of the experiments provided a negligible advective component to drug
transport. Therefore, a 1D diffusion-dissolution model was deemed appropriate (4.127-4.136).
With some modifications, this model could be coupled with model equations (6.34-6.43) to test
the theoretical ability of the porous pin to deliver a dissolving antibiotic, with the objective of
eliminating a contaminating population of bacteria.
Consider a 1D geometry, comprised of four regions (Figure 6.14), each having a dissolved
antibiotic concentration cj(r, t), with j = d, p, B,m. The last two regions additionally have
bacterial concentration Bi(r, t), where i = B,m. Similarly to the previous section, the sub-
script d, p, B,m indicate which region of the domain model components are associated with: d
indicates the region containing the initial concentration of undissolved antibiotic, b0; p indicates
the porous wall region of the pin; B indicates the region containing the initial population of
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bacteria, B0, and; m indicates the region which, although initially empty, the bacteria are able
to move into and colonise. From left to right: the innermost region of radius Ld is the drug
core of the porous pin, which holds an initial concentration of undissolved antibiotic b0, with
an undissolved antibiotic concentration, b(r, t); the next region, of thickness Lp, is the porous
wall of the pin, with porosity φ; the next region, with thickness LB, is the layer in which the
initial contaminating bacterial population, B0, resides and; the last region, with thickness Lm,
is additional space for the bacteria to be able to diffuse into and grow. The position of the in-
terfaces are defined to be the addition of layer thicknesses, such that L1 = Ld, L2 = Ld + Lp,
L3 = Ld + Lp + LB and the rightmost endpoint is L4 = Ld + Lp + LB + Lm.
Figure 6.14: Illustration of the 1D domain comprised of four layers: The first layer contains
the initial undissolved drug concentration, b0; the second layer is the porous wall of the pin; the
third region contains the infecting bacteria and; the last region is empty available space for the
bacteria to move into and grow. The endpoints, r = 0 and r = L4 and the position of the layer
interfaces, r = L1, r = L2 and r = L3, are shown.
The governing equations proposed to model bacterial growth, subject to a dissolving antibiotic
being released from the porous pin are:
∂b
∂t
= −ηbε (S − cd) , 0 < r < L1, t > 0, (6.54)
∂cd
∂t
= Df
(
1
r
∂cd
∂r
+
∂2cd
∂r2
)
+ ηbε (S − cd) , 0 < r < L1, t > 0, (6.55)
φ
∂cp
∂t
= Dp
(
1
r
∂cp
∂r
+
∂2cp
∂r2
)
, L1 < r < L2, t > 0, (6.56)
∂ci
∂t
= Df
(
1
r
∂ci
∂r
+
∂2ci
∂r2
)
−Bi kmaxci
ci + c50
, t > 0, (6.57)
∂Bi
∂t
= DB
(
1
r
∂Bi
∂r
+
∂2Bi
∂r2
)
+ gBi
(
1− Bi
Bmax
)
−Bi kmaxci
ci + c50
, t > 0, (6.58)
i = B : L2 < r < L3, i = m : L3 < r < L4.
Note that equations (6.57-6.58) are valid for both i = B and i = M . The dissolution equation
(6.54) differs only symbolically from its usage in chapter 4. In the equation, η is the dissolution
rate of the antibiotic, ε is the reaction exponent which governs the type of reaction and S is the
solubility of the antibiotic. Also returning from chapter 4 is the notion of an effective diffusion
coefficient, Dp. This diffusion coefficient is applicable to the antibiotic whilst diffusing through
the pin’s porous wall and is defined Dp = φeDf/τ , where φe and τ are the effective porosity
and level of tortuosity of the porous wall, respectively. For simplicity, it is assumed that the
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bacteria cannot colonise the porous region of the pin, should the antibiotic fail to eliminate the
bacteria. In reality, the bacteria may be able to enter the pin if they are sufficiently small. The
scale bar shown in the scanning electron microscope image of Figure 4.1 (a), has a reference
size of 10µm and although this suggests that the pore sizes of the pin’s porous wall are small,
bacteria may be able infiltrate the pin regardless. However, if this is the case, it is likely that the
rate at which the bacteria can diffuse through the porous wall is relatively low, when compared
to being able to diffuse in regions without the low level of porosity. The governing equations
(6.54-6.58) are coupled with the following boundary and initial conditions:
−Df ∂cd
∂r
= 0, r = 0, t > 0, (6.59)
cd = cp, −Df ∂cd
∂r
= −Dp∂cp
∂r
, r = L1, t > 0, (6.60)
cp = cB, −Dp∂cp
∂r
= −Df ∂cB
∂r
, r = L2, t > 0, (6.61)
−DB ∂BB
∂r
= 0, r = L2, t > 0, (6.62)
cB = cm, −Df ∂cB
∂r
= −Df ∂cm
∂r
, r = L3, t > 0, (6.63)
BB = Bm, −DB ∂BB
∂r
= −DB ∂Bm
∂r
, r = L3, t > 0, (6.64)
−Df ∂cm
∂r
= 0, −DB ∂Bm
∂r
= 0, r = L4, t > 0, (6.65)
b = b0, 0 ≤ r ≤ L1, t = 0, (6.66)
cd = 0, 0 ≤ r ≤ L1, cp = 0, L1 < r ≤ L2,
cB = 0, L2 < r ≤ L3, cm = 0, L3 < r ≤ L4, t = 0, (6.67)
BB = B0, L2 ≤ r ≤ L3, Bm = 0, L3 < r ≤ L4, t = 0. (6.68)
For simplification, the following constants are defined: χ = ηbε0/kmax; S
∗ = S/b0; β1 =
Df/kmaxL
2
d; β2 = Dp/kmaxL
2
d; β3 = DB/kmaxL
2
d; γ = Bmax/S; δ = c50/S; α = g/kmax;
D = Dp/Df ;B∗ = B0/Bmax; r1 = L1/Ld, which by definition means that r1 = 1; r2 = L2/Ld;
r3 = L3/Ld and; r4 = L4/Ld. Model equations (6.54-6.68) are nondimensionalised with the
following scalings:
B ′i =
Bi
Bmax
, c ′j =
cj
S
, b ′ =
b
b0
, r ′ =
r
Ld
, t ′ = kmaxt,
where i = B,m and j = d, p, B,m. The simplifications and scalings result in the following
nondimensional model (omitting the primes for clarity):
∂b
∂t
= −χS∗bε (1− cd) , 0 < r < 1, t > 0, (6.69)
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∂cd
∂t
= β1
(
1
r
∂cd
∂r
+
∂2cd
∂r2
)
+ χbε (1− cd) , 0 < r < 1, t > 0, (6.70)
φ
∂cp
∂t
= β2
(
1
r
∂cp
∂r
+
∂2cp
∂r2
)
, 1 < r < r2, t > 0, (6.71)
∂ci
∂t
= β1
(
1
r
∂ci
∂r
+
∂2ci
∂r2
)
− γBi ci
ci + δ
, t > 0, (6.72)
∂Bi
∂t
= β3
(
1
r
∂Bi
∂r
+
∂2Bi
∂r2
)
+ αBi (1−Bi)−Bi ci
ci + δ
, t > 0, (6.73)
i = B : r2 < r < r3, i = m : r3 < r < r4.
The nondimensional governing equations (6.69-6.73) are coupled with the following nondimen-
sional boundary and initial conditions:
∂cd
∂r
= 0, r = 0, t > 0, (6.74)
cd = cp,
∂cd
∂r
= D
∂cp
∂r
, r = 1, t > 0, (6.75)
cp = cB, D
∂cp
∂r
=
∂cB
∂r
, r = r2, t > 0, (6.76)
∂BB
∂r
= 0, r = r2, t > 0, (6.77)
cB = cm,
∂cB
∂r
=
∂cm
∂r
, r = r3, t > 0, (6.78)
BB = Bm,
∂BB
∂r
=
∂Bm
∂r
, r = r3, t > 0, (6.79)
∂cm
∂r
= 0,
∂Bm
∂r
= 0, r = r4, t > 0, (6.80)
b = 1, 0 ≤ r ≤ 1, t = 0, (6.81)
cd = 0, 0 ≤ r ≤ 1, cp = 0, 1 < r ≤ r2,
cB = 0, r2 < r ≤ r3, cm = 0, r3 < r ≤ r4, t = 0, (6.82)
BB = B
∗, r2 ≤ r ≤ r3, Bm = 0, r3 < r ≤ r4, t = 0. (6.83)
Dimensional parameters associated with the porous pin are the same as those used in the
porous pin sensitivity study of chapter 4 (see Table 6.1), except for the value of solubility, which
was chosen to be S = 50 kg/m3. This value of solubility was chosen as it is the higher value
of solubility of the two antibiotics used by Gimeno et al. in their drug release experiments for
the orifice pins (cefazolin sodium and linezolid) [12]. Although cefazolin sodium was not used
in the drug release experiments with the porous pin, it was deemed that this value of solubil-
ity would be a suitable starting point. Model equations (6.69-6.83) were solved numerically
using COMSOL®, version 5.3a, using the PARDISO method, with the BDF to handle time ad-
vancement and using the physics-based default relative and absolute tolerance levels. The 1D
geometry was discretised using the densest built-in mesh settings. The 1D geometry was dis-
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cretised using the densest built-in mesh settings, giving 2510 spatial points, which provided
negligible error in the numerical solution at no appreciable increase in computational cost. The
numerical concentration solutions were then exported and plotted using MATLAB®R2019a.
Parameter Value
Ld 1.575× 10−3 m [11]
Lp 1.6× 10−3 m [11]
τ 3 [48]
φ 0.17 [11]
φe 0.9× φ
ε 2/3 [34]
Df 1× 10−9 m2/s
Dp = φeDf/τ 5.1× 10−11 m2/s
η 10−5 s−1(m−3kg)2/3
b0 505.19 kg/m
3 [11]
S 50 kg/m3 [12]
Table 6.1: Dimensional parameter values. These values are taken from the literature or inferred
from [11]. The initial mass concentration, b0, is calculated from the assumed drug mass loading
of 100 mg and dividing by the interior volume of the porous pin.
Figures 6.15 and 6.16 show the results of the study into the theoretical ability of the porous
pin to deliver antibiotic and eradicate a contaminating bacterial population. The results of the
study suggest that there is a close link between the potency of the antibiotic and the outcome.
This may be inferred from the fact that in both cases, the same mass of antibiotic is used, the only
difference is the change in potency of the antibiotic. Dimensionally, this change corresponds to
changing the value of c50 from 1 to 0.1, which changes the nondimensional parameter δ from
2×10−2 to 2×10−3. The lowering of the value of c50 has the effect of lowering the concentration
of antibiotic required to provide a 50 % killing rate i.e. kmax/2. Interestingly, in the early stages,
both Figures 6.15 (a) and 6.16 (a) are quite similar, despite an order of magnitude difference
in antibiotic potency. The high dependency on antibiotic potency is reasoned from the long-
term behaviour of the model. Closer inspection of the plots shows that the concentration of
antibiotic leaving the pin is relatively low and this may be a result of the low level of porosity
of the pin limiting the release of the antibiotic. Compounding the limited release of antibiotic
further is that the antibiotic must first dissolve before it may diffuse out of the porous pin, unlike
all other previous models, which assumed that the antibiotic was initially in the solute phase.
Examining Figures 6.15 (b) and 6.16 (b) show the consequences of changing antibiotic potency
on the outcome. In Figure 6.15 (b), the antibiotic fails to eliminate the bacteria and this likely
due to the low concentration of antibiotic being released, coupled with low antibiotic potency.
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(a) (b)
Figure 6.15: Plots showing the nondimensional concentrations of antibiotic (c) and bacteria (B)
versus nondimensional space, where the dash-dotted lines indicate the position of the interfaces
between the regions. The nondimensional parameter values used were: χ = 6.3431 × 10−4;
S∗ = 0.098973; β1 = 4.0312× 10−4; β2 = 2.0559× 10−5; β3 = 4.0312× 10−6; γ = 2× 10−1;
δ = 2 × 10−2; α = 10−3; D = 0.051 and; B∗ = 10−1. Parameter values not associated with
the porous pin were arbitrarily chosen to demonstrate how the model works. (a) After 18 hours
of simulated time, the initially contaminated region is free of bacteria. (b) After 72 hours of
simulated time, almost all of the antibiotic has been consumed and the bacteria are free to grow.
As a result, the bacteria are able to continue growing whilst the antibiotic has a minimal effect.
Despite the antibiotic being released at relatively low concentrations, the more potent antibiotic
(Figure 6.16 (b)) is able to slowly kill the bacteria in spite of low concentrations of antibiotic,
until it is able to overcome the growing bacteria. Additionally, an antibiotic of low potency
but high solubility may be a suitable alternative, rather than the use of a more potent antibiotic.
This is likely possible as although not relatively potent, such an antibiotic will have a greater
concentration at the implant surface and hence, a higher effective killing rate.
It may be the case that this model is not fully representative of a realistic scenario. As
previously discussed, bacteria may be able to enter the porous pin should the antibiotic fail to
eliminate them, as the pore sizes of the pin’s porous wall, although small, may be large enough
to allow small bacterial cells in. One such example, which is one of the most common causes of
implant-associated infection, is the spherically shaped S. aureus, with an approximate diameter
of 1µm [110]. Should an antibiotic fail to eradicate an infecting S. aureus population, the
possibility of the bacteria colonising the interior of the pin poses a significant potential risk of
implant failure. This further emphasises that the loaded mass of antibiotic must be sufficient,
but also potent enough, to deal with the infecting bacteria.
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(a) (b)
Figure 6.16: Plots showing the nondimensional concentrations of antibiotic (c) and bacteria (B)
versus nondimensional space, where the dash-dotted lines indicate the position of the interfaces
between the regions. The nondimensional parameter values used were identical to those used to
generate the plots in Figure 6.15, except for a change to δ, which was decreased to δ = 2×10−3.
(a) Similarly to Figure 6.15 (a), after 18 hours of simulated time, the initially contaminated
region is free of bacteria. (b) After 72 hours of simulated time, all the bacteria have been
eliminated.
6.6 Antibiotic release from the 8-orifice pin
The orifice pins, examined experimentally by Gimeno et al. [12], are a collection of prototype
drug-releasing fixation pins with a differing number (2, 4, 6 or 8) of equidistant orifices. The
extreme cases (the 2 and 8-orifice pins) were investigated mathematically in chapter 5. Some
key findings of the chapter were that the orifice pins were an example where 3D mathematical
modelling was required, as symmetry was not a viable option and because fluid flow could have
a notable influence on the release of drug from the orifice pins. Although the drug release data
collected by Gimeno et al. could not be captured by the model (5.29-5.40), there are many
reasons discussed in chapter 5 as to why this may be the case. However, this does not halt
further study into the theoretical abilities of the orifice pins to tackle a contaminating population
of bacteria. With some modifications, model equations (5.29-5.40) may be coupled with model
equations (6.34-6.43) to test the theoretical ability of the 8-orifice pin to release a dissolving
antibiotic, with the aim of eradicating a contaminating population of bacteria. In this study, the
8-orifice pin was chosen, over the 2-orifice pin, as it was deemed the most likely of the two pins
to achieve the desired outcome, since it has more orifices to release an antibiotic.
The geometry considered for this study is one quarter of the original orifice pin geometry,
without the release medium component, as shown in Figure 5.2 (a) in chapter 5. This is due to
the presence of two lines of symmetry: one cutting the pin in half and the other cutting through
the centre of the orifices, to give a wedge-shaped geometry. These lines of symmetry are accept-
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able to use in this study as it is assumed that the transport of antibiotic is diffusion-based and
there is no fluid flow and thus, no advective component in both bacterial and antibiotic trans-
port equations. Therefore, consider a 3D geometry, which is comprised of four regions (Figure
6.17), the first region is the inner drug core of the 8-orifice pin, with radius Ld, denoted Ω1,
which contains the initial concentration of undissolved antibiotic, b0, and has a defined undis-
solved antibiotic concentration of b(x, y, z, t). The next region is the collection of the pin’s
orifices, which, for the purpose of the mathematical investigation, are collectively denoted Ω2
and have length Lo. It should be noted that although there appears to be more space than just
the orifices in this region, this apparent space is actually the stainless-steel casing of the pin.
The next region is Ω3, with thickness LB, and is the region that contains the initial contaminat-
ing bacterial population, B0. Lastly, region Ω4, with thickness Lm, is additional space for the
bacteria to move into and grow. All regions have a defined bacterial and dissolved antibiotic
concentration Bi(x, y, z, t) and ci(x, y, z, t), respectively, where i = Ω1,Ω2,Ω3,Ω4. The bacte-
rial concentration is defined throughout the entire geometry as, unlike the porous pin study in
the previous section, it is assumed that the bacteria could colonise the 8-orifice pin in the event
the antibiotic fails to eliminate them. This is reasoned to be a valid assumption as the orifices
of the pin have a diameter of 0.5 mm [12], which is likely sufficiently large enough to allow the
bacteria to diffuse into the pin.
The boundaries of the geometry are defined: Γ1, this is the collection of all outer boundary
surfaces of the geometry and the surfaces of the two caps at the top and bottom of the pin; Γ2
is defined as the collection of semi-circular surfaces at the end of the orifices connecting Ω1 and
Ω2; similarly, Γ3 is the collection of semi-circular surfaces connecting Ω2 and Ω3 and; Γ4 is the
curved surface connecting Ω3 and Ω4.
Figure 6.17: Illustration of the 3D geometry comprised of four regions: The first region, Ω1,
contains the initial undissolved drug concentration, b0; the second region, Ω2 is comprised of all
the orifices of the geometry; the third region, Ω3, contains the initial bacterial population and;
the last region, Ω4 is empty available space for the bacteria to move into and grow. The location
of the boundaries Γ1, Γ2, Γ3 and Γ4 are also shown.
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The governing equations proposed to model bacterial growth, subject to a dissolving antibiotic
being released from the pin are:
∂b
∂t
= −ηbε (S − cΩ1) , in Ω1, t > 0, (6.84)
∂cΩ1
∂t
= Df∇2cΩ1 + ηbε (S − cΩ1)−BΩ1
kmaxcΩ1
cΩ1 + c50
, in Ω1, t > 0, (6.85)
∂BΩ1
∂t
= DB∇2BΩ1 + gBΩ1
(
1− BΩ1
Bmax
)
−BΩ1
kmaxcΩ1
cΩ1 + c50
, in Ω1, t > 0, (6.86)
∂cn
∂t
= Df∇2cn −Bn kmaxcn
cn + c50
, t > 0, (6.87)
∂Bn
∂t
= DB∇2Bn + gBn
(
1− Bn
Bmax
)
−Bn kmaxcn
cn + c50
, t > 0, (6.88)
n = Ω2,Ω3,Ω4.
The model is broadly similar to the model in the study of the porous pin in the previous section
and parameters associated with the dissolution equation (6.84), have the same definition. The
governing equations (6.84-6.88) are coupled with the following boundary and initial conditions:
− nˆ ·Df∇cΩ1 = 0, −nˆ ·Df∇cΩ2 = 0,
− nˆ ·Df∇cΩ3 = 0, −nˆ ·Df∇cΩ4 = 0, on Γ1, t > 0, (6.89)
cΩ1 = cΩ2 , −nˆ ·Df∇cΩ1 = −nˆ ·Df∇cΩ2 , on Γ2, t > 0, (6.90)
BΩ1 = BΩ2 , −nˆ ·DB∇BΩ1 = −nˆ ·DB∇BΩ2 , on Γ2, t > 0, (6.91)
cΩ2 = cΩ3 , −nˆ ·Df∇cΩ2 = −nˆ ·Df∇cΩ3 , on Γ3, t > 0, (6.92)
BΩ2 = BΩ3 , −nˆ ·DB∇BΩ2 = −nˆ ·DB∇BΩ3 , on Γ3, t > 0, (6.93)
cΩ3 = cΩ4 , −nˆ ·Df∇cΩ3 = −nˆ ·Df∇cΩ4 , on Γ4, t > 0, (6.94)
BΩ3 = BΩ4 , −nˆ ·DB∇BΩ3 = −nˆ ·DB∇BΩ4 , on Γ4, t > 0, (6.95)
b = b0, in Ω1, t = 0, (6.96)
cΩ1 = 0, in Ω1, cΩ2 = 0, in Ω2,
cΩ3 = 0, in Ω3, cΩ4 = 0, in Ω4, t = 0, (6.97)
BΩ1 = 0, in Ω1, BΩ2 = 0, in Ω2,
BΩ3 = B0, in Ω3, BΩ4 = 0, in Ω4, t = 0, (6.98)
where nˆ is the outward facing unit normal appropriate for each surface. For simplification, the
constants defined in the previous section are used again in this study: χ = ηbε0/kmax; S
∗ = S/b0;
β1 = Df/kmaxL
2
d; β2 = DB/kmaxL
2
d; γ = Bmax/S; δ = c50/S; α = g/kmax and; B
∗ =
163
B0/Bmax. Model equations (6.84-6.98) are nondimensionalised with the following scalings:
B ′i =
Bi
Bmax
, c ′i =
ci
S
, b ′ =
b
b0
, x ′ =
x
Ld
, y ′ =
y
Ld
, z ′ =
z
Ld
t ′ = kmaxt,
where i = Ω1,Ω2,Ω3,Ω4. The simplifications and scalings result in the following nondimen-
sional model (omitting the primes for clarity):
∂b
∂t
= −χS∗bε (1− cΩ1) , in Ω1, t > 0, (6.99)
∂cΩ1
∂t
= β1∇2cΩ1 + χbε (1− cΩ1)− γBΩ1
cΩ1
cΩ1 + δ
, in Ω1, t > 0, (6.100)
∂BΩ1
∂t
= β2∇2BΩ1 + αBΩ1 (1−BΩ1)−BΩ1
cΩ1
cΩ1 + δ
, in Ω1, t > 0, (6.101)
∂cn
∂t
= β1∇2cn − γBn cn
cn + δ
, t > 0, (6.102)
∂Bn
∂t
= β2∇2Bn + αBn (1−Bn)−Bn cn
cn + δ
, t > 0, (6.103)
n = Ω2,Ω3,Ω4.
The nondimensional governing equations (6.99-6.103) are coupled with the following nondi-
mensional boundary and initial conditions:
nˆ · ∇cΩ1 = 0, nˆ · ∇cΩ2 = 0,
nˆ · ∇cΩ3 = 0, nˆ · ∇cΩ4 = 0, on Γ1, t > 0, (6.104)
cΩ1 = cΩ2 , nˆ · ∇cΩ1 = nˆ · ∇cΩ2 , on Γ2, t > 0, (6.105)
BΩ1 = BΩ2 , nˆ · ∇BΩ1 = nˆ · ∇BΩ2 , on Γ2, t > 0, (6.106)
cΩ2 = cΩ3 , nˆ · ∇cΩ2 = nˆ · ∇cΩ3 , on Γ3, t > 0, (6.107)
BΩ2 = BΩ3 , nˆ · ∇BΩ2 = nˆ · ∇BΩ3 , on Γ3, t > 0, (6.108)
cΩ3 = cΩ4 , nˆ · ∇cΩ3 = nˆ · ∇cΩ4 , on Γ4, t > 0, (6.109)
BΩ3 = BΩ4 , nˆ · ∇BΩ3 = nˆ · ∇BΩ4 , on Γ4, t > 0, (6.110)
b = 1, in Ω1, t = 0, (6.111)
cΩ1 = 0, in Ω1, cΩ2 = 0, in Ω2,
cΩ3 = 0, in Ω3, cΩ4 = 0, in Ω4, t = 0, (6.112)
BΩ1 = 0, in Ω1, BΩ2 = 0, in Ω2,
BΩ3 = B
∗, in Ω3, BΩ4 = 0, in Ω4, t = 0. (6.113)
Dimensional parameters associated with the 8-orifice pin in this study are the same as those
used in the orifice pin sensitivity study of chapter 5 (see Table 6.2). Model equations (6.99-
6.113) were solved numerically using COMSOL®, version 5.3a, using the GMRES method,
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with the BDF to handle time advancement and using the physics-based default relative and
absolute tolerance levels. The 3D geometry of Figure 6.17 was discretised using the built-in
mesh settings using the “Normal” element size, this gave a mesh consisting of 6536 domain
elements, 3738 boundary elements, and 489 edge elements (Figure 6.18).
Figure 6.18: FEM mesh generated for the 3D 8-orifice pin geometry for the bactericidal study.
Mesh consists of 6536 domain elements, 3738 boundary elements, and 489 edge elements.
Parameter Value
Ld 1.4× 10−3 m [11]
Lo 1.6× 10−3 m [11]
ε 2/3 [34]
Df 1× 10−9 m2/s
η 10−5 s−1(m−3kg)2/3
b0 193.8 kg/m
3 [11]
S 50 kg/m3 [12]
Table 6.2: Dimensional parameter values. These values are taken from the literature or inferred
from [11]. The initial mass concentration, b0, is calculated from the drug mass loading of 100 mg
and dividing by the interior volume of the porous pin, then taking one quarter of this value since
the 8-orifice has been reduced to one quarter of its original size.
Concentration plots in 3D do not necessarily provide immediate information on the overall be-
haviour of a model. Therefore, it was deemed reasonable to compute the nondimensional mass
of b, c and B, to give a measure of model performance. The dimensional mass of b, c and B can
be calculated via:
Mb(t) =
∫
Ω1
b dΩ1, Mc(t) =
Ω4∑
i=Ω1
∫
i
ci di, MB(t) =
Ω4∑
i=Ω1
∫
i
Bi di,
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The mass equations for b and c may be normalised with the initial drug mass, M0, and the mass
equation for B may be normalised with the initial mass of bacteria, M0B. As this is a purely
numerical investigation, not only are the masses of b, c and B approximated, but so too are the
initial masses b0 and B0, which can be calculated via the integrals:
M0 = b0
∫
Ω1
dΩ1, M
0
B = B0
∫
Ω3
dΩ3.
Using the nondimensional scalings, the normalised equations for mass are:
Mb(t)
M0
=
b0L
3
d
∫
Ω ′1
b ′ dΩ ′1
b0L3d
∫
Ω ′1
dΩ ′1
,
Mc(t)
M0
=
SL3d
Ω ′4∑
i=Ω ′1
∫
i
c ′i di
b0L3d
∫
Ω ′1
dΩ ′1
,
MB(t)
M0B
=
BmaxL
3
d
Ω ′4∑
i=Ω ′1
∫
i
B ′i di
B0L3d
∫
Ω ′3
dΩ ′3
.
Simplifying and dropping the primes for clarity:
Mb(t)
M0
=
∫
Ω1
b dΩ1∫
Ω1
dΩ1
,
Mc(t)
M0
=
S∗
Ω4∑
i=Ω1
∫
i
ci di∫
Ω1
dΩ1
,
MB(t)
M0B
=
Ω4∑
i=Ω1
∫
i
Bi di
B∗
∫
Ω3
dΩ3
. (6.114)
The set of nondimensional mass equations (6.114) were computed using Gaussian quadrature
within COMSOL®, version 5.3a, and the numerical masses were then exported and plotted using
MATLAB®R2019a.
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(a) (b)
Figure 6.19: Plots showing the nondimensional masses of b, c and B versus time. The nondi-
mensional parameter values used were: χ = 8.4387× 10−4; S∗ = 0.0645; β1 = 5.102× 10−4;
β2 = 5.102 × 10−6; γ = 2 × 10−1; δ = 2 × 10−2; α = 10−3; and; B∗ = 10−1. Parame-
ter values not associated with the 8-orifice pin were arbitrarily chosen to demonstrate how the
model works. (a) Plot showing both undissolved and dissolved antibiotic consumption, with
almost all antibiotic consumed by 42 days of simulated time. (b) Corresponding plot showing
bacterial growth. After 42 days of simulated time, the bacteria are able to grow unhindered, as
the antibiotic is almost completely consumed.
(a) (b)
Figure 6.20: Plots showing the nondimensional masses of b, c and B versus time. The nondi-
mensional parameter values used were identical to those used to generate the plots in Figure
6.19, except for a change to the dimensional solubility of the antibiotic, S, which was increased
from 50 to 200. This changes the value of three model parameters, which have the new val-
ues: S∗ = 0.258, γ = 5 × 10−2 and δ = 5 × 10−3. (a) Plot showing the consumption of the
undissolved and dissolved antibiotic, indicating that approximately a third of the antibiotic has
dissolved after 24 hours of simulated time. (b) Corresponding plot showing the nondimensional
mass of bacteria. Although there is a burst of growth in the early stages, the more soluble an-
tibiotic is able to kill the diffusing and growing bacteria by approximately 24 hours of simulated
time.
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(a) (b)
Figure 6.21: Plots showing the average antibiotic concentration at Γ3, which is the collection of
semi-circular boundary surfaces connecting Ω2 and Ω3. (a) Plot showing the average concentra-
tion of antibiotic, of solubility 50 kg/m3, at Γ3. The bumps in the plot are numerical artifacts
which would be smoothed by taking more time steps, increasing the computational cost. (b) Plot
showing the average concentration of antibiotic, of solubility 200 kg/m3, at Γ3.
Figures 6.19 and 6.20 show the results of the study into the theoretical ability of the 8-
orifice to deliver antibiotic and eradicate a contaminating bacterial population. The results of the
study suggest that there is a close link between the solubility of the antibiotic and the outcome.
This may be inferred from the results: although the same mass of antibiotic is used in both
cases, the only difference is the change in the solubility of the antibiotic. Dimensionally, this
change corresponds to changing the value of S from 50 to 200, which results in a change in the
value of three nondimensional parameters: S∗, whose value increases from 0.0645 to 0.258; γ,
whose value decreases from 2× 10−1 to 5× 10−2 and; δ, whose value decreases from 2× 10−2
to 5 × 10−3. This increase in antibiotic solubility has the effect of increasing the antibiotic
concentration at the pin’s surface and thus, increasing the effective killing rate of the antibiotic.
This increase in concentration can be seen when comparing the plots in Figure 6.21, which
indicate that the concentration at the surface of the pin, adjacent to the orifices, is able to reach
considerably higher values, as a result of increased antibiotic solubility. Further examination of
the results also suggests that the geometry of the 8-orifice pin is an important factor to consider
as the orifices of the pin are reasonably small in diameter (0.5 mm) and so will limit the rate at
which the antibiotic may be release from the pin. Much like the porous pin study in the previous
section, the release of antibiotic is also further limited by the antibiotic dissolution process. From
these observations, it is reasonable to conclude that these antibiotic release limitations may be
alleviated through the use of a more soluble antibiotic or perhaps through geometric changes,
such as increasing, or decreasing, the diameter of the orifices. The outcome of low antibiotic
solubility is shown in Figure 6.19, which despite the antibiotic being released, the bacteria are
able to diffuse and grow as shown by the mass increase in Figure 6.19 (b), ultimately depleting
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the entire supply of antibiotic. The desirable outcome is shown in Figure 6.20, in which the
more soluble antibiotic is able to be released at considerably higher concentrations. Although
the bacteria have time to grow initially, as shown by the increase of bacterial mass in Figure
6.20 (b), the concentration of antibiotic is much too high and so the bacteria are eventually
eliminated. Alternatively, the antibiotic could may continue to have a low solubility, but be more
potent. Although the concentration of antibiotic would be relatively low, the higher potency
would mean that the effective killing rate would be greater.
6.7 Conclusions
This chapter details the process of mathematically modelling bacterial growth, subject to the
presence of an antibiotic. Although initially simplistic, it is worth considering the basics of
bacterial growth and as such, the modelling reflects this. For example, the structure of the
mathematics which inform the growth of bacteria plays an important role in forming the later,
more complex, mathematical models. In light of that, it was assumed that logistic bacterial
growth would be a reasonable starting point to build upon. Also considered was the form of
the reaction an antibiotic has on a bacterial population. To begin with, a constant decay rate
was considered, where the antibiotic was infinite in its supply. This, of course, is not realistic
for two main reasons: an antibiotic is not limitlessly available, there is a finite amount and the
killing effect of an antibiotic is not constant, it is variable since below a certain concentration, an
antibiotic has little to no effect. Therefore, it was assumed that Michaelis-Menten-like reaction
kinetics would account for a varying killing effect of an antibiotic, based on its concentration.
The mathematical modelling at this point worked as expected: if there was too little antibiotic,
the bacteria would be permitted to grow. However, the one assumption that was clearly not
suitable, was that the antibiotic was initially mixed in with the bacterial population, when in
fact, in the context of delivery of antibiotics from OIs, the antibiotic would be delivered.
In the case of antibiotic delivery, the antibiotic would be considered as spatially varying and
with that, the need for PDEs arises. Although a constant source of antibiotic was studied at
first, the results demonstrated that the model worked as expected and with that, the shift to a
model where a finite amount of antibiotic was made. This point in the modelling investigation
considered the scenario where the release process of the antibiotic and its action on a bacterial
population could be uncoupled. This is a useful simplification where it is possible to use analyt-
ical solutions, however, it may not be the case that this is possible as the action of an antibiotic
on bacteria may influence the release process. Therefore, the next reasonable step was to couple
these two processes, along with the addition of bacterial diffusion. It is known that bacteria are
able to move, either in an active or passive way, they are not necessarily static and confined to
one point. There has been research in the past that sought to quantify the diffusion coefficients
of different species of bacteria, both motile and nonmotile, and one important result, relevant
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to this chapter, is that motile bacteria may move as much as three orders of magnitude faster
than nonmotile species. Therefore, based upon this previous research and that bacteria are very
small, so may be considered small particles, the inclusion of bacterial diffusion was deemed
reasonable. The results of this addition are as expected, with the delivery of an antibiotic, a
bacterial population need not remain in place and succumb to the antibiotic, but rather spread
out into more space and grow. The results also clearly demonstrated the need for a sufficient
amount of antibiotic for a specific level of potency.
Lastly, the most complete model of bacterial growth subject to an antibiotic was, with some
modifications, applied to the porous pin and 8-orifice pin of chapters 4 and 5, respectively.
There are a few major differences between these pins and one of the most important was that the
release process of antibiotic from the porous pin could be reduced to a 1D model, whereas the
8-orifice pin required 3D modelling. One more addition was made at this stage of the modelling
investigation and that was the dissolution of the antibiotic. This was thought to be necessary to
increase the realistic nature of the models as an antibiotic would be likely loaded into a device as
dry powder. The results from the two models suggested that the outcome is dependent on both
the properties of the antibiotic and the geometry of the device releasing the antibiotic. It was
found that both the solubility and the potency of the antibiotic had an influence on the outcome.
Should an antibiotic have too low a solubility or if not potent enough, the antibiotic would
likely fail to eliminate the bacteria. Complicating matters is that the geometry of the antibiotic-
releasing device is also an important factor in determining the concentration of antibiotic at the
surface of the device i.e. the concentration of released antibiotic. Should the device not release
antibiotic in sufficient quantities, the antibiotic is likely to fail. This is particularly a potential
risk in the context of orthopaedic devices as if the scenario should arise where an antibiotic fails
to eradicate the bacterial population, the bacteria may then move into and colonise the device.
This is a serious outcome and may lead to device failure and would require costly surgery to
rectify.
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Chapter 7
Conclusions and future research
7.1 Conclusions
The early chapters of this thesis comprised a detailed review of the existing literature on drug
releasing OIs. This somewhat detailed exploration revealed a promising opportunity for the use
of mathematical modelling as an additional tool in the development of enhanced OIs. Using a
combination of analytical and numerical approaches, a series of models of increasingly com-
plexity were developed, starting from the description of drug release from a general two-layer
porous material, before specialising to two specific porous prototype implants that had been in-
vestigated experimentally in the literature. The research presented in this thesis concluded with
a series of models representing a “first attempt” at understanding the interplay between drug re-
lease from OIs and bacterial inhibition. A number of conclusions arise from the work and may
be summarised as follows:
The scientific literature lacks mathematical modelling of drug release from OIs
The scientific literature contains numerous examples of experimental research into the general
subject of drug release from orthopaedic devices. These experiments not only cover the topic
of drug release, but also the study of novel materials, with a view of using these materials in
an orthopaedic setting. One important finding from the literature review, was that most research
is currently focussed on in vitro studies, with very few examples that extend to the in vivo
setting. This suggests that this particular area of research is fairly new. Despite mathematical
modelling of drug release now being a mature topic, it was striking that there was a lack of such
modelling in the particular field of orthopaedics. As a result of this, a paper was written, and
published, which investigated the likelihood of mathematical modelling being of great benefit to
this research field [112].
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Variable porosity can be used to fine-tune drug release
There is plentiful experimental research into OIs, which make use of porosity, on various scales,
to control the release of drugs. This idea was explored mathematically in chapter 3. This work
centred on the idea of using variable porosity as a novel approach in controlling the release of
a drug from a device. Presented in chapter 3 is the derivation of an appropriate model and its
semi-analytical solution, along with a sensitivity analysis of a few key system parameters. The
model results indicate that certain parameters may be tuned to provide the desired drug release
profile, particularly the ratio of the effective diffusion coefficients, χ.
Experimental conditions matter
To provide the greatest possible benefit and usefulness, a mathematical model must reflect the
conditions of an experimental setup. One key feature that appeared in the experimental work on
the porous and orifice pins, was that the release medium was stirred. This stirring may have a
sizeable influence on the release of drug from both pins and was worth investigating the extent
to which fluid flow could theoretically affect the release of drug from the pins. The result of
this investigation gave two completely different outcomes for the respective pins. In the case
of the porous pin, it was found that fluid flow had no appreciable influence on the rate of drug
release from the pin. On the other hand, in the case of the orifice pins, fluid flow was important,
especially as the number of orifices the pin had drilled into its outer wall increased. This is an
important result as it suggests that the experimental setup is likely to influence the results of the
experiment. In other words, how the release medium is stirred, and at what rate, may be crucial
factors to consider when designing an experimental setup, especially if the in vivo release profile
is to be inferred from the in vitro experiments.
Additionally, what drugs are used is most likely another heavily contributing factor in the
release of drug during an experiment as drug solubility was a component that received much
consideration in the mathematical models of chapter 4 and 5. It was demonstrated that the
inclusion of nonlinear dissolution within the governing equations significantly slowed the drug
release compared with a diffusion-only or advection-diffusion model. From the results of the
mathematical investigation of the pins, it is also reasonable to conclude that the overall design
of the geometry of the device may have a highly influential role in determining the rate of drug
release and how the experiment should be conducted. The porous pin, for example, is for the
most part, impervious to fluid flow and therefore, the stirring of the release medium may not
be crucial to the release profile, although it may help ensure a uniform concentration of drug in
the release medium for sampling purposes. On the other hand, in the case of the orifice pins,
particularly the 2-orifice pin, the release profiles for both drugs used in the experiments are quite
similar. From this it would seem that the geometry of the pin limited the release of drug, despite
an order of magnitude difference in solubility between the two drugs: this is an effect that may
be explained with the model. From the literature, much of the experimental research is centred
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on in vitro studies and therefore, one needs to be careful what conclusions are drawn from such
studies and how they may relate to the in vivo scenario. Ideally, the in vitro conditions should
be chosen to mimic as closely as possible the intended in vivo environment.
Drug dissolution is an important consideration, and could be the rate-limiting process
Another key experimental component was that the drugs used were in a powdered form and, as a
result, the drug must dissolve in the release medium before transport out of the pins is possible,
whether it be by purely diffusive means in the case of the porous pin or by a combination
of diffusion and advection in the case of the orifice pins. Although the models constructed
included an equation which accounted for the dissolution process, this does however introduce
more parameters, whose values are uncertain.
1D modelling is often sufficient
One particularly interesting result that arose from the work in this thesis is that mathematical
modelling need not always require full 3D modelling to be representative of reality. For in-
stance, drug release from the porous pin is very likely a 1D problem as a result of the cylindrical
geometry, this is evidenced by the fluid flow study results, which suggest that the stirred release
medium had a negligible influence on the rate of drug release. The benefits of a 1D mathe-
matical model include the reduction of the spatial component to an interval and with that, the
governing equations may be represented in a simpler way. Additionally, 1D models may also
be solved analytically, or semi-analytically. Although it would be much quicker to solve a 1D
model numerically, an analytical solution offers insight into how model parameters may relate
and to what extent their influence may be. Most importantly, in the case of the porous pin,
the demonstration that the 3D geometry could be reduced to a 1D model through consideration
of an analytical solution allowed the more complex dissolution-diffusion model to be solved
numerically in only one dimension, greatly reducing computation time.
Parameter values
A mathematical model can only ever be as accurate as its inputs and therefore, accurate param-
eter values are often necessary, and this lack of information should be urgently addressed. For
example, precise values for diffusion coefficients for the drugs used in the experiments is un-
known and if they were available, they would most likely correspond to diffusion in water, not
SBF. Although drug solubility values in water are available, these values are likely to change
in SBF, since SBF is comprised of charged particles. Compounding uncertainty further is the
lack of data on the fluid properties of SBF, for example, dynamic viscosity and density. These
are necessary pieces of information as they inform how a fluid flows and thus, how an advec-
tive component of a drug transport equation will behave. Therefore, in lieu of some necessary
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information, it was assumed that the release medium was water and a sensitivity analysis was
performed using key system parameters, such as drug solubility, the drug dissolution rate, the
level of porosity in the case of the porous pin and orifice diameter is the case of the orifice pins.
The results demonstrated that there was a range of sensitivity in changes to the release profiles
for different parameters, in which slight changes to one or two parameters could drastically
change the release profile. The lack of accurate parameter values likely explains the somewhat
unsatisfactory agreement between model output and experimental data, particularly in the case
of the orifice pins.
Bacterial infection
The penultimate chapter of this thesis focussed on the growth of bacteria subject to the presence
of an antibiotic and two clear conclusions can be drawn from the results. The antibiotic release
profile and the concentration of antibiotic close to the surface of the device are crucial factors in
eliminating an infecting bacterial population. There are two distinct outcomes, either the antibi-
otic eradicates the bacteria, or the bacteria are able withstand the antibiotic until it is consumed,
then are able to grow. The results suggest that there are complex relationships between the suc-
cess of an antibiotic, its inherent qualities and how it is released from a device. For example,
when considering antibiotic release from the porous pin, the antibiotic is released from the pin
at relatively low concentrations, most likely due to the low level of porosity of the pin’s outer
wall. This results in the effective killing rate of the antibiotic being rather low, however, when
altering the potency of the antibiotic, despite the low level of concentration, the antibiotic is able
to eliminate the bacteria. In the case of antibiotic release from the 8-orifice pin, although surface
concentration is low initially, allowing for a more soluble antibiotic boosts the surface concen-
tration and thus increases the effective killing rate of the antibiotic, resulting in the successful
removal of the bacteria. It is evident that the outcome of antibiotic treatment is dependent on
the antibacterial ability of a drug, but also the design of the drug-releasing device. Mathemat-
ical modelling may be of use to optimise device design parameters, where experimentation on
different device designs may be far too costly.
7.2 Future work
There are many avenues which arise directly from the work in this thesis, which one may follow.
One potential direction is to conduct more mathematical analysis via approximate solutions to
some of the more complex models, by exploiting nondimensional parameters that may be large
or small in certain cases. Another area of work is to address the assumptions and limitations of
the models derived in the thesis. There are three main assumptions which arose: drug is instantly
fully wetted; the method of including fluid flow is simplified and; linezolid is actually comprised
of several chemical components.
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The nonlinear dissolution model employed here assumes that the powdered drug becomes
instantly wetted upon submersion in the release medium, such that dissolution can occur every-
where from the outset. This approach may be justified through the inherent “porosity” of the
material allowing fluid to penetrate quickly. This may not always be a suitable assumption and
fluid penetration of the drug may be required to provide a more realistic mathematical model.
One possible method likely worth investigating is modelling the dissolution process of the drug
as a moving boundary, in which the drug dissolves on a moving front. This may be more math-
ematically tractable in the case of the porous pin, where a 1D model may suffice. However, for
the orifice pins, the solution of such a 3D moving boundary problem is likely to be computation-
ally expensive, perhaps prohibitively so. It was assumed that reducing the method of stirring,
in chapters 4 and 5, to a rotating fluid volume would suffice. However, in reality, the method
is much more complex and one potential way to improve the applicability of the models is to
include the likely sloshing effects which would appear due to the forces a release medium would
experience atop a typical rotating plate. Lastly, it was assumed that linezolid consisted purely
of the active ingredient, however, it in fact contains many other compounds, such as glucose.
Therefore, another possible route of study is to investigate multi-component models, in which
the bulk of the ingredients may be modelled. It should be noted that aside from introducing
much more complex models, accounting for more realistic fluid flow and multi-component drug
transport, it may be a possibility that experiments may be simplified, which would permit the
use of the models in this thesis. Although repeating the experiments investigated is not likely to
happen, it does however, suggest that it would be beneficial for experimentalists and theorists to
collaborate. This would allow for both groups to inform the work of the other and minimise the
number of assumptions one would have to make. This would allow for models to be calibrated
and validated iteratively before embarking on more complex scenarios.
It may be the case that the most fruitful future research lies in the cooperation with an ex-
perimental group with a research interest in this field. The vast majority of the current research
into drug-releasing orthopaedic devices is experimental and thus there may be opportunities for
collaboration with experimental groups. Such cooperation could be focussed on in vivo drug
release research. There are some important differences between in vitro and in vivo release
processes, which may result in the drug release profile being drastically different in each case.
This may be due to a variety of reasons, such as complex geometric shapes that are composed
of different materials, such as a femur which is mainly composed of bone marrow, cortical and
trabecular bone tissue: do these different materials have an influence on drug release, and if so,
to what extent? Is there appreciable fluid flow within bone, such that it could have an influence
on the release of a drug? Another important difference that could affect how drug is released, is
the potential for drug particles binding to tissues immediately surrounding an implant. In short,
there are many open questions and it is through collaborative efforts, that these questions may
be answered.
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Lastly, with reference to the literature, in addition to much of the research being experimen-
tal, a lot of focus is on orthopaedic associated infection, for example, the prototype fixation pins
investigated by Gimeno et al. [11, 12]. Therefore, there is the possibility that future research
may be centred on the ideas discussed in chapter 6 and expanded upon, but with the addition
of an experimental group. Such a collaboration would allow for a more thorough investigation
of bacterial growth subject to an antibiotic. Raw experimentation coupled with mathematical
modelling would be a boon in such a research field as there are some open questions that arise
from chapter 6. One question is that, although it is clear that the concentration of antibiotic at
the surface of an implant is an important factor in determining the effectiveness of a released
antibiotic, but to what extent? The effect of antibiotic is also likely dependent on the subsequent
transport when eluted, but again, to what extent? Mathematical modelling may help to estimate
these, particularly the former, as the concentration of antibiotic at the surface of a device may be
difficult to measure in practice as experiments are limited by number of samples and how often
measurements may be taken. It may be the case that mathematical modelling, done in isolation,
may only result in more questions, however, the answers may be less murky via cooperation
between theorists and experimentalists.
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